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 According to the Human Development Index, it is estimated that all cancer cases will rise 
from 12.7 million cases in 2008 to 22.2 million by 2030.  Traditional therapies, including 
surgery, radiation therapy, and chemotherapy, have difficulty in specifically selecting malignant 
tissues for destruction.  To overcome these limitations, nucleic acid-based therapies, such as 
short interfering RNAs (siRNAs), have been developed to aid in the regulation of proteins.  
SiRNAs serve as substrates for the highly conserved RNA interference (RNAi) pathway, which 
gives rise to their high degree of mRNA target specificity and their catalytic nature.  However, 
the full potential of these therapeutic drugs will not be attained unless better methodologies are 
developed to enhance target delivery and to enhance resistance to ribonuclease-mediated 
degradation.  The focus of this study was to chemically modify the sense strand of an siRNA 
duplex with a triazole backbone unit and pyrimidine-modified hydrophobic substituents in an 
attempt to improve its pharmacokinetic and pharmacodynamic properties.  This was 
accomplished by linking together uracil and cytosine monomers with the Cu(I)-assisted Huisgen 
1,3-dipolar cycloaddition reaction to create a cytosine-triazole-uracil-iodine dimer (CtU
I
).  The 
dimer was further modified at the C5 position of uracil with various lipophilic moieties including 
cholesterol and phenylacetylene utilizing the Sonogashira cross-coupling reaction.  Subsequent 
reactions were performed on the dimer to give rise to a 4,4’-dimethoxytrityl (DMT)-protected 
phosphoramidite building block, which allowed for its site-specific incorporation into an 
oligonucleotide using solid-phase synthesis.  Once the modified strand was annealed to its 
counterpart, circular dichroism measurements revealed that modified siRNA duplexes retained 
their standard A-form helix.  Thermodynamic profiling of the siRNA library illustrated that 




destabilizing.  Furthermore, the lipophilic moieties protruding off of the uracil base did not have 
a profound effect on the stability of the duplex.  Results from cell-based assays indicated that 
that triazole-modified siRNAs bearing hydrophobic groups were compatible with the RNA 
induced silencing complex (RISC) and effectively silenced reporter gene, firefly luciferase, and 
an endogenous gene, BCL-2, in a dose-dependent manner.  Further exploration of the effect of 
the hydrophobic moieties in a carrier-free assay revealed that the added cholesterol group was 
able to enhance the delivery of native siRNAs.  To the best of my knowledge, this is the first 
time that the effect of a non-ionic linkage unit derivatized with a base-modified hydrophobic 
group has been explored within siRNAs.  The following study demonstrated the compatibility of 
these novel constructs within the RNAi pathway and helped to better understand the structure-
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Chapter 1: Literature Review 
1.1 Defining Cancer 
Cancer can be defined as a disease in which mutated cells have developed pathological 
changes within their genome giving them a competitive advantage over normal cells (Croce, 
2008).  These pathological changes shift the homeostatic balance within the cell cycle towards 
cellular growth, which results in cancerous cells that live longer or divide more rapidly (Croce, 
2008).  On a genetic level, cancer cells acquire their unique autonomy by undergoing mutations 
that result in either a hyperactive gene product (dominant mutation) or the complete destruction 
of proper gene functionality (recessive mutation) (Weinberg, 1994).  Dominant mutations result 
from a single mutational event in a proto-oncogene, which gives rise to an oncogene (Weinberg, 
1994).  Oncogenes, in turn, cause excessive cell survival (Weinberg, 1994).  Recessive mutations 
are a result of two mutational events that knockdown both gene copies of a tumor suppressor 
gene (Weinberg, 1994).  In this case, the inactive tumor suppressor gene, like an oncogene, 
causes excessive cell survival (see Figure 1-1; Weinberg, 1994). 
Excessive cell survival is a trait that is characteristic of all types of cancer cells, but the 
mode of action in which this trait is inherited is variable.  Dominant and/or recessive mutations 
promote excessive cell survival by permitting cancerous cells to have a reduced dependence on 
other cells (Song, et al., 2010) avoiding apoptosis (Abrol, et al., 2012), being abnormally 
invasive (Chaffer & Weinberg, 2011), and being able to proliferate indefinitely (Clarke & Fuller, 
2006).  Malignant cells develop these mutations through the malfunctioning of the maintenance 
of their genome and/or through the exposure of external risk factors within their environment.  In 




have shown that when proofreading or mismatch repair machinery is lost, there is a 10- to 1000-
fold increase in spontaneous mutation rate (Preston, et al., 2010).  Additionally, during normal 
cell division, DNA is replicated with approximately 10
-10
 mutations per base-pair per cell 
division (Preston, et al., 2010).  External biological factors, on the other hand, have contributed 
to the causation of cancer through: viruses, obesity, and smoking.  The human papilloma virus 
works in an oncogenic manner by provoking uncontrolled proliferation (Walboomers, et al., 
1999).  Obesity is linked with a state of prolonged hyperinsulinemia, which ultimately promotes 
antiapoptotic behaviour (Roberts, et al., 2010).  Tobacco smoking exposes the body to numerous 
cancer-causing chemicals that cause lung cancer to develop by either the direct carcinogenic 
action of smoke on human bronchial epithelium or by making the individual susceptible to 
another carcinogen within the environment (Cornfield, et al., 2009).   Due to the vast number of 
ways in which cancer is able to develop, cancer has become the number one leading cause of 
death in economically developed countries (Jemal, et al., 2011).  For this reason, it is essential to 
develop therapeutics that target both dominant and recessive mutations that contribute to the 






1.2 Overview of Common Cancer Treatments and Their Limitations 
As mentioned, cancer cells have a reduced dependency on other cells, can avoid 
apoptosis, are invasive, and can proliferate indefinitely (Song, et al., 2010; Abrol, et al., 2012; 
      
Normal cell Oncogene stimulates 
excessive cell survival  
Single mutation event in proto-oncogene 
creates oncogene 
(A) Dominant Mutation 
         













gene copy Inactive tumor 
suppressor gene 
stimulates excessive cell 
survival  
(B) Recessive Mutation 
Figure 1-1: Mutational events depicting the development of a cancerous cell from a normal cell.  
(A) Dominant mutations arise when a normal cell experiences a single mutational event in a 
proto-oncogene to create an oncogene.  The hyperactive oncogene stimulates excessive cell 
survival.  This type of mutation only needs to affect one of two gene copies within a cell.  (B)  
Recessive mutations arise when a normal cell experiences two mutational events that inactivate 
both gene copies of a tumor suppressor gene.  The inactivity of the tumor suppressor gene 




Chaffer & Weinberg, 2011; Clarke & Fuller, 2006).  By knowing the basic fundamental 
characteristics of cancer, many different methods to treat the disease have been developed 
including: surgery, radiation therapy, and chemotherapy.  Surgery is an invasive procedure that 
involves the complete physical removal of a malignant tumor.  In the process, a margin of 
healthy tissue is also removed to ensure the complete removal of all cancerous cells.  Radiation 
therapy uses ionizing radiation to damage the DNA of cancerous cells, leading to their 
destruction (Terasawa, et al., 2009).  This type of therapy is limited in targeting only cancer cells 
due to the clustering of normal cells surrounding the tumor.  Chemotherapy, often used in 
conjunction with surgery, uses chemotherapeutic agents that are often designed to target rapidly 
dividing cells, as that is one of the characteristics of a cancerous cell (Perumal, et al., 2009).  
Unfortunately, humans have normal cells within their bodies that also divide rapidly in nature, 
i.e. red blood cells, cells that line the gastrointestinal tract, spermatogonia, etc (Markert, 1968).  
As a result, both malignant and rapidly dividing healthy cells experience the toxic effects 
presented by chemotherapeutic agents.   
All of the cancer treatments that were previously described share a common denominator; 
each method involves the indirect destruction of normal tissues.  In order to overcome these 
limitations, drugs such as nucleic acids have been developed to aid in the regulation of 
problematic proteins by interfering with their expression on a transcriptional or translational 
level (Jarald, et al., 2004). 
1.3 Various Nucleic Acid Therapeutics and Their Actions within the Central Dogma 
The central dogma refers to a series of processes where genomic information is used to 
make the necessary proteins required for biological activity (Crick, 1970).  The entire process 




(2) DNA transcribes its code to mRNA; (3) mRNA is processed and exits the nucleus into the 
cytoplasm and (4) ribosomes “read” and translate the information carried by mRNAs to make 
proteins (see Figure 1-2; Crick, 1970).   
 
Figure 1-2: The points of interference of various nucleic acid-based therapies within the central 
dogma.  All nucleic acid-based therapies are accentuated with a red font.  The majority of these 
therapies attempt to interfere with overexpressed genes by blocking their transcription, 
translation or interfering with the overexpressed protein itself.  These types of therapies are used 
to help regulate hyperactive oncogenes.  Gene therapy, on the other hand, introduces a foreign 
gene into a target cell in an attempt to rescue the decreased production of a protein product.  This 
type of therapy is used to help stimulate the activity of tumor suppressor genes. 
When natural processes within the central dogma malfunction, nucleic acid therapeutics 
can be used to help compensate for the over/under production of a particular protein.  One 




therapy works by packaging a foreign gene in some form of vector and introducing the package 
to a host cell (Misra, 2013).  Upon delivery, the cell uptakes and expresses the foreign gene, 
which results in the synthesis of the downregulated protein (Misra, 2013).  Although this 
treatment has resulted in devastation in the past, such as the famous case of Jesse Gelsinger in 
1999 (Misra, 2013), many advances in the field have led to the first marketed gene therapy 
within Europe and the United States in 2012 known as Glybera (Bryant, et al., 2013).  To date, 
Glybera remains on the market and is under surveillance for any unsuspected downstream side 
effects (Bryant, et al., 2013).   
In opposition to gene therapy, antigene sequences, ribozymes, antisense oligonucleotides, 
short interfering RNAs, and aptamers are nucleic acid-based therapies that promote the 
downregulation or inactivity of overexpressed proteins.  Antigene sequences are DNA or RNA 
based oligonucleotides that function by inhibiting the transcription of a specific gene (Praseuth, 
et al., 1999).  These agents block transcription by hybridizing within the ‘major groove’ of DNA 
to form a triple helix (Praseuth, et al., 1999).  The binding of the antigene sequence is 
accomplished through the use of ‘Hoogsteen base-pairs,’ as shown in Figure 1-3 (Praseuth, et 
al., 1999).  The newly generated secondary structure of DNA, in turn, impedes with the binding 
of transcription factors to enhancer or promoter regions on DNA and/or interferes with the 
unwinding of the duplex necessary for transcription.  Ultimately, transcription is blocked.  Some 
advantages to this approach are: (1) there are only two genes per cell to target rather than 






Figure 1-3: A comparison of adenine-thymine and guanine-cytosine base-pairing using the 
Watson-Crick model and Hoogsteen’s model.  (A) The Watson-Crick model shows how a purine 
and pyridine base-pair together when both bases adopt an anti-conformation.  (B) Hoogsteen 
base-pairing requires rotation around the glycosidic bond from the anti to the syn conformation 
of a purine base before binding to an anti-conformed pyridine. 
In contrast to antigene sequences, ribozymes have been used to downregulate protein 
production on a translational level.  These catalytic molecules consist of a conserved catalytic 
core made up of a single-stranded stretch of nucleotides in the order of N-U-X, counting from 
the 5’-end, where N = any nucleotide and X = C, U or A (Citti & Rainaldi, 2005).  Due to the 
fact that this triplet is quite variable, it is likely to occur at least once in nearly all mRNA targets 
(Citti & Rainaldi, 2005).  Target specificity of the ribozyme comes from the binding domain, 
which allows the ribozyme to bind to a complementary mRNA transcript (Citti & Rainaldi, 
2005).  With the cleavage of the catalytic domain and the specificity of the binding domain, 




oligonucleotides and short-interfering RNAs also work by blocking the translation of mRNA; 
however, their modes of action vary.  For more information on antisense oligonucleotides see 
Section 1.4.  For more information on siRNAs see Sections 1.5-1.12.   
Using a different approach, aptamers are nucleic acids that have been used to inhibit the 
activity of proteins by folding into a three dimensional structure that allows for high affinity 
binding to their target (White, et al., 2000).  They can be viewed as macromolecular drugs that 
mimic the actions of small molecule drugs or monoclonal antibodies (White, et al., 2000).  
Aptamers are generally generated by developing a combinatorial library composed of random 
single-stranded nucleic acid sequences (DNA, RNA or modified analogues) flanked by a fixed 
sequence for a primer binding site (Stoltenburg, et al., 2007).   This library is then subjected to an 
in vitro selection technique, named Systematic Evolution of Ligands by Exponential Enrichment 
(SELEX) by Gold and Tuerk, where candidates bound to their target protein are isolated, 
amplified, and undergo another round of selection (Stoltenburg, et al., 2007).  When the cycle is 
complete, high affinity ligands are sequenced and evaluated for their ability to bind to their target 
(see Figure 1-4; Stoltenburg, et al., 2007).  All of the previously described nucleic acid therapies 
have successfully demonstrated the ability to control the regulation of disease-associated genes 
or proteins.  With the development of a suitable drug delivery system, these nucleic acid-based 






Figure 1-4: A schematic diagram of aptamer selection using SELEX. (1) A library of aptamers 
is developed by synthesizing a combinatorial library or using genomic DNA for naturally 
occurring aptamers.   RNA oligonucleotides are made with in vitro transcription of a DNA 
template with T7 RNA polymerase. (2) The compiled aptamers are incubated with their target 
and are examined for binding.  (3) Unbound oligonucleotides are removed through a series of 
washing steps and target-bound oligonucleotides are eluted.  (4) The selected aptamers are 
amplified by PCR for DNA oligonucleotides or RT-PCR for RNA oligonucleotides.  (5) The 
cycle is continued for another 6-20 times until the enriched aptamer pool consists of high-affinity 






1.4 Antisense Oligonucleotides 
 In 1978, John Hachmann synthesized a tridecamer deoxyribonucleotide that was 
complementary to 13 nucleotides within 35S RNA of the Rous sarcoma virus (RSV) (Zamecnik 
& Stephenson, 1978).  In an attempt to inhibit the production of RSV, Zamecnik and Stephenson 
administered the tridecamer to infected chick embryo fibroblast cells.  The tridecamers 
successfully inhibited 35S RNA, which suggested that antisense oligonucleotides have the ability 
to interrupt with the intrinsic function of RNA molecules (Zamecnik & Stephenson, 1978).  
Since their discovery, antisense oligonucleotides have been used as a therapeutic to target and 
degrade complementary mRNA molecules on a translational level.  Antisense oligonucleotides 
operate by hybridizing to an mRNA molecule via Watson and Crick-based nucleotide base-
pairing (Jarald, et al., 2004).  Once the strands anneal, genetic expression of the target mRNA is 
downregulated by either a ribosomal arrest in which the duplex sterically prevents mRNA from 
being “read” by the ribosomal complex or the RNA-DNA hybrid activates RNase H, which 
hydrolyzes the RNA strand of the heteroduplex (see Figure 1-5; Jarald, et al., 2004).  Over the 
course of 36 years, Zamecnik and Stephenson’s discovery led to the first commercially available 
antisense oligonucleotide known as Vitravene, in 1989 (Stahel & Zangemeister-Wittke, 2003), 
followed by Mipomersen, in 2013.   
Despite the immense success of antisense oligonucleotides, the recent discovery of 
double-stranded siRNAs has gained attraction as an alternative therapeutic.  The double-stranded 
nature of siRNAs makes it easier to design oligonucleotides because their secondary RNA 
structure is not an obstacle for their construction (Wang, et al., 2008).  In addition, in vitro 
studies suggest the duration of mRNA knockdown by siRNAs is similar to second generation 




Therefore, the remainder of this thesis will use the foundation of knowledge gained from 
antisense oligonucleotides as a source of efficient siRNA design and evaluation. 
 
Figure 1-5: A schematic diagram depicting the mechanisms of antisense oligonucleotides.  
Antisense oligonucleotides function by binding to an RNA target based off of complementarity 
to make a DNA/RNA hybrid.  The heteroduplex prevents mRNA translation by recruiting RNase 
H to destroy mRNA or by causing a translational arrest by sterically preventing ribosomes from 
“reading” their mRNA substrate. 
1.5 The Origins of siRNA 
RNA interference has proven to be an invaluable tool in functional genomics, has given 
insight into evolutionary processes, and has provided a promising approach for the treatment of 
many illnesses.   A mechanism with such a diverse number of applications took many years to 
fully understand and comprehend.  The first RNAi type phenomenon was reported in 1990 when 
Napoli and Jorgensen hypothesized that a transgene was responsible for the suppression of the 
endogenous chalcone synthase (CHS) gene (Napoli, et al., 1990)  Two years later, Ramano and 
Macino noted that homologous RNA sequences caused the repression of an endogenous gene in 




findings to animal models by introducing a sense or antisense RNA strand that was 
complementary to par-1 mRNA in C. elegans (Guo & Kemphues, 1995).  Their results showed 
that the par-1 message within the signalling pathway was not delivered and the single-stranded 
RNA molecules worked as antisense strands to eliminate gene expression (Guo & Kemphues, 
1995).  It was not until 1998 when Andrew Fire and Craig Mello reported that it was double-
stranded RNA and not single-stranded RNA strands that caused potent and specific mRNA 
interference (Fire, et al., 1998).  Their method involved the subjection of dsRNA molecules 
encoding an unc-22 exon segment to striated muscle cells of C. elegans (Fire, et al., 1998).  Unc-
22 is an abundant but non-essential protein known to have several thousand mRNA transcripts in 
each muscle cell (Fire, et al., 1998).  Elimination of this protein results in severe muscle 
twitching, which was the phenotypic response that was observed when Fire and Mello tested 
their sense-antisense RNA mixture against unc-22 production.  Due to the fact that only a few 
molecules of double-stranded RNA were capable of producing such severe responses per 
affected cell, it was suspected that there was most likely an amplification or catalytic component 
within the interference process (Fire, et al., 1998).  Insight into an effective system capable of 
knocking down mRNA transcripts highlighted the need to identify the silencing intermediate 
within the RNAi pathway.  In 2000, two groups of biochemists independently found that 21-23 
nt long RNA was co-purified with RNAi components in Drosophila extracts (Hammond, et al., 
2000; Zamore, et al., 2000).  One year later, Tuschl, et al. synthesized 21-22 nucleotide double-
stranded RNAs with 2-3 nucleotide overhangs on their 3’-ends, known as short interfering 
ribonucleic acids (siRNAs) (Sen & Blau, 2006).  These constructs were capable of silencing 




1.6 The Mechanism of Short Interfering Ribonucleic Acids 
1.6.1 Dicer: The Designer of siRNA Constructs 
In nature, the role of RNAi is to defend cells against parasitic nucleotide sequences 
originating from viruses, transgenes or transposons (Carthew & Sontheimer, 2009).  The RNAi 
process begins with an RNase III enzyme known as Dicer, which recognizes foreign double-
stranded RNA and catalytically cleaves the strand into smaller fragments (see Figure 1-6; 
Carthew & Sontheimer, 2009). Dicer is characterized by several distinct domains in a specific 
order from the amino to the carboxyl terminus: a DExD/H ATPase domain, a DUF283 domain, a 
PAZ domain, two adjacent RNase III domains and a dsRNA-binding domain (dsRBD) (Carthew 
& Sontheimer, 2009).  Of the six domains, the PAZ domain and the RNase III domain have 
proven to play central roles in the processing of siRNAs (Carthew & Sontheimer, 2009).  The 
PAZ domain functions by binding to the ends of the RNA substrate and positioning the nucleic 
acid within the active sites of the RNase III domains (Carthew & Sontheimer, 2009). When the 
substrate reaches the processing center, the RNase III domains cleave the duplex leaving ~2-nt 
3’-overhanges to create siRNAs (Carthew & Sontheimer, 2009).  The cleavage event ceases a 5’-
monophosphate group on each end of the siRNA, which is critical for downstream silencing 






Figure 1-6: A schematic diagram depicting the mechanism of siRNA-initiated RNA 
interference.  Within this pathway, long, double-stranded RNA molecules are cleaved by Dicer 
to make siRNAs.  The RISC complex takes up siRNA, selectively incorporates the antisense 
strand into its complex, and discards the sense strand.  The antisense strand then binds to its 
target mRNA based off of complementarity and the mRNA transcript is cleaved by Argonaute 2.  





1.6.2 TRBP: The Adjudicator of Proper Strand Selection 
Once the siRNA is created, it is recognized by RISC, where the duplex dissociates and 
the antisense strand is incorporated into the RISC loading complex (Carthew & Sontheimer, 
2009).  The RISC loading complex consists of three essential proteins: (1) Dicer, (2) trans-
activation response RNA binding protein (TRBP), and (3) Argonaute 2 (Ago2).  (Daniels & 
Gatignol, 2012).  Two of these proteins, Dicer (described in Section 1.6.1) and TRBP, are 
essential for the initial processes of the siRNA mechanism.  TRBP consists of three structural 
domains: dsRBD1, dsRBD2, and the C4 domain (Daniels & Gatignol, 2012).  The dsRBD 
domains are responsible for binding to an RNA substrate while the C4 domain mediates protein-
protein interactions (Daniels & Gatignol, 2012).  The C4 domain binds to the ATPase/helicase 
domain of Dicer and strengthens TRBP-Dicer interactions within the RISC complex (Daniels & 
Gatignol, 2012).  Although much is established about RISC assembly, how and when the siRNA 
is processed is still unknown (Wilson & Doudna, 2013).  In vitro experiments have shown that 
TRBP alone can sense the thermodynamically stable end of an siRNA molecule (Gredell, et al., 
2010).  Once the TRBP protein is bound to one end of the siRNA, Dicer is left to bind to the 
opposite end (Gredell, et al., 2010).  In this manner, one strand of the duplex is selectively 
chosen to be the antisense strand, while the other is destined to be the sense strand (Gredell, et 
al., 2010).  
1.6.3 Argonaute: At the Centre of mRNA Silencing 
Upon antisense strand selection by RISC, a third protein, known as the Argonaute  




 positions, counting from the 5’-end, to 




characterized by four different domains: the PAZ domain, the PIWI domain, the N domain, and 
the Mid domain (Wang, et al., 2008). Crystallized structures of Argonaute loaded with an 
antisense strand from Thermus thermophiles have given hints as to the contribution of each 
domain in nucleic acid binding (Wang, et al., 2008).  The PAZ domain has RNA 3’-terminus 
binding activity used for antisense strand binding (Wang, et al., 2008).  The Mid domain has a 
5’-phosphate binding pocket, which recognizes the 5’-end of the antisense strand (Wang, et al., 
2008).  The backbone of the antisense strand is attracted to a positively charged surface that is 
formed by all of the domains (Wang, et al., 2008).  This positively charged surface allows for a 
diverse number of antisense sequences to associate with Argonaute (Wang, et al., 2008).  The 
PIWI domain is the domain that is responsible for endonucleolytic cleavage of a base-paired 
target (Wang, et al., 2008).  It adopts an RNase H-like fold and produces the initial cleavage that 
causes RNA destabilization and ultimately the dissociation of the sense strand (Wang, et al., 
2008).  The sense strand is then targeted by XRN1 and exosome exonucleases where its 
degradation process is completed (Orban & Izaurralde, 2005). 
1.6.4 Current Models Explaining the siRNA Mechanism 
Although the role of the Argonaute protein is believed to be associated with the 
degradation of the sense strand, a number of studies have suggested that cleavage is not an 
essential feature for the formation of an active RISC complex (Kawamata & Tomari, 2010).  
Therefore, the active RISC complex is believed to occur in one of two ways (Carthew & 
Sontheimer, 2009).  The first method, known as the “helicase model,” suggests that Dicer, with 
its helicase domain, recruits helicase to the RISC complex where it actively unwinds siRNA and 
incorporates the resultant single antisense strand into the RISC complex (Kawamata & Tomari, 




because helicase is more likely to unwind the less thermodynamically stable end of an siRNA 
molecule (Kawamata & Tomari, 2010).  The “helicase model” is the model that has gained the 
most acceptance as to how siRNAs are processed (Kawamata & Tomari, 2010).  Another model, 
known as the “duplex-loading model,” suggests that the siRNA duplexes are loaded into 
Argonaute proteins and the strands do not dissociate from one another before loading (Kawamata 
& Tomari, 2010).  Experiments supporting the plausibility of this model include the substitution 
of the Argonaute 2 cleavage site with: a phophorothioate linkage, a pre-cleaved sense strand, and 
a non-cleavable alkyl chain (Matranga, et al., 2005; Leuschner, et al., 2006; Efthymiou, et al., 
2012).  In each case, the modified siRNAs still possess the ability to silence their mRNA target 
without the need of RISC-mediated cleavage, which suggests that there may be an alternative 
mechanism in which the sense strand is removed (Efthymiou, et al., 2012).  In either case, the 
end result is a RISC complex possessing an antisense strand that can bind to and degrade 
complementary mRNA. 
1.6.5 The Degradation of mRNA from Active RISC.   
Active RISC is believed to process mRNA in a manner similar to which it processes the 
sense strand of the siRNA.  After the antisense strand within the active RISC complex binds to 
its complementary target, the phosphodiester bond within mRNA is cleaved between the 




 position of the antisense siRNA strand, 
counting from the 5’-end (Carthew & Sontheimer, 2009).  Once the mRNA is cleaved into two 
fragments, cellular exonucleases locate and digest the fragments into mononucelotides.  
Messenger RNA decay ensues two pathways; one for each fragment.  The 5’-capped mRNA 
fragment is decapped with DCP2 decapping enzyme and undergoes exonucleolytic degradation 




mRNA fragment is deadenylated by the CAF1-CCR4-NOT complex and endures exonucleolytic 
digestion by the exosome in the 3’5’ direction (Eulalio, et al., 2007).  This digestion process is 
regulated by a complex of SKI proteins (Eulalio, et al., 2007).  The moment that the fragmented 
sense strand dissociates from active RISC, the complex can continue to undergo multiple rounds 
of mRNA cleavage and amplify the interference mechanism. 
1.6.6 The use of Processing Bodies to Enhance Post-transcriptional Silencing 
It has been shown that siRNAs and their target mRNAs localize in foci called P-bodies to 
enhance post-transcriptional silencing (Liu, et al., 2005).  P-bodies are small cytoplasmic foci 
that contain most enzymes that are required for mRNA degradation (Kulkarni, et al., 2010).  
Examples of proteins which have been isolated from P-bodies are: (1) all four human Ago 
proteins, (2) GW182 (a family of proteins that interact with Ago), and (3) two RNA helicases, 
Rck and MOV10 (Kulkarni, et al., 2010).  Although P-body localization does not appear to be a 
crucial requirement for RNAi, having an environment enriched with mRNA degradation factors 
helps to enhance siRNA activity (Carthew & Sontheimer, 2009).  Therefore, through the process 
of slicing dsRNA into siRNA, incorporating it into a RISC loading complex, removing the sense 
strand of the siRNA duplex, and cleaving mRNA with an active RISC complex, RNAi can be 
used to effectively defend cells against foreign double-stranded ribonucleic acids. 
1.7 General Rules to Abide for the Design of Synthetic siRNA Sequences 
Long, double-stranded RNA molecules that were initially used in RNAi induced 
interferon responses, and were toxic to mammalian cells (Robbins, et al., 2009).  Therefore, in 
order to create an effective therapeutic capable of silencing mRNA while at the same time 




strategy that was employed was the construction of pre-processed siRNAs (Elbashir, et al., 
2001).  By introducing pre-synthesized 21-nt long siRNAs, the Dicer processing phase of the 
siRNA mechanism is bypassed, and the pathway begins with the recognition of siRNA by the 
RISC complex (Bumcrot, et al., 2006).  Once recognized, the remainder of the siRNA 
mechanism continues until the target mRNA is degraded (Bumcrot, et al., 2006).   
In order to target a particular gene of interest, synthetic siRNAs are designed to have a 
sense strand that has a nucleotide sequence that is identical to its target mRNA and an antisense 
strand that has a complementary sequence to the sense strand (Heidenreich, 2009).  The exact 
sequence acquired by the siRNA is dependent on the sequence of the target mRNA transcript 
(Heidenreich, 2009).  Due to the fact that mRNA molecules are generally longer than 21-nt long 
siRNAs, there are multiple target sites available for an siRNA (see Figure 1-7).   One method 
that has been used to identify potent target sites is the “shotgun” or “blind” approach.  Within 
this approach, siRNAs are designed to target various regions of a specific mRNA and are 
individually tested for their ability to downregulate its production (Harborth, et al., 2003).  A 
second method entails the use of computer programs, such as “MysiRNA-Designer,” which 
predicts the secondary structure of mRNA targets and designs siRNA sequences based off of 
accessibility, their ability to avoid off-target effects, and taking transcript variations into 
consideration (Mysara, et al., 2011).  Computer programs, such as “MysiRNA-Designer,” are 
likely to gain popularity in the near future due to its free accessibility and its ability to design 





Figure 1-7: A diagram depicting the multiple sites on an mRNA transcript available for siRNA 
targeting. 
1.8 Barriers and Modifications 
Although siRNAs have proven to be successful in silencing genes on a post-
transcriptional level, better methodologies for targeted delivery to cells need to be developed 
before they can be used therapeutically.  Some barriers in which siRNAs encounter are: (1) 
stability, (2) biodistribution, (3) immune activation, (4) cellular uptake and (5) off-target effects 
(Juliano, et al., 2009; Bumcrot, et al., 2006).  To circumvent these problems, biochemists have 
introduced a wide variety of chemical modifications within oligonucleotides in an attempt to 
enhance the properties of native siRNAs. 
1.8.1 Stability 
 Upon systemic administration, one of the first biological barriers presented to an siRNA 
are endo- and exo-ribonucleases within the blood (Haupenthal, et al., 2006).  Out of the RNases 
found within blood, the RNase A family of enzymes have been shown to specifically digest 
siRNAs with 3’-overhangs (Haupenthal, et al., 2006).  RNase A enzymes function by cleaving 
the phosphodiester backbone of an RNA molecule using a basic histidine residue to deprotonate 
the 2’-OH group of the ribose sugar and an acidic histidine residue to assist the departure of the 




2’-OH group, the alkoxide will attack the adjacent phosphate group forming a 2’,3’-cyclic 
phosphodiester truncated product as shown in Figure 1-8 (Breslow & Chapman, 1996). 
 
Figure 1-8: An example of a favoured mechanism of the cleavage of the phosphodiester 
backbone of an RNA molecule by ribonuclease A.  Histidine residues, within the active site, are 
believed to act as hydrogen bond acceptors and donors to facilitate a nucleophilic attack of the 
2’-OH group against the phosphorus atom of the phosphate group to make 2’,3’-cyclic 
phosphodiester truncated product. 
One way to overcome this limitation is by replacing the phosphate backbone or the ribose 
sugar with chemical modifications so that the substrate required for ribonucleases is eliminated 
and the half-life of the siRNA is enhanced.  Some backbone modifications that have been used 
are phosphorothioates, boranophosphates, peptide nucleic acids, and peptide nucleic acid 
derivatives, as depicted in Figure 1-9.  Phosphorothioate (PS) modifications replace the non-
bridging oxygen atom with sulfur (Li, et al., 2005).  These modifications improved ribonuclease 
resistance and enhanced activity when incorporated into the 3, 5, and 17 positions of the sense 
strand, counting from the 5’-end (Li, et al., 2005).  Drawbacks include enhanced binding to non-
specific membrane proteins, which can cause toxicity (Amarzguioui, et al., 2003).  
Boranophosphates replace the non-bridging phosphodiester oxygen with an isoelectric borane 




when compared to native siRNAs (Li, et al., 2007).  However, it should not be heavily 
incorporated into the antisense strand of an siRNA duplex because the hydrophobic group could 
interfere with the activity of Ago2 (Hall, et al., 2006).  Peptide nucleic acids (PNAs) replace the 
phosphate backbone by linking nucleosides with amide bonds (Gong & Desaulniers, 2012).  
When these modifications were placed on the 3’-ends of one or both ends of the modified 
siRNA, the siRNAs were shown to have increased ribonuclease resistance (Gong & Desaulniers, 
2012).  Further investigation also demonstrated that these modified siRNAs were able to retain 
silencing activity (Gong & Desaulniers, 2012).  Triazole backbone modifications based on a 
PNA-like scaffold replace the entire phosphate group with an aromatic nitrogen containing ring, 
and also showed resistance to ribonucleases (Gong & Desaulniers, 2012; Efthymiou, et al., 
2012).  One disadvantage of siRNAs with PNA or PNA-like backbones is the tedious synthesis 
that is required in order to incorporate the modification (Efthymiou, et al., 2012).  In each case, 
the chemical modifications reduce or eliminate the substrate affinity for ribonucleases and thus 
help to provide siRNAs with ribonuclease resistance.  
Other modifications that do not replace the facile phosphodiester bond but reduce 
ribonuclease activity include sugar modifications such as: 2’-OMe, 2’-O-MOE, 2’-LNA, and 4’-
Thio.  2’-OMe modifications slightly improve ribonuclease resistance and have been shown to 
have enhanced silencing activity when placed into specific positions within the sense strand 
(Prakash, et al., 2005).  2’-O-methoxyethyl (2’-O-MOE) modifications have a longer alkyl chain 
projecting from the 2’-OH group when compared to 2’-OMe modifications (Prakash, et al., 
2005).  This added bulky structure further improves ribonuclease resistance; however, it can also 
interfere with the activity of Ago2 in position-dependent locations, which can result in less 




4’-positions of the ribose ring into a 3’-endo conformation (Braasch, et al., 2003).  Due to the 
highly rigid conformation of this modification, a single LNA incorporation has the ability to 
increase the thermodynamic stability of the duplex by 5-10°C (Braasch, et al., 2003).  When 
LNA modifications are placed at the 3’-ends, the duplexes gain protection against 3’-
exonucleases.  However, too many modifications can ablate siRNA activity, likely due to 
difficulty in unwinding the duplex (Braasch, et al., 2003).  4’-Thio modifications possess a 
carbon-sulfur bond rather than a carbon-oxygen bond (Yokoyama, 2000).  A carbon-sulfur bond 
is longer than a carbon-oxygen, which may alter the spatial conformation of the ribose sugar and 
give it ribonuclease resistance (Yokoyama, 2000).  Such a modification has been shown to have 
an improved binding affinity to mRNA, but the cleavage efficiency is highly dependent on the 
position of the modification within the duplex (Yokoyama, 2000).  Therefore, by eliminating the 
substrate for ribonucleases, whether it is by chemically modifying the phosphate backbone or the 





Figure 1-9: A list of selected sugar, backbone and base modifications that have been 
incorporated into siRNAs.  Sugar modifications are highlighted in red.  Backbone modifications 






 The biodistribution of siRNAs represent another problem to siRNA therapy because once 
the foreign siRNA is in the circulatory system, the body will attempt to metabolize and clear the 




I show that siRNA distribution is highest within the kidneys and the liver of mice (see 
Figure 1-10; Braasch, et al., 2003).  One way in which the siRNA half-life can be enhanced 
within the bloodstream is through the incorporation of bioactive conjugates.  Cholesterol-
conjugated siRNAs have exhibited enhanced binding to serum lipoproteins and/or albumin 
resulting in longer circulation within the blood (Juliano, et al., 2009).  In addition to their 
enhanced biodistribution, these siRNAs retain their potency and have demonstrated their 
effectiveness on a wide variety of targets including apolipoprotein B and gene products 
associated with Huntington’s disease (Whitehead, et al., 2009).  Due to the success of 
cholesterol-modified siRNAs, Wolfrum, et al., explored the effects of other lipophilic moieties 
including long and short chain fatty acids on siRNA activity (Wolfrum, et al., 2007).  It was 
found that fatty acid chain lengths >C18 had a stronger binding affinity to HDL, thus enhancing 
their biodistribution, and were able to effectively induce mRNA silencing when compared to 
shorter chain fatty acids (Wolfrum, et al., 2007).  Another effective bioactive conjugate involves 
the introduction of vitamin E to the 5’-end of a 27/29-mer siRNA (Nishina, et al., 2008).  
Vitamin E is essential to all cell-types of the human body, cannot be synthesized, and is not toxic 
at high concentrations (Nishina, et al., 2008).  Therefore, vitamin E-siRNA conjugates have a 
driving force that pushes the siRNA into the cell (Nishina, et al., 2008).  Once delivered, Dicer 
cleaves the extra lengthened siRNA to a 21-mer and releases vitamin E so that the siRNA can be 





Figure 1-10: Selected siRNAs with bioactive conjugates that either help to improve the 
pharmacodynamic and/or pharmacokinetic properties of siRNAs or help to monitor their 
biodistribution (as in the case of the radiolabelled tyrosine derivative). 
1.8.3 Immune Activation 
Another hurdle for canonical siRNAs is the innate immune system and its many diverse 
defense mechanisms that have evolved to protect the body against foreign invaders.  In terms of 




receptor (TLR) mediated or (2) non-toll-like receptor (nonTLR) mediated.  Of the 13 different 
toll-like receptors identified in humans, TLR3, 7, and 8 have been identified as RNA sensing 
receptors (Robbins, et al., 2009).  TLR3 is found on the surface of certain cell types and within 
endosomal compartments, while TLR7 and 8 are found only within endosomal compartments 
(Robbins, et al., 2009).  TLR7 and 8 are phylogenically related and both recognize siRNA in a 
sequence-dependent manner, while TLR3 is primarily activated in a length-dependent manner 
(Robbins, et al., 2009).  Due to the fact that TLR3 is usually activated by dsRNAs longer than 
21-23 nts, the immunostimulatory effects of TLR7 and 8 have been more extensively 
investigated than TLR3 in immunological siRNA studies (Robbins, et al., 2009).  These three 
receptors are immunostimulatory due to the release of various types of interferons and cytokines 
upon activation (Robbins, et al., 2009).  One second generation chemical modification that has 
been shown to inhibit the stimulation of such TLRs and maintain potent siRNA activity, is the 
2’-OMe modification (Shukla, et al., 2010).  2’-OMe modifications protect siRNAs against 
TLR7 activation when placed on uridine or guanosine residues of highly immunostimulatory 
siRNAs by acting as competitive inhibitors against TLR7 (Shukla, et al., 2010).  The exact 
mechanism of recognition is unknown, but it is predicted that uracil and the 2’-OH group of the 
ribose sugar are major components involved in their activation (Shukla, et al., 2010).  Due to the 
fact that TLR7 and 8 are activated in a sequence-dependent manner, mainly GU and AU-rich 
motifs, base modifications within siRNAs have also been explored to evade TLR activation 
(Shukla, et al., 2010).  Some of the modifications that have been explored for protection against 
TLRs: include N6-methyladenosine and 2-thiouridine.  These modifications showed protection 
against TLR3, 7 and 8 with a decrease in immunostimulatory activity directly proportional to the 




In terms of nonTLRs, dsRNA-dependent protein kinase (PKR) and retinoic acid inducible 
protein (RIG-1) are two sequence-independent cytosolic proteins that induce interferon responses 
(Manche, et al., 1992; Marques, et al., 2006).  PKR can interact with dsRNA strands that are as 
short as 11 bases long (Manche, et al., 1992).  Crystallized structures of RNA bound PKR have 
shown that the 2’-OH group of the ribose sugar is recognized by the kinase (Nallagatla & 
Bevilacqua, 2008).  Elimination of this group and replacement with a 2’-deoxy modification 
hampers with PKR activation.  However, replacement of the 2’-OH group with a 2’-F 
modification still results in PKR activation because fluorine retains its ability to hydrogen bond 
with nearby protons within the active site of this enzyme (Nallagatla & Bevilacqua, 2008).  It is 
presumed that any modification that greatly hinders the ability for hydrogen bonding to take 
place with the 2’-OH group will reduced the activity of PKR (Nallagatla & Bevilacqua, 2008).  
RIG-1 binds to dsRNA in a length-dependent manner and increases in activity when the length 
of an siRNA increases from 21 to 27 nucleotides long (Manche, et al., 1992).  RIG-1 has evolved 
to combat viral RNAs and, therefore, has an affinity for uncapped 5’-triphosphates (Pichlmair, et 
al., 2006).  By capping siRNAs with a phosphate group or a 7-methylguanosine (m7G) analogue, 
siRNAs are equipped with protection against RIG-1 activation (Pichlmair, et al., 2006).   
1.8.4 Cellular Uptake 
 If the siRNA passes through the endothelial cells that line blood vessels, its next 
objective is to cross the cell membrane of a target cell.  Some major drawbacks of cellular uptake 
with siRNAs reside within their chemical makeup.  SiRNAs are relatively large in size, have a 
polyanionic backbone, and a high molecular weight when compared to small molecule 
pharmaceutical drugs (Bumcrot, et al., 2006).  Furthermore, siRNAs are extremely hydrophilic 




et al., 2006).  Due to the fact that the overall molecular weight and size of an siRNA cannot be 
significantly reduced, chemical modifications and bioactive conjugates can be incorporated into 
siRNAs to increase the likelihood of cellular internalization.   
Long chain spermine residues consisting of 30 repeated units connected to the 5’-end of 
siRNAs have been added in an attempt to convert the overall net charge of an siRNA from 
negative to positive (Perche, et al., 2013).  By doing so, the need for a cationic lipid carrier is 
eliminated and a driving force is created that pushes the modified siRNA into the negatively 
charged target tissue (Perche, et al., 2013).  Such siRNAs were effective at 10-100 nM and had 
low toxicity (Perche, et al., 2013).   
Another approach involves the conjugation of membrane permeant peptides (MPPs) to 
the 5’-end of the sense strand of an siRNA linked together by a disulfide bond (Muratovska & 
Eccles, 2004).  Two MPP-siRNAs that have been synthesized and tested for activity include: 
penetratin and transportan (Muratovska & Eccles, 2004).  These conjugated siRNAs are capable 
of transporting across the cell membrane in an energy-independent manner without the need for 
receptor-mediated uptake or endocytosis (Muratovska & Eccles, 2004).  In addition, the disulfide 
bond linking the MPP to the siRNA becomes reduced in the cytosol, thereby releasing the 
bioactive siRNA in its natural unmodified form to degrade mRNA (Muratovska & Eccles, 2004).   
A method that has been considered for the use of cell-type specific cellular uptake is the 
use of aptamer-siRNA chimeras (McNamara, et al., 2006).  Aptamer-siRNAs have an advantage 
over many proteins and antibodies because they are relatively small in size <15kD, have low 
immunogenicity, can be easily synthesized in large quantities, and are amenable to chemical 




Presently, an aptamer-siRNA chimera with an aptamer portion designed to bind to prostate-
specific membrane antigen (PSMA) has been successfully internalized by PSMA-expressing 
cells but not PSMA-negative cells (McNamara, et al., 2006).  Furthermore, these aptamer-
siRNAs were shown to have retained siRNA activity (McNamara, et al., 2006).    
1.8.5 Off-Target Effects 
 The final major limitation of siRNA therapy is “off-targeting,” which is the result of the 
siRNA participation in unwanted micro RNA (miRNA)-like pathways or the incorporation of the 
sense strand into the RISC complex (Shukla, et al., 2010).  Thorough bioinformatics analyses 
have revealed that nucleotides found within positions 2-8, counting from the 5’-end of the 
antisense strand, also known as the “seed region,” were important determinants of siRNA off-
targeting (Bumcrot, et al., 2006).  Once siRNAs are incorporated into the RISC complex to make 
active RISC, they have the ability to act as miRNAs and target the 3’-untranslated region (UTR) 
of non-target mRNA (Shukla, et al., 2010).  This activity is performed when there is high 
complementarity between the seed region of the antisense strand and the off-target (Shukla, et 
al., 2010).  Due to the fact that the seed region only consists of 7 nucleotides, and off-target 
effects can be detected even in the presence of up to two seed region mismatches, the chances of 
off-target binding are quite high (Shukla, et al., 2010).  To prevent off-target effects, 2’-OMe 
modifications have been incorporated into the 2
nd
 position from the 5’-end of the antisense strand 
(Jackson, et al., 2006).  It is hypothesized that this modification works by causing a 
conformational change in the PIWI domain of Argonaute 2, which causes inefficient cleavage of 
target strands possessing mismatches (Jackson, et al., 2006).  Therefore, 2’-OMe modified 




Off-target effects involving the miRNA pathway can also be regulated by lowering the 
Tm values of the duplex within the seed region (Somoza, et al., 2008).  By lowering the Tm value 
within the duplex, non-complementary off-target transcripts will have difficulty hybridizing to 
active RISC (Somoza, et al., 2008).  1’-(2,4-dichlorobenzyl)-ribonucleotide (rL) and 1’-(2,4-
difluoro-5-methyl-benzyl)-ribonucleotide (rF) modifications lack Watson-Crick pairing, which 
lowers the thermodynamic melting temperature of the duplex and leads to a reduction in off-
target effects (Somoza, et al., 2008).  The replacement of RNA with DNA in the seed region also 
decreases the Tm value of the duplex, and reduces miRNA related off-target effects (Ui-Tei, et 
al., 2008).   
Off-target effects can also be caused when the sense strand of an siRNA duplex is 
incorporated into the RISC complex rather than the antisense strand.  To overcome this obstacle, 
it is possible to promote antisense strand selection by choosing sequences that either destabilize 
the 3’-end of the sense strand or stabilize its 5’-end.  This can be performed by filling the 3’-end 
of the sense strand with AU rich residues and filling the 5’-end with GC rich residues.  
Alternatively, chemical modifications can also be used to alter the thermodynamic stability of an 
siRNA duplex, while at the same time providing the advantageous features offered by the unique 
chemical modification.  Destabilizing modifications include: OXE, UNA, dihydrouracil, or PS, 
while stabilizing modifications include: LNA, 2’-F and 2’-OMe (Bramsen & Kjems, 2012).  
Another way to promote antisense strand incorporation into the RISC complex is by cleaving the 
sense strand with a nick before duplex annealing to create an unstable small internally segmented 
interfering RNA (sisiRNA) (Watts, et al., 2008).  This strategy also employs the use of 
stabilizing LNA modifications placed within the sense stand because unmodified siRNAs would 




strategy, introduced by Dharmacon, employs the use of a library of uniquely sequenced siRNAs 
that target different regions within a particular transcript (Watts, et al., 2008).  Such a strategy is 
suspected to maintain efficient knockdown of a particular target while diluting any off-target 
effects (Watts, et al., 2008). 
1.9 SiRNA Carriers 
 Another way to overcome the aforementioned barriers is to encapsulate and deliver 
siRNAs using carriers, which are commonly divided into two different categories: viral and non-
viral vectors.  Many viral vectors that have been investigated thus far, including retroviral 
(Storvold, et al., 2007) and adeno-associated viruses (Tomar, et al., 2003), have the ability to 
integrate their genomic material into the recipient cell genome.  Therefore, the strategy for 
siRNA delivery using viral delivery vehicles varies from the traditional approach.  These 
approaches involve replacing endogenous viral genes required for viral replication with an 
exogenous sequence of interest that will ultimately result in the production of a short dsRNA 
containing a hairpin loop (Tomar, et al., 2003).  These small hairpin RNAs (shRNAs) are 
processed by Dicer into siRNAs, which enter into the RNAi pathway (Tomar, et al., 2003).  Due 
to the potential toxicities and random incorporation into the host genome, non-viral vehicles have 
become popular alternatives (Wang, et al., 2010).   
Many non-viral vectors complexed with siRNAs involve positively charged vectors such 
as cationic lipids, cationic polymers, cationic dendrimers, and cationic cell penetrating peptides.  
A cationic lipid carrier, such as N-(1-Aminoethyl) iminobis[N-(oleoylcysteinylhistinyl-1-
aminoethyl)propionamide] (EHCO), has multifunctional properties including two lipophilic tails, 
a protonatable amino head, and two cysteine residues (Kummitha, et al., 2012).  These groups 




facilitating endosomal release, due to the protonation of the amino head groups within an acidic 
environment, and allowing a quick release of the siRNA into the cytoplasm through the 
reduction of the disulfide bonds encapsulating the siRNA with glutathione (Kummitha, et al., 
2012).   
In terms of cationic polymers, poly(trehalose), with aminoethylmethacrylamide (AEMA) 
extensions, have been used to electrostatically bind with siRNAs and efficiently deliver their 
cargo into the cell (Sizovs, et al., 2013).  Upon delivery, poly(trehalose) is metabolized by 
trehalase enzymes into glucose (Sizovs, et al., 2013).  The quickly digested carrier results in near 
zero cytotoxicity at concentrations up to 10 mg/mL (Sizovs, et al., 2013).   
Dendrimers, which are synthetic macromolecules with a unique multivalence spread 
throughout multiple domains, constitute another form of drug delivery (Liu, et al., 2013).  
Dendrimers are composed of three domains: a central core, growing units that are repeated in a 
geometric fashion, and a large number of terminals on the outer surface (Liu, et al., 2013).  
Cationic poly(amidoamine) (PAMAM) dendrimers have been extensively used in siRNA 
delivery and function by bearing a positively charged amine functionality at the surface of the 
molecule for siRNA binding and holding tertiary amine groups within its core that promote the 
intracellular release of the siRNA when protonated in an endosomal compartment (Liu, et al., 
2013).   
Cationic cell penetrating peptides (CCPPs) present another method of delivering siRNA 
into a target cell (Asbeck, et al., 2013).  CCPPs are often cationic or amphipathic sequences of 
about 5-30 amino acids (i.e. lysine and arginine) that electrostatically bind to siRNAs and deliver 




disintegration of the nano complex due to polyanionic glycocalyx on the surface of the target cell 
whereby the siRNAs are released and undergo endocytosis to enter the cell and ultimately 
degrade mRNA (Asbeck, et al., 2013).  To date, it is not clear which type of carrier will prevail 
in clinical trials, but it is believed that a combination of both chemically modified siRNAs 
equipped with a delivery vehicle may offer the best delivery route for in vivo applications.  The 
diverse group of carriers that have been designed for siRNA therapy goes beyond the scope of 
this thesis and the remainder of this study will focus on the incorporation of chemical 
modifications into siRNAs to overcome the aforementioned barriers.    
1.10 Current Progress of siRNA Therapeutics 
There have been more than 30 clinical trials involving drugs such as siRNAs or shRNAs 
used to treat various types of diseases in a gene-sequence specific manner (Burnett, et al., 2011).  
Each drug that has reached clinical trials can be categorized according to their method of 
administration: ex vivo or in vivo (Burnett, et al., 2011)  Ex vivo treatments involve cells that are 
extracted from a patient, incubated with siRNA, and injected back into the patient (Burnett, et al., 
2011).  A present example of ex vivo administration involves a Phase I study with an siRNA 
designed to target inducible immunoproteasome subunits in monocytes to treat metastatic 
melanoma (Dannull, et al., 2007).  This treatment works by causing monocytes to differentiate 
into dendritic cells and enhancing melanoma antigen presentation by the treated cells (Dannull, 
et al., 2007).  Such a response results in cancerous cells that are attacked by the patient’s own 
immune system (Dannull, et al., 2007).   
In vivo administration of siRNAs, on the other hand, can be sub-divided into four 
different categories: intravenous, intravitreal, topical, or inhalation.  Most siRNA therapeutics 




currently testing the effects of siRNA-lipoplex against protein kinase N3 (PKN3) in an attempt to 
treat advanced solid cancers (Burnett, et al., 2011).  Intravitreal injections of siRNAs targeting 
VEGF A reached Phase I and II clinical trials for the treatment of age-related macular edema 
(AMD) (Burnett, et al., 2011).  However, Phase III clinical studies were terminated in March 
2009 due to the belief that such a treatment would not successfully reduce vision loss in AMD 
patients, despite being non-harmful and showing promising results in terms of biological activity 
(Burnett, et al., 2011).  SiRNAs that target beta-2 adrenergic receptor (ADRB2) on the ciliary 
epithelium have also been administered topically to treat glaucoma (Burnett, et al., 2011).  This 
drug works by reducing the production of aqueous humor to relieve ocular hypertension and is 
currently in Phase II clinical trials (Burnett et al., 2011).  SiRNAs have also been inhaled to treat 
asthma (Burnett, et al., 2011).  When the production of spleen tyrosine kinase (Syk) is 
downregulated by an siRNA therapeutic, the activation of several pro-inflammatory transcription 
factors is inhibited and thus the symptoms presented by asthma are alleviated (Burnett, et al., 
2011).  Most patients report an improvement of breathing after several days of inhaled siRNA 
therapeutics, which has pushed the drug into Phase II clinical trials (Burnett, et al., 2011).  Due 
to the fact that the discovery of RNA interference has only been known since 1998 and siRNAs 
have already reached clinical trials with numerous routes of administration and a wide variety of 
targets, the potential of siRNAs to be used as a therapeutic is evident.  
1.11 Click-modified siRNAs: A Background to Research Objectives 
 Although there is a wide range of chemical modifications that alter the properties of 
nucleic acids, the incorporation of triazole functional groups with click chemistry have become 
universal due to their ease of performance, tolerance to water and oxygen, and high yields with a 




the introduction of triazole functional groups within siRNAs, which either extend from 
nucleobases or sugar units or replace the phosphate backbone.   
In terms of chemically modified nucleobases, the click reaction enables: the introduction 
of base analogues for the analysis of structure/function relationships (Chittepu, et al., 2008), the 
tagging of flurophores to monitor molecular trafficking (Chittepu, et al., 2008; Gramlich, et al., 
2008), and the conjugation of bioactive molecules to enhance the properties of an siRNA 
(Willibald, et al., 2012).  Although less common, the click reaction has also been used to 
functionalize the 2’ and 3’ hydroxyl groups of the ribose sugar unit within siRNAs (Yamada, et 
al., 2011).  One example stems from the synthesis of 2’- and 3’-O-propargyl-5-methyl-uridine 
phosphoramidites followed by their incorporation into a nucleic acid from a solid support 
(Yamada, et al., 2011).  Once incorporated, the nucleic acids were functionalized with a triazole 
group using the click reaction with various small molecules each carrying a unique azido group 
to enhance the properties of an siRNA (Yamada, et al., 2011).   
1,2,3-Triazole functional groups have also been used to replace the labile phosphodiester 
linkages that  hold together the backbone of nucleic acids.  Such a modification is thought to 
enhance the cellular uptake properties of a native siRNAs by replacing the polyanionic structure 
of the phosphate backbone with a non-ionic site.  Triazole functional groups also have the ability 
to interact with proteins through hydrogen bonding with the N2 and N3 nitrogen atoms of the 
cyclic ring (Sharpless & Kolb, 2003).  With the lone pairs of N2 and N3 acting as hydrogen bond 
acceptors, triazole-linked siRNAs could interact with blood-serum proteins thereby increasing 
their half-life.  Site-specific triazole backbones that mimic a PNA-like scaffold have been shown 
to have enhanced resistance against ribonucleases (Efthymiou, et al., 2012), which could also 




of melting temperatures at site-specific locations within an siRNA duplex (Efthymiou, et al., 
2012).  By analyzing which site-specific areas of the duplex are stabilizing or destabilizing, 
favourable siRNA activity could be promoted by destabilizing the 5’-end of the antisense strand 
to increase the likelihood of its incorporation into the RISC complex. 
1.12 Research Objectives  
Due to the success and the marginal investigation of the triazole-linked backbone with a 
PNA-like scaffold, the purpose of this study was to further chemically modify the triazole-linked 
phosphoramidite building block (CtU dimer), reported by Efthymiou, et al., with various 
hydrophobic moieties in an attempt to further improve the overall hydrophobic character of an 
siRNA molecule (see Figure 1-11).  This was accomplished by utilizing the Sonogashira cross-
coupling reaction to incorporate either a hydrophobic phenylacetylene group or a hydrophobic 
cholesterol group at the C5 position of a uracil residue.  Cholesterol modifications have been 
extensively reported throughout the last decade due to their success in improving the properties 
of siRNAs regarding increased cellular uptake and increased biodistribution in in vivo 
experiments.  However, to the best of my knowledge, a method has not been developed to 
incorporate cholesterol within the internal region of an siRNA duplex.  By utilizing 
phosphoramidite chemistry with these novel CtU hydrophobic dimers, this approach allows for 
the site-specific incorporation of these modifications at any position within the duplex, while at 
the same time completely retaining the oligonucleotide target sequence.  Due to the fact that 
cholesterol was being added to an already highly modified CtU dimer, it was difficult to predict 
whether or not the modified siRNAs would retain their activity.  For this reason, a 
phenylacetylene group, which has a structure significantly smaller than the large hydrophobic 




to improve the overall hydrophobicity of an siRNA molecule, while at the same time not 
significantly deviating from the functionally active triazole-linked siRNAs.  Therefore, the goal 
of this study was to characterize novel phosphoramidite molecules featuring a non-ionic triazole-
linked backbone with a hydrophobic moiety and to evaluate the effects of these modifications on 
an siRNA molecule within the RNAi pathway.   
There were four steps that were taken in order to accomplish this goal:  
1) The phosphoramidites and all of the intermediate compounds, leading to their 




C NMR and ESI-HRMS in order to ensure 
the successfulness of each individual reaction. 
2) The phosphoramidites were incorporated into an oligonucleotide at site-specific 
locations through the use of solid-phase RNA phosphoramidite chemistry.  The chemically 
modified oligonucleotides were then characterized through ESI Q-TOF MS analysis to ensure 
their successful incorporation, and to ensure that all protecting groups on the phosphoramidite 
building blocks were successfully removed. 
3)  The modified siRNA duplexes were characterized by circular dichroism and UV-
monitored thermal denaturation to determine the overall secondary structure of the siRNA 
duplexes and their stabilities, respectively.  These biophysical measurements were performed in 
order to better understand the behaviour of the siRNA constructs within cell-based assays. 
4) The siRNAs were evaluated for biological activity against exogenous target, firefly 
luciferase, using the Dual-Luciferase Reporter Assay, and endogenous target BCL-2, using RT-
qPCR.  These cell-based assays were performed to investigate the effect of the site-specific 




hydrophobic substituents on siRNA activity within a biological system, and to better understand 
the structure-function relationships of these constructs within the RISC complex. 
 
Figure 1-11: A comparison between the CtU triazole-linked phosphoramidite dimer synthesized 




 triazole-linked phosphoramidite dimers synthesized 





triazole-linked phosphoramidite dimers.  Where “Ph” represents phenylacetylene as the R group 





Chapter 2: The Synthesis of Novel Triazole-Linked Phosphoramidite Dimers and Their 
Site-Specific Incorporation into Oligonucleotides 
2.1 Introduction 





 phosphoramidites.  The intermediate compounds of each individual reaction, leading to 




C NMR and ESI-HRMS.  These 
phosphoramidites were then incorporated into oligonucleotides, to ultimately generate a library 
of novel siRNA constructs. 
2.1.1 Biological Synthesis of Oligonucleotides 
 The need to generate oligonucleotides goes beyond the scope of short interfering RNAs 
and extends to primers, DNA chip arrays, and antiviral medications.  For these reasons, it is not 
surprising that scientists have worked to develop efficient practical methods for synthesizing 
oligonucleotides in a sequence-specific manner.  In nature, DNA and RNA oligonucleotide 
chains are synthesized enzymatically by DNA polymerase and RNA polymerase, respectively.  
These types of enzymatic syntheses require a template, primers, and nucleotide triphosphates 
(Rothwell & Waksman, 2005).  A template and specific primers are required so that the nucleic 
acid is synthesized in a sequence-dependent manner, while nucleotide triphosphates are the 
building blocks used for chain elongation (Rothwell & Waksman, 2005).  DNA/RNA 
polymerases link nucleotides together by guiding the 3’-OH group of one nucleotide triphosphate 
to attack an incoming α-phosphorus atom of another nucleotide triphosphate (Rothwell & 
Waksman, 2005).  As this cycle is repeated multiple times, the oligonucleotide grows from the 




from the newly synthesized polymer (Rothwell & Waksman, 2005).  An enzymatically-driven 
synthesis is useful in generating long nucleic acid transcripts; however, NTPs and the appropriate 
enzymes are expensive, short sequences cannot be generated, and only traditional DNA or RNA 
can be made.  These drawbacks brought forth the development of solid-phase synthesis; a way of 
chemically synthesizing nucleic acids. 
2.1.2 Dissecting the Phosphoramidite Monomer: The Building Block for Chemical 
Oligonucleotide Synthesis 
 The chemical synthesis of an oligonucleotide offers many advantages over an 
enzymatically driven synthesis.  By chemically synthesizing an oligonucleotide, it is possible to 
add interesting chemical modifications or tags within a sequence, build oligonucleotides in high 
yields with excellent purity, and make short sequences with an automated instrument.  One 
common method that is utilized in many laboratories is the coupling of commercially available 
phosphoramidite monomers from a solid-support (see Figure 2-1).   
Phosphoramidite monomers are ideal building blocks for oligonucleotide synthesis 
because they maintain the parent structure of a natural nucleotide and have a 5’-OH group that 
can react at the phosphorus center of an incoming phosphoramidite (Russell, et al., 2008).  These 
monomers are equipped with protecting groups to avoid side reactions during the growth of an 
oligonucleotide.  One protecting group that is added to the phosphoramidite monomer is the 
DMT group.  This protecting group is specifically added for several reasons (Marshall & Kaiser, 
2004).  First, the structure of a DMT group is quite large and bulky, which makes it protect 
primary alcohols over the more hindered secondary alcohols of the ribose sugar (Marshall & 




force to remove the DMT group and yield a stable positively charged species under mildly acidic 
conditions.  Other alcohol protecting groups that require stronger acids for their removal face the 
problem of depurination.  Lastly, the DMT carbocation is highly conjugated and appears orange 
in colour (Marshall & Kaiser, 2004).  Qualitative and quantitative measurements can be taken 
and compared to the by-product of the previous step in the phosphoramidite cycle to monitor the 
coupling efficiency of each individually added phosphoramidite.   
The phosphite moiety is also equipped with two special groups each with unique 
properties (Russell, et al., 2008).  The 2’-cyanotheyl group prevents undesirable reactions from 
occurring at the phosphorus atom during oligonucleotide synthesis.  This group is easily removed 
at the end of the synthesis under basic conditions due to the highly acidic protons next to the 
cyano-group.  The diisopropylamino group is a good leaving group under acidic conditions, 
thereby allowing facile substitution with an incoming nucleophile.  This helps to promote high 
yielding coupling reactions.   
The exocyclic amino groups of cytosine, guanine and adenine are generally protected 
with benzoyl or isobutyryl groups to avoid their nucleophilic attack on any incoming 
phosphoramidite monomers.  These groups are not acid-labile and remain protected during the 
entire chain assembly until the end of the synthesis where they are removed under basic 
conditions.  Uracil does not have an exocyclic amino group and does not require protection.   
Lastly, an unprotected 2’-OH group would cause sequence truncation or phosphate 
migration under the basic conditions that are necessary for exocyclic amine deprotection and 
cleavage from the solid support.  The most common 2’-OH protecting group is tert-




under acidic conditions and TBDMS-protected phosphoramidites give high coupling yields at a 
reasonable price. 
 
Figure 2-1: A phosphoramidite monomer and a dissection of all of its protecting groups required 
for its utilization in chemical oligonucleotide synthesis.  (A) The structure of a phosphoramidite 
monomer.  (B) The individual components of a phosphoramidite building block. 
2.1.3 Solid Supports Used for Solid-Phase Synthesis 
 The chemical synthesis of most oligonucleotides begins on a solid-phase support 
consisting of a controlled pore glass (CPG).  The CPG beads contain deep pores (typically 500 Å 
for the synthesis of short oligonucleotides) where oligonucleotide synthesis takes place.  These 
types of beads are bound to long chain alkylamino (lcaa) groups and are reacted with succinic 
anhydride to yield a succinylamido-bound CPG.  The succinylamido-support is subsequently 
reacted with a DMT-protected thymidine residue (in the case of a dT-CPG column) or a pre-
synthesized carbomoylation linker (in the case of a universal column) to yield a solid-phase 
support that can be utilized for oligonucleotide synthesis (see Figure 2-2).  For the generation of 
oligonucleotides that were modified internally or on the 5’-end, dT-CPG columns were used 




ribonuclease resistance of siRNAs (Elbashir, et al., 2001).  Universal columns were used to 
generate oligonucleotides whose 3’-ends were modified because these beads were made in the 
absence of a pre-attached base.  In addition to the standard dT-CPG and Universal columns, a 
commercially available 3’-cholesteryl-triethylene glycol (TEG) CPG was purchased from Glen 
Research (Sterling Virginia) so that the activity of all novel cholesterol-containing siRNAs could 
be compared to a commercially available product.  In all of the above cases, solid-phase 
synthesis is completed by undergoing multiple rounds of phosphoramidite coupling cycles on a 
DNA/RNA synthesizer until the final oligonucleotide of specific length and sequence is 
generated. 
 
Figure 2-2: A diagrammatic representation of all of the solid-phase supports that were used in 
this study.  (A) The dT-CPG column was used to incorporate chemical modifications internally 
or at the 5’-end of an oligonucleotide.  (B) The Universal-CPG column was used to incorporate 




column was used to synthesize sequences with a commercially available cholesterol modification 
at the 3’-end of an oligonucleotide. 
2.1.4 The Phosphoramidite Coupling Cycle 
 The phosphoramidite coupling cycle consists of four basic steps that are repeated until an 
oligonucleotide of a specific length and sequence are reached.  These steps are commonly known 
as deprotection, coupling, capping, and oxidation (see Figure 2-3).  They are carried out in this 
order 
Step #1: Deprotection 
 A solid-support is initially inert because the reactive primary alcohol groups are DMT-
protected.  In order for the protected primary alcohol to couple to an incoming 3’-
phosphoramidite, the acid-labile DMT-group must be removed (Roy & Caruthers, 2013).  This is 
accomplished using trichloroacetic acid (Roy & Caruthers, 2013).  Upon removal, the column is 
washed to get rid of any remaining by-products and extra acid.  Once flushed, the exposed 
alcohol is now ready to react with an incoming 3’-phosphoramidite building block.  The 
resulting DMT carbocation by-product can also be collected and quantified so that the efficiency 
of the reaction can be monitored at the beginning of each cycle. 
Step #2: Coupling 
 Before coupling two nucleobases together, the 3’-phosphoramidite must be activated with 
protonated tetrazole (Roy & Caruthers, 2013).  Tetrazole has an acidic proton (pKa = 4.9), which 
is deprotonated by the tertiary isopropylamine group of the 3’-phosphoramidite (Russell, et al., 
2008) but cannot be deprotonated by the DMT protecting group.  Upon protonation, the 




displace the cationic diisopropylamine group (Russell, et al., 2008).  The newly activated 3’-
phosphoramidite, with a very good leaving group, is then presented to the primary alcohol on the 
solid support and the two nucelobases are coupled together (Roy & Caruthers, 2013).  The 
column is then flushed to remove any unreacted tetrazole and by-products. 
Step #3: Capping 
 Although the coupling efficiency is quite high, there are remaining alcohol groups that 
did not successfully react with the incoming 3’-phosphoramidite.  To prevent these nucleophiles 
from reacting with any successive nucleobases, the column is flushed with an acetic anhydride 
solution (Roy & Caruthers, 2013).  This step stops the generation of mixed sequences and 
enhances the purity of the final polymerized product (Roy & Caruthers, 2013).  Once the 
unreacted hydroxyl groups are “capped” by acetylation, the column is washed to remove any 
acetic anhydride residues.   
Step #4: Oxidation 
 The coupled 3’-phosphoramidite, with its unstable phosphite group, is then oxidized with 
a solution of I2, water and pyridine.  I2 acts as a Lewis acid and donates iodine to the phosphite 
group of the coupled 3’-phosphoramidite giving the electrophilic phosphorus atom a positive 
charge.  Water (pKa = 15.7) is then deprotonated by pyridine to make a hydroxide ion, which 
attacks the positively charged phosphorus atom.  The intermediate species in then deprotonated 
with excess pyridine, resulting in a coupled dimer with a phosphotriester backbone that can 





Figure 2-3: The phosphoramidite coupling cycle on a dT-CPG column.  The first step of this 
cycle involves DMT removal of a primary alcohol with trichloroacetic acid.  The second step 
involves the activation of an incoming phosphoramidite with tetrazole, followed by a coupling 
reaction between the activated phosphoramidite and the bound nucleobase.  The next step is 
performed to prevent any unreacted 5’-OH groups attached to the solid support from reacting 
with future phosphoramidites as the cycle repeats.  This is accomplished by protecting the 
primary alcohol with an acetate group using acetic anhydride.  The last step involves the 
oxidation of the phosphite group to a phosphate group using I2, H2O, and pyridine.  At this point 
the cycle can either continue or the oligonucleotide can be removed from the solid support using 




  Once the oligonucleotide has undergone multiple rounds of the phosphoramidite coupling 
cycle and the sequence is complete, it must be cleaved and deprotected to yield the final desired 
oligonucleotide (Roy & Caruthers, 2013).  To remove the strand from the solid support, the 
column is treated with concentrated ammonium hydroxide (Roy & Caruthers, 2013).  In the 
process, all of the nucleobase exocyclic amines are deprotected and the β-cyanoethyl protecting 
groups are removed to generate a phosphate backbone (Roy & Caruthers, 2013).  The resulting 
2’-O-TBDMS-protected oligonucleotides are then deprotected in the presence of a fluoride ion-
labile reagent such as tetrabutylammonium fluoride (TBAF) or HF. 
2.1.5 Alternative Protecting Group Strategies 
 Despite the fact that the TBDMS protecting group is the most commonly used 2’-OH 
protecting group for RNA synthesis, it has some drawbacks.  For instance, this group is 
sometimes removed under basic conditions required for cleavage from the solid support.  In such 
a case, the resulting hydroxyl group is likely to be deprotonated and attack the adjacent 
phosphate group to give a 2’, 3’-cyclic phosphodiester truncated product (Muller, et al., 2004).  
Alternatively, the attack could also result in a 3’ to 2’ phosphate migration, also yielding an 
undesired product.  To circumvent these problems, other protecting groups, including 2’-O-
Triisopropylsilyloxymethyl (TOM) and bis(acetoxyethoxy)orthoformate (ACE) have been 
introduced into phosphoramidites (see Figure 2-4).  The TOM protecting group increases the 
efficiency of the coupling reaction because it has an added acetal group, which pushes the 
protecting group away from the coupling site (Pitsch, et al., 2001).  This acetal group also 




 When ACE protecting groups are used to protect the 2’-OH group, the 5’-OH groups are 
protected with silyl ether groups rather than a DMT group.  The ACE protecting groups are 
compatible with the conditions required for chemical oligonucleotide synthesis and are 
advantageous to the traditional TBDMS approach because RNA can be purified with the 
protecting groups still bound to the 2’-OH group.  This approach prevents RNA degradation by 
RNase enzymes during purification (Hartsel, et al., 2005) and is commonly used by industries 
such as IDT and Alnylam Pharmaceuticals.  These alternative protecting groups have many 
advantages over the commonly used TBDMS protecting; however, TBDMS-protected 
phosphoramidites generally give high yielding reactions (typically 95-99%) and are cheaper.  For 
these reasons, the monomers that were used in this study were the commercially available 2’-
protected TBDMS phosphoramidites. 
 
Figure 2-4: Alternative 2’-OH protecting groups used to chemically synthesize oligonucleotides. 
(A)  A 2’-TBDMS-protected phosphoramidite with a uracil base.  (B) A 2’-TOM-protected 
phosphoramidite with a uracil base.  (C) A 2’-ACE-protected phosphoramidite with a uracil 
base.  With an ACE protecting group, the 5’-OH group is silyl-protected rather than DMT-










 Taking what is known about the phosphoramidite coupling cycle described in Section 
2.1.4, it is clear that any molecule can be incorporated into a chemically synthesized 
oligonucleotide as long as it is equipped with a phosphoramidite group so that it can be added to 
the growing chain and a DMT-protected alcohol group so that the chain can be elongated.  In 
addition, all other reactive functional groups must be protected to avoid by-product formation.  





) phosphoramidites were synthesized so that they could be incorporated into 
oligonucleotides.  The strategy for synthesizing these compounds was to first build a library of 
modified pyrimidine bases (Scheme 2-1).  In order to incorporate the cytosine and uracil bases 
into the triazole-linked phosphoramidite, N
1
-substituted acetic acids of the bases were 
synthesized.  For the synthesis of of 5’-iodouracil-1-yl acetic acid (3), uracil was halogenated at 
the C5 position with iodine monochloride to make iodouracil (2).  Iodouracil was then alkylated 
at the N1 position with bromoacetic acid in aqueous sodium hydroxide.  Upon completion, the 
pH was lowered and the precipitated product (3) was collected.  Cytosine was modified by 
alkylating the N1 position with methyl bromoacetate in the presence of NaH to give 5.  The 
exocyclic amine of this intermediate was protected with benzoylchloride and was saponified with 





Scheme 2-1: A general scheme for the preparation of 5’-iodouracil-1-yl acetic acid (3) from 
uracil and (N
4
-(benzoyl)cytosine-1-yl)acetic acid (6) from cytosine. 
Next, a library of alkyne and azide linkers was synthesized to make the parent structure 
of the triazole phosphoramidite backbone (Scheme 2-2).  The alkyne linker (9) was generated by 
protecting ethanolamine with a TBS-protecting group to give intermediate 8.  This intermediate 
was reacted with limiting amounts of propargyl bromide to give 9.   
The azide linker (14) was synthesized by linking together the products of two 
independent reactions.  Compound 11 was synthesized by reacting sodium azide with 
bromoethanamine.  Compound 13 was created by subjecting 2-bromoethanol to TBS-Cl.  These 
compounds were linked together in the presence of N, N-diisopropylethylamine (DIPEA) to yield 





Scheme 2-2: A general scheme for the preparation of alkyne linker (9) and azide linker (14). 
The alkyne linker (9) was then coupled to 5’-iodouracil-1-yl acetic acid (3) with N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC·HCl) to generate the alkyne 
monomer (15) (Scheme 2-3).  The azide linker (14) was coupled to (N
4
-(benzoyl)cytosine-1-
yl)acetic acid (6) with EDC·HCl to generate the azide monomer (16).  This azide monomer was 
then TBS deprotected with 3HF/TEA to yield 17.   Intermediate compound 17 was reacted with 
DMT-chloride to give the DMT-protected azide monomer (18), which now held one of the two 





Scheme 2-3: A general scheme for the preparation of alkyne monomer (15) and azide monomer 
(18). 
Next, the two monomers (15 and 18) were coupled together using the copper-catalyzed 
click reaction to make a cytosine-triazole-uracil-iodine (CtU
I
) dimer (19) (Scheme 2-4).  The 
halogen of compound 18 was displaced with phenylacetylene utilizing the Sonogashira reaction 
to give 20.  The TBS-group of 20 was removed with TBAF to yield 21.  This intermediate was 
phosphitylated with cyanoethyl diisopropylphosphoramidochloridite in the presence of 4-
(dimethylamino)pyridine (DMAP) and DIPEA to yield the CtU
Ph







Scheme 2-4: A general scheme for the preparation of the cytosine-triazole-uracil-
phenylacetylene phosphoramidite (22). 
 The synthesis of the CtU
Ch
 phosphoramidite (27) was synthesized in a similar fashion 
(Scheme 2-5).  To generate propargyl cholesterol (24), a substrate for the Sonogashira reaction, 
propargyl bromide was added to cholesterol in the presence of NaH.  Propargyl cholesterol (24) 
was then added to compound 19 and the Sonogashira reaction was performed to give 25.  The 
TBS-protected alcohol of compound 25 was deprotected with TBAF to yield 26.  This 
intermediate was phosphitylated with cyanoethyl diisopropylphosphoramidochloridite in the 
presence of DMAP and DIPEA to yield the CtU
Ch





Scheme 2-5: A general scheme for the preparation of the cytosine-triazole-uracil-cholesterol 
phosphoramidite (27). 
 The strategy for the aforementioned synthesis was to use already published high yielding 




developing methodology for new reactions has little value, as the end goal is to generate 
sufficient quantities of final phosphoramidite in order to investigate the properties of a wide 
range of uniquely-modified siRNAs.  If the modified siRNAs showed promising biological 





 phosphoramidites and optimize individual lower yielding reactions or attempt to make 
a shorter synthetic scheme. 
2.2 Experimental Procedures 
2.2.1 Synthesis of CtUPh and CtUCh Phosphoramidites 
 Unless otherwise noted, all starting materials that were used were obtained from 
commercial sources and without any additional purification.  Anhydrous CH2Cl2, tetrahydrofuran 
(THF), and N, N-dimethylformamide (DMF) were purchased from Sigma-Aldrich and degassed 
by stirring under a dry N2 atmosphere.  Flash column chromatography was performed with 
Silicycle Siliaflash 60 (230-400 mesh) according to the procedure of Still, Kahn, and Mitra (Still, 
et al., 1979).  NMRs were performed on a Varian 400 MHz spectrometer.  All 
1
H NMRs were 
recorded for either 32 or 64 transients at 400 MHz, all 
13
C NMRs were typically run overnight 
for 20k to 50k transients at 100 MHz and all 
31
P NMRs were recorded for 256 transients at 167 
MHz.  Spectra were processed and integrated using ACD/NMR Processor Academic Edition.  
1
H 
NMR peaks were referenced to 7.27 ppm for experiments performed in CDCl3 or 2.50 ppm for 
experiments performed in d6-dimethylsulfoxide (DMSO).  
13
C NMR peaks were referenced to 
77.00 for experiments performed in CDCl3 or 39.51 for experiments performed in d6-DMSO.  
ESI-HRMS were recorded on an Agilent Q-TOF and all novel compounds were analyzed 
through positive or negative electrospray ionization using a mobile phase of acetonitrile/MeOH 




5, 6, 8, 9, 11, 13, 14, 17 and 18 have been reported by Efthymiou and colleagues (Efthymiou, et 
al., 2012).  The experimental procedure used to synthesize propargyl cholesterol has been 
reported by Philippe and Gulhem (Philippe & Gulhem, 2009) and NMR data has been reported 
by Ohkubo and colleagues (Ohkubo, et al., 2007). 
5-Iodopyrimidine-2,4(1H,3H)-dione (2): 
 
 Iodine monochloride (40 g, 0.25 mol) was added to a stirred suspension of 1 (13.8 g, 0.12 
mol) in 146 mL of MeOH and this solution was heated in a warm sand bath to 50°C.  The 
progress of the reaction was monitored by TLC using 10% MeOH in CH2Cl2 as a mobile phase.  
After 8.5 hours, TLC analysis revealed that the starting material (1) was consumed and the newly 
formed product 2 (Rf = 0.45) had an increase in Rf.  The mixture was vacuum filtered and the 
crystals were washed with ice cold Et2O to remove trace amounts of iodine monochloride.  The 
filtrate was chilled in a freezer overnight and a second crop was collected on the following 
morning by re-filtering the filtrate and washing any remaining crystals with ice cold Et2O.  The 






2-(5-Iodo-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetic acid (3): 
 
Pelleted NaOH (11.50 g, 288 mmol) was dissolved in 50 mL of H2O to make an alkaline 
solution.  Once the pellets completely dissolved, compound 2 (17.84g, 75 mmol) was added to 
the solution and this solution was heated in a sand bath set to 45°C.  In a separate flask, 
bromoacetic acid (15.63 g, 112.5 mmol) was dissolved in 25 mL of H2O and added to the 
reaction vessel over a period of 30 minutes.  The progress of the reaction was monitored by TLC 
using 50% MeOH in CH2Cl2 as a mobile phase.  After 4.5 hours, 5-iodouracil was consumed and 
the newly formed product (3) (Rf = 0.39) was retarded in mobility due to the highly polar 
carboxylic acid functional group.  Upon completion, the reaction vessel was allowed to cool to 
room temperature and the pH was adjusted to 5.5 with concentrated HCl.  The solution was then 
cooled in a freezer for 2 hours and any precipitate (unreacted 5-iodouracil) was removed through 
vacuum filtration.  To precipitate the product, the pH of the filtrate was adjusted to 2 with 
concentrated HCl and placed back in a freezer overnight.  On the following day the frozen 
filtrate was removed from the freezer, left to thaw and the precipitate was collected through 
vacuum filtration.  The final product (3) was left to air dry for 24 hours and yielded a white 
powder (10.21 g, 46%). 
1
H NMR (500 MHz, (CD3)2SO) δ 4.41 (s, 2H), 8.19 (s, 1H), 11.71 (s, 
1H), 13.19 (br s, 1H); 
13
C NMR (125 MHz, (CD3)2SO) δ 48.63, 68.04, 150.28, 150.71, 161.10, 
169.37; ESI-HRMS (ES
-
) m/z calcd for [C6H5IN2O4 - H]
-









Compound 3 (4.00 g, 13.5 mmol) was dissolved in 100 mL of anhydrous DMF under a 
dry nitrogen atmosphere.  Once dissolved, the reaction mixture was placed in a 4°C ice bath and 
compound 9 (2.42 g, 12.1 mmol) and EDC·HCl (5.18 g, 27.0 mmol) were both quickly added to 
the vessel.  The reaction mixture stirred for 30 minutes while submerged in a 4°C ice bath 
followed by another 24 hours at room temperature.  On the following day, TLC analysis showed 
a newly formed UV active product (15) (Rf = 0.51) with a migratory rate slightly slower than 9 
using 1:1 (v/v) EtOAc/hexanes as a mobile phase.  Upon completion, a liquid-liquid extraction 
was performed using EtOAc and this organic layer was washed with brine (x3) to remove any 
unreacted EDC·HCl.  The organic fraction was dried with Na2SO4 and concentrated in vacuo to 
afford a thick oil.  The oil was purified using flash column chromatography with a step gradient 
of hexanes/EtOAc (7:3 v/v, then 6:4 v/v, then 5:5 v/v, then 3:7 v/v, then 100% EtOAc) to afford 
compound 15 as an off-white powder (4.06 g, 61%).  Compound 15 is a pair of rotamers; 
wherever possible, the signals to the major (ma.) and minor (mi.) rotamers are designated; 
1
H 
NMR (500 MHz, CDCl3) δ 0.06 (s, 2H, mi.), 0.10 (s, 4H, ma.), 0.89 (s, 3H, mi.), 0.92 (s, 6H, 
ma.), 2.27 (t, 0.66H, J = 2.5 Hz, ma.), 2.43 (t, 0.33H, mi.), 3.60 (t, 0.6H, J = 5.5 Hz, mi.), 3.65 (t, 




2H), 4.69 (s, 0.6H, mi.), 4.71 (s, 1.4H, ma.), 7.58 (s, 0.66H, ma.), 7.61 (s, 0.33H, mi.); 
13
C NMR 
(125 MHz, CDCl3) δ -5.48, -5.43, 18.31, 25.85, 25.90, 35.23, 48.26, 48.78, 60.54, 67.70, 72.85, 
73.78, 78.03, 149.51, 150.52, 160.22, 166.31; ESI-HRMS (ES
+
) m/z calcd for [C17H26IN3O4Si + 
H]
+








 To a solution of compound 15 (0.85 g, 1.72 mmol) and 18 (1.14 g, 1.62 mmol) dissolved 
in 70 mL of THF/H2O (3:2) was added (+)-sodium L-ascorbate (0.52 g, 2.6 mmol) and copper(II) 
sulfate pentahydrate (0.22 g, 880 µmol).  The resulting mixture was left to stir for 6 hours and 
the progress of the reaction was monitored by TLC using 5% MeOH in CH2Cl2 as a mobile 
phase.  TLC analysis indicated the consumption of 18 and a newly formed product 19 (Rf = 0.48) 
of lower Rf than either starting materials.  When the reaction was complete the product was 
extracted with EtOAc and this organic layer was washed with H2O (x3) to remove any excess 




The resulting oil was purified by flash column chromatography using a step gradient of MeOH 
(2%, 3.5% and 5%) in CH2Cl2 to afford the title compound 19 as a white solid (1.34 g, 70%).  
Compound 19 is a mixture of slowly-exchanging rotamers; 
1
H NMR (500 MHz, CDCl3) δ 0.02 
(s, 2H), 0.07 (s, 4H), 0.86 (s, 3H), 0.89 (s, 6H), 2.97 (m, 1.5H), 3.07 (m, 0.5 H), 3.17-3.28 (m, 
2H), 3.39 (m, 0.5H), 3.45-3.54 (m, 2H), 3.55-3.64 (m, 2H), 3.72 (m, 2H,), 3.78 (s, 1.5H), 3.81 (s, 
4.5H), 4.5 (m, 1.5H), 4.56 (m, 1H), 4.64 (m, 1H), 4.72 (m, 2.5H,) 4.79 (s, 1H), 4.91 (s, 1H), 
6.79-6.81 (m, 1H), 6.84 (d, 3H, J = 8.6 Hz), 7.18-7.26 (m, 5H), 7.31 (m, 4H), 7.49 (t, 2.5H, J = 
7.4), 7.56-7.61 (m, 1.5H), 7.68 (s, 0.33H), 7.73 (s, 0.66H), 7.84 (s, 1H), 7.88 (s, 0.5H), 7.99 (d, 
2H, J = 7.4 Hz), 8.1 (m, 0.5H), 9.84 (br s, 2H); 
13
C NMR (125 MHz, CDCl3) δ -5.45, -5.43, 
18.10, 18.29, 25.82, 25.90, 30.86, 40.85, 41.95, 47.58, 48.15, 49.00, 49.09, 51.05, 55.24, 60.61, 
60.74, 67.40, 77.21, 87.30, 87.37, 113.06, 113.11, 113.26, 127.22, 127.74, 127.81, 127.94, 
127.98, 128.02, 128.14, 128.31, 128.40, 128.65, 128.77, 128.81, 129.07, 129.91, 130.09, 132. 84, 
133.07, 135.04, 135.81, 144.11, 144.13, 150.03, 150.36, 150.68, 150.76, 158.71, 160.90, 166.25, 
167.08, 167.41, 167.59; ESI-HRMS (ES
+
) m/z calcd for [C55H63IN10O10Si + H]
+
: 1179.3615, 
found 1179.3597 [M + H]
+
; for [C55H63IN10O10Si + Na]
+












A 0.13 M solution of 19 (300 mg, 0.254 mmol) in dry DMF was flushed with nitrogen 
gas and treated with tetrakis(triphenylphosphine)palladium(0) (29.4 mg, 0.025 mmol), copper(I) 
iodide (9.69 mg, 0.051 mmol), triethylamine (TEA) (70.97 µL, 0.509 mmol) and 
phenylacetylene (139.70 µL, 1.27 mmol) in that order.  The resulting reaction mixture was then 
stirred at room temperature for 72 hours.   TLC analysis indicated that the title compound 20 (Rf 
= 0.53) had a faster migration rate than the starting material 19 (Rf = 0.48) using 5% MeOH in 
CH2Cl2 as a mobile phase.  The title compound 20 was easily distinguished from the starting 
material 19 due to a long UV wavelength active property inherited by the newly formed 
conjugated system between phenylacetylene and the pyridine ring.  Upon completion, the crude 
sample was concentrated in vacuo and loaded directly onto a column for purification.  The 
product was purified with a step gradient of 100% CH2Cl2 1% MeOH in CH2Cl2  2.5% 
MeOH in CH2Cl2  4% MeOH in CH2Cl2  6% MeOH in CH2Cl2 to afford a light-yellow 
solid (261 mg, 89%). Compound 20 is a mixture of slowly exchanging rotamers; 
1
H NMR (500 
MHz, CDCl3) δ 0.04 (s, 2H), 0.10 (s, 4H), 0.88 (s, 3H), 0.91 (s, 6H), 2.98 (m, 1.5H), 3.08 (m, 
0.5H), 3.21 (m, 1.5H), 3.24 (0.5H), 3.49 (m, 0.5H), 3.51-3.56 (m, 1.5H), 3.62 (m, 1.5H), 3.76 
(m, 3H), 3.79 (s, 1.5H), 3.80 (s, 4.5H), 4.52 (t, 1.5H, J = 4.9 Hz), 4.58 (br s, 1H), 4.61-4.67 (m, 




= 2.7 Hz), 7.23-7.26 (m, 2H), 7.31(d, 5H, J = 3.1 Hz), 7.36 (m, 0.5H), 7.38 (m, 0.5H), 7.46 (t, 
3H, J = 7.8 Hz), 7.51-7.61 (m, 2H), 7.77 (br s, 1H), 7.85-7.94 (m, 2.5H), 8.06 (m, 0.5H) 9.29 (br 
s, 2H); 
13
C NMR (125 MHz, CDCl3) δ -5.40, 18.16, 18.38, 25.87, 25.97, 29.67, 36.45, 41.85, 
47.68, 48.33, 49.17, 49.31, 51.13, 55.23, 55.28, 60.71, 77.21, 80.53, 87.32, 93.51, 99.44, 113.16, 
113.29, 122.54, 122.59, 124.85, 125.14, 127.25, 127.77, 128.01, 128.13, 128.16, 128.18, 128.24, 
128.34, 128.52, 128.62, 128.83, 129.96, 130.12, 131.42, 131.45, 131.53, 133.05, 135.10, 135.86, 
143.40, 144.13, 144.18, 144.27, 148.74, 149.89, 158.44, 158.76, 162.04, 162.49, 163.19, 166.04, 
167.08, 167.51, 167.67, 178.52, 185.81; ESI-HRMS (ES
+
) m/z calcd for [C63H68N10O10Si + H]
+
: 








To a solution of compound 20 (43.56 mg, 0.378 mmol) dissolved in 10 mL of THF was 
added a 1.0 M solution of TBAF in THF (0.55 mL, 0.0552 mmol) and the reaction mixture was 




phase, the newly formed product 21 (Rf = 0.21) had a slower migration rate when compared to 
the starting material 20 (Rf = 0.53) due to the regeneration of the hydroxyl functional group.  
After 3 hours, THF was evaporated under reduced pressure to concentrate the crude product.  
The crude product was purified by flash column chromatography using a step gradient of 100% 
CH2Cl2, then 2% MeOH in CH2Cl2, then 4% MeOH in CH2Cl2, then 6% MeOH in CH2Cl2, then 
8% MeOH in CH2Cl2 to yield 21 as a light-yellow solid (250 mg, 64%).  Compound 21 is a 
mixture of slowly exchanging rotamers;  
1
H NMR (500 MHz, CDCl3) δ 3.03 (m, 1.5H), 3.11 (m, 
0.5H), 3.18-3.27 (m, 2H), 3.53-3.64 (m, 3.5H), 3.66-3.73 (m, 2H), 3.76 (m, 0.5H), 3.78 (s, 6H), 
4.50 (m, 1.5H), 4.57 (m, 0.5H), 4.66 (m, 3.5 H), 4.78 (m, 0.5H), 4.95 (s, 1.5H), 6.79 (m, 0.5H), 
6.83 (d, 3.5H, J = 9.0 Hz), 7.11-7.17 (m, 1.5H), 7.19 (d, 3H, J = 3.5 Hz), 7.22 (d, 3H, 3.1 Hz), 
7.23-7.26 (m, 0.5H), 7.29 (m, 5H), 7.36 (m, 0.5H), 7.38 (d, 1.5H, J = 7.4 Hz), 7.41 (m, 0.5H), 
7.45-7.56 (m, 2.5H), 7.75 (m, 1H), 7.88 (d, 1.5H, J = 7.4 Hz), 7.96 (d, 1H, J = 7.4 Hz), 8.07 (d, 
1.5H, J = 5.9 Hz), 10.09 (br s, 2H); 
13
C NMR (125 MHz, CDCl3) δ 29.60, 31.34, 36.39, 43.18, 
47.22, 48.18, 49.17, 51.14, 51.25, 55.21, 59.58, 60.66, 77.21, 80.61, 80.82, 87.24, 87.31, 93.23, 
93.38, 97.19, 99.10, 99.43, 113.12, 113.23, 122.43, 122.62, 124.91, 127.15, 127.91, 127.95, 
128.09, 128.12, 128.54, 128.59, 129.88, 130.07, 131.31, 131.39, 132.62, 132.87, 135.07, 143.20, 
144.11, 144.17, 144.55, 149.29, 149.97, 150.16, 150.27, 158.66, 162.35, 162.41, 162.47, 163.48, 
167.38, 167.46, 167.74 ; ESI-HRMS (ES
+
) m/z calcd for [C57H54N10O10 + H]
+
: 1039.4097, found 











 Compound 21 (0.16 g, 0.154 mmol) was added to 10 mL of dry CH2Cl2 under N2 and 
stirred until dissolved.  To this mixture was added distilled DIPEA (0.15 mL, 0.87 mmol), 
DMAP (9.40 mg, 76.9 µmol) and 2-cyanoethyl N,N-diisopropylchlorophosphoramidite (0.1 mL, 
0.462 mmol).  TLC analysis indicated reaction completion by revealing the formation of a new 
product (22) of higher Rf than the starting material (21) using 2% triethylamine in 3:1 (v/v) 
acetone/hexanes as a mobile phase 3 hours after the reaction began.  The reaction mixture was 
dried down in vacuo to afford a crude product.  The crude product was then redissolved with 
minimal amounts of 2% triethylamine in CH2Cl2 and purified by flash column chromatography 
using a step gradient of 2% triethylamine in acetone/hexanes (3:2 v/v, then 2:1 v/v, then 3:1 v/v, 
then 4:1 v/v, then 100% acetone) to afford the title compound (22) as a light-yellow solid (0.14 
g, 72%).  Compound 22 is a mixture of slowly exchanging rotamers; 
1
H NMR (500 MHz, 
CDCl3) δ 1.13-1.23 (m, 9H), 1.26 (s, 7.5H), 1.28-1.38 (m, 2.5 H), 2.63-2.68 (m, 2H), 2.99 (br s, 
1H), 3.02-3.12 (m, 1H), 3.21 (t, 1H, J = 3.9 Hz), 3.24-3.29 (m, 1H), 3.53-3.67 (m, 5.5H), 3.73-
3.78 (m, 2.5H), 3.79 (s, 1.5H), 3.80 (s, 5H), 3.83-3.93 (m, 1.5H), 4.52 (t, 1.5H, J = 4.5 Hz), 4.58 
(m, 1H), 4.64-4.70 (m, 2H), 4.73-4.81 (m, 1.5H), 4.89 (s, 1H), 4.95 (s, 0.5H), 4.99 (s, 0.5H), 6.84 
(d, 4H, J = 8.6 Hz), 7.21 (d, 2.5H, J = 1.6 Hz), 7.22-7.26 (m, 5.5H), 7.28-7.29 (m, 0.5H), 7.31 (d, 




(s, 0.5H), 7.83-7.87 (m, 0.5H), 7.93 (d, 2H, J = 7.4 Hz), 7.98 (s, 0.5H), 8.10 (m, 2H); 
13
C NMR 
(125 MHz, CDCl3) δ 14.09, 19.79, 20.44, 22.36, 22.64, 24.65, 24.70, 29.26, 29.34, 29.67, 30.01, 
31.71, 31.91, 32.72, 37.07, 41.83, 43.03, 45.94, 46.19, 47.03, 47.67, 48.34, 49.08, 51.23, 53.80, 
55.28, 58.47, 60.45, 60.72, 65.61, 69.49, 77.21, 87.33, 87.41, 93.48, 96.93, 99.60, 113.16, 
113.30, 117.43, 117.84, 122.62, 124.89, 127.25, 127.88, 128.02, 128.19, 128.80, 130.14, 131.46, 
133.03, 135.12, 144.18, 148.93, 150.06, 152.63, 156.18, 158.56, 158.78, 159.91, 162.03, 163.31, 
166.71, 167.20, 167.78, 170.81; 
31
P NMR (167 MHz, CDCl3) δ 147.93 and 148.55; ESI-HRMS 
(ES
+
) m/z calcd for [C66H71N12O11P]
+
: 1238.5103 found 1170.4187.  Methylated 











To a solution of 19 (0.1 g, 84.8 µmol) in a 0.13 M solution of anhydrous DMF was added 
tetrakis(triphenylphosphine)palladium(0) (9.8 mg, 8.48 µmol), copper iodide (3.23 mg, 16.96 
µmol), triethylamine (23.66 µL, 0.170 mmol) and propargyl cholesterol (0.18 g, 0.242 mmol) 
under nitrogen gas.  The reaction mixture was stirred for 72 hours at room temperature until TLC 
analysis indicated the formation of compound 7 (Rf = 0.54), which had a slightly faster migratory 
rate than the starting material 19 (Rf = 0.48) using 5% MeOH in CH2Cl2 as a mobile phase.  The 
reaction mixture was then concentrated using a rotary evaporator.  The crude product was 
purified by flash column chromatography with a step gradient of MeOH (1%, then 2%, then 4%) 
in CH2Cl2 to afford compound 25 as a light-yellow solid (0.12 g, 94%).  Compound 25 is a 
mixture of slowly exchanging rotamers; 
1
H NMR (500 MHz, CDCl3) δ 0.03 (s, 0.25H), 0.04 (s, 
0.75H), 0.07 (s, 0.5H), 0.08 (s, 1.5H), 0.67 (s, 3H), 0.86 (d, 4H, J = 2 Hz), 0.88 (d, 5H, J = 1.6 
Hz), 0.89-0.92 (m, 8H), 0.93 (m, 2H), 0.96 (s, 2H), 0.98-1.06 (m, 4H), 1.07-1.19 (m, 5H), 1.20-
1.29 (m, 2H), 1.30-1.65 (m, 10H), 1.74-1.89 (m, 3H), 1.90-2.08 (m, 3H), 2.09-2.18 (m, 0.5H), 
2.26-2.44 (m, 0.5H) 2.92-3.00 (m, 1.5H), 3.03-3.11 (m, 0.5H), 3.12-3.33 (m, 3H), 3.42-3.54 (m, 
2H), 3.56-3.65 (m, 2H), 3.69-3.77 (m, 1H), 3.78 (s, 2H), 3.80 (s, 6H), 4.18 (s, 0.5H), 4.19 (s, 
1.5H), 4.28-4.39 (m, 0.5H), 4.40-4.60 (m, 2.5H), 4.61-4.68 (m, 1.5H), 4.68-4.71 (m, 0.5 H), 4.74 
(s, 2H), 4.77 (s, 0.75H), 4.79-4.83 (m, 0.25H), 4.87-4.95 (m, 0.5H), 5.32 (m, 1H), 6.78-6.81 (m, 
1H), 6.84 (d, 3H, J = 8.6Hz), 7.18-7.21 (m, 2.5H), 7.22-7.23 (m, 2H), 7.23-7.26 (m, 2H), 7.28-
7.29 (m, 1H), 7.31 (d, 3H, J = 3.9 Hz), 7.32-7.39 (m, 1H), 7.51 (t, 2.5H, J = 7.6 Hz), 7.59 (d, 1H, 
7 Hz), 7.71-7.74 (m, 0.5 H), 7.77 (s, 0.5 H), 7.99 (d, 2H, J = 7Hz) ; 
13
C NMR (125 MHz, CDCl3) 
δ-5.45, -5.43, 11.81, 18.13, 18.34, 18.67, 19.27, 21.00, 22.52, 22.78, 23.78, 24.24, 25.81, 25.85, 
25.92, 25.94, 25.98, 27.96, 27.99, 28.18, 29.64, 31.82, 31.87, 35.74, 36.14, 36.73, 37.00, 38.65, 




56.10, 56.71, 60.68, 60.78, 76.53, 77.20, 78.21, 87.28, 87.32, 87.37, 90.40, 98.82, 113.13, 
113.27, 121.82, 124.84, 127.24, 127.87, 127.99, 128.14, 128.65, 128.87, 129.94, 130.09, 133.09, 
135.07, 135.09, 135.84, 140.42, 144.15, 144.22, 149.26, 150.00, 150.42, 158.74, 160. 84, 162.25, 
163.28, 166.95, 167.10, 167.46, 167.64; ESI-HRMS (ES
+
) m/z calcd for [C85H110N10O11Si + H]
+
: 










Compound 25 (0.1 g, 67.75 µmol) was added to 2 mL of THF and the solution was 
stirred until it was completely dissolved.  To this mixture, a 1.0 M solution of TBAF in THF 




revealed reaction completion 2 hours later and showed a new product 26 (Rf = 0.35) with a 
slower migratory rate than the starting compound 25 (Rf = 0.54) using 5% MeOH in CH2Cl2 as a 
mobile phase.  The reaction mixture was then concentrated under reduced pressure using a rotary 
evaporator.  Flash column chromatography was performed to purify the product (26) using a step 
gradient of MeOH (4%, 6%, 8% and 10%) in CH2Cl2 to afford a light-yellow solid (44 mg, 
48%).  Compound 26 is a mixture of slowly exchanging rotamers; 
1
H NMR (500 MHz, CDCl3) δ 
0.67 (s, 3H), 0.86 (d, 3H, J = 1.6 Hz), 0.88 (d, 3H, J = 1.6 Hz), 0.90-0.93 (m, 3H), 0.94-0.95 (m, 
2H), 0.96-0.99 (m, 3H), 1.00 (m, 1H), 1.03-1.20 (m, 6H), 1.23-1.28 (m, 2H), 1.31-1.63 (m, 10H), 
1.71-1.88 (m, 3.5H), 1.89-2.37 (m, 3.5H), 2.96-3.03 (m, 1H), 3.04-3.10 (m, 1H) 3.11-3.16 (m, 
0.5H), 3.17-3.33 (m, 3.5H), 3.55-3.64 (m, 3H), 3.65-3.77 (m, 3H), 3.79 (s, 1.5H), 3.81 (s, 4.5H), 
4.09 (s, 1.5H), 4.22 (s, 0.5H), 4.46-4.82 (m, 6H), 4.9 (s, 2H), 5.29-5.34 (m, 1H), 6.85 (d, 4H, J = 
8.6 Hz), 7.18-7.21 (m, 2H), 7.21-7.23 (d, 2H, J = 2.7 Hz), 7.24-7.26 (m, 2H), 7.27-7.29 (m, 1), 
7.32 (d, 3.5H, J = 3.9 Hz), 7.32-7.40 (m, 0.5H), 7.51 (t, 3H, J = 7.6 Hz), 7.54-7.69 (t, 2H, J = 7 
Hz), 7.77 (s, 0.5H), 7.99 (d, 1.5H, J = 7 Hz);
 13
C NMR (125 MHz, CDCl3) δ 11.84, 13.54, 18.70, 
18.85, 19.29, 20.15, 21.04, 22.54, 22.80, 23.82, 24.28, 25.12, 27.99, 28.21, 29.68, 31.85, 31.90, 
35.77, 36.18, 36.76, 37.00, 38.62, 38.95, 39.49, 39.76, 42.29, 42.90, 47.34,49.20, 49.40, 50.03, 
52.18, 55.29, 55.74, 56.14, 56.73, 70. 52, 78.28, 78.36, 87.34, 97.20, 98.68, 99.03, 112.85, 
113.30, 121.86, 124.95, 127.25, 128.02, 128.21, 128.88, 130.15, 132.74, 133.17, 135.09, 135.13, 
140.41, 140.46, 144.20, 146.54, 150.10, 156.99, 158.75, 158.77, 159.92, 162.11, 165.78, 167.44, 
172.83, 174.33, 174.88, 178.12, 180.86, 183.44, 186.26, 187.74, 192.78, 202.65 ;ESI-HRMS 
(ES
+
) m/z calcd for [C79H96N10O11+ H]
+












cyanoethyl) diisopropylphosphoramidite (27): 
 
To a solution of compound 26 (150.9 mg, 0.111 mmol) in 10 mL of anhydrous CH2Cl2 
under N2 was added distilled DIPEA (109 µL, 0.623 mmol), DMAP (6.77 mg, 55.41 µmol) and 
2-cyanoethyl N,N-diisopropylchlorophosphoramidite (74 µL, 0.332 mmol).  TLC analysis 
revealed the formation of 27 with a higher Rf than the starting material (26) 3 hours after the 
commencement of the reaction using 3:1 (v/v) acetone/hexanes in 2% triethylamine as a mobile 
phase. The reaction mixture was concentrated using a rotary evaporator to afford a crude 
product.  The crude product was then redissolved with minimal amounts of 2% triethylamine in 




in acetone/hexanes (3:2 v/v, then 2:1 v/v, then 3:1 v/v, then 4:1 v/v, then 100% acetone) to afford 
the title compound (27) as a light-yellow solid.  Compound 27 is a mixture of slowly exchanging 
rotamers; 
1
H NMR (500 MHz, CDCl3) δ : 0.66 (s, 3H), 0.86 (d, 5H, J = 6.6 Hz), 0.90 (d, 3.5H, J 
= 6.6 Hz), 0.94-1.04 (m, 6H), 1.06-1.22 (m, 15H), 1.24 (s, 5.5H), 1.29-1.61 (m, 12.5), 1.65-1.69 
(m, 0.5H), 1.73-1.87 (m, 2.5H), 1.88-2.04 (m, 2H), 2.06-2.14 (m, 0.5H), 2.20-2.41 (m, 1H), 2.61-
2.70 (m, 2H), 2.90-3.12 (m, 3H), 3.15-3.32 (m, 3H), 3.49-3.66 (m, 6H), 3.68-3.77 (m, 3H), 3.79 
(s, 5.5H), 3.81-3.91 (m, 1.5H), 4.18 (s, 2H), 4.41-4.60 (m, 4H), 4.62-4.98 (m, 4H), 5.28-5.35 (m, 
1H), 6.79-6.81 (m, 0.5H), 6.83 (d, 3.5H, J = 9 Hz), 7.19 (d, 2H, J = 2.3 Hz), 7.21 (d, 2H, J = 2.7 
Hz), 7.23-7.26 (m, 2H), 7.30 (d, 3H, J = 3.9 Hz), 7.33-7.38 (m, 0.5H), 7.49 (m, 3H), 7.57 (d, 1H, 
J = 7.4 Hz), 7.59-7.69 (m, 0.5H), 7.71 (s, 0.5H), 7.77 (s, 0.5H), 7.83 (s, 0.5H), 7.98 (d, 1.5H, J = 
7.4 Hz), 8.02-8.11 (m, 0.5H), 8.20 (m, 0.5H);
 13
C NMR (125 MHz, CDCl3) δ 11.79, 14.04, 
18.64, 19.25, 20.41, 20.97, 22.49, 22.61, 22.74, 22.90, 23.75, 24.22, 24.52, 24.59, 24.65, 24.70, 
25.64, 27.93, 27.97, 28.16, 28.84, 29.21, 29.61, 31.14, 31.67, 31.79, 31.84, 35.70, 36.11, 36.69, 
36.96, 38.63, 39.44, 39.70, 42.24, 42.99, 43.09, 46.00, 47.67, 48.21, 49.14, 49.99, 51.13, 53.78, 
55.22, 55.72, 56.07, 56.67, 58.19, 58.40, 60.77, 69.44, 77.21, 78.22, 87.23, 87.33, 90.29, 96.88, 
98.73, 98.83, 106.52, 112.23, 117.82, 118.09, 121.80, 124.79, 125.24, 127.18, 127.95, 128.13, 
128.80, 128.98, 129.90, 130.07, 132.85, 133.03, 135.09, 140.37, 144.14, 149.44, 150.06, 158.68, 
162.35, 163.20, 167.07, 167.48, 167.60, 210.71; 
31
P NMR (167 MHz, CDCl3) δ 147.93 and 
148.55; ESI-HRMS (ES
+
) m/z calcd for [C88H113N12O11P+ H]
+
: 1560.8339, found 1478.7298 [M 
+ H]
+
.  Hydrolyzed phosphoramidite was calcd for 1478.7240. 
2.2.2 Synthesis of Natural or Modified Oligonucleotides 
 All standard β-cyanoethyl 2’-O-TBS-protected phosphoramidites, reagents, and solid 




strands including the sense and 5’-phosphorylated antisense strand were purchased and purified 
from IDT (Coralville, Iowa).  All commercial phosphoramidites were dissolved in anhydrous 





phosphoramidites were dissolved in 3:1 (v/v) acetonitrile:CH2Cl2 to a concentration of 0.08 M.  
The lower concentration (0.08 M) of chemically synthesized triazole-linked phosphoramidites 
was prepared so that more chemically modified sequences could be generated at various 
positions within the strand.  The reagents that were used for the phosphoramidite coupling cycle 
were: acetic anhydride/pyridine/THF (Cap A), 16% N-methylimidazole in THF (Cap B), 0.25 M 
5-ethylthio tetrazole in ACN (activator), 0.02 M iodine/pyridine/H2O/THF (oxidation solution), 
and 3% trichloroacetic acid/dichloromethane.  All sequences were synthesized on 0.2 µM or 1.0 
µM dT solid supports except for sequences that were 3’-modified, which were synthesized on a 
1.0 µM Universal III solid support.  The entire synthesis ran on an Applied Biosystems 394 
DNA/RNA synthesizer using 0.2 µM or 1.0 µM cycles kept under nitrogen at 55 psi.  Standard 
phosphoramidites ran with coupling times lasting up to 16 minutes, while chemically synthesized 
phosphoramidites lasted up to 20 minutes.  Antisense sequences were chemically phosphorylated 
at the 5’-end by using 2-[2-(4,4’-dimethoxytrityloxy)ethylsulfonyl]ethyl-(2-cyanoethyl)-(N,N-
diisopropyl)-phosphoramidite.  At the end of every cycle, the columns were removed from the 
synthesizer, dried with a stream of nitrogen gas, sealed, and stored at -20°C. 
2.2.3 Oligonucleotide Cleavage from Solid Support and Deprotection 
 A solution of 1 mL of EMAM (methylamine 40% wt. in H2O and methylamine 33% wt. 
in ethanol, 1:1 (Sigma-Aldrich)) was passed through the column and left to sit for 30 minutes at 
room temperature with the solution in full contact with the controlled pore glass.  The solution 




of EMAM with the solution in full contact with the controlled pore glass.  After a 30 minute 
incubation period at room temperature, the solution was added to the same centrifuge tube 
totalling the volume to 1.5 mL.  The oligonucleotides were then incubated for 16 hours at room 
temperature in EMAM to deprotect the bases.  On the following day, the samples were 
concentrated on a Speedvac evaporator for 16 hours.  Once dried, the samples were resuspended 
in a solution of DMSO:3HF/TEA (100 µL:125 µL) and incubated at 65°C for 2.5 hours in order 
to remove the 2’-O-TBS groups.  The crude samples were then dried down on a Speedvac 
evaporator for 24 hours and stored in a freezer. 
2.3 Results and Discussion 
 To synthesize 5’-iodouracil-1-yl acetic acid (3), uracil was first halogenated at the C5 
position with iodine (Scheme 2-6).  This was accomplished using a protocol adopted from 
Giziewicz, et al., where iodine monochloride was added to uracil in methanol to give 2 in 90% 
yield (Robins, et al., 1982).  This reaction selectively adds iodine to the C5 position because this 
position has a slightly more negative dipole when compared to the C6 position.  Optimization of 
this reaction has highlighted the importance of methanol as a solvent because other solvents for 
this type of chemistry, such as acetonitrile, produce emulsions that make it difficult to isolate the 
product (Robert, et al., 2002).  
The syntheses proceeded by subjecting iodouracil to bromoacetic acid in aqueous sodium 
hydroxide to give compound 3 in 46% yield.  Robert, et al., reported similar reaction conditions, 
but used chloroacetic acid instead of bromoacetic acid as an alkylating reagent (Robert, et al., 
2002).  This group also reported a low yielding reaction due to either the instability of iodouracil 
in aqueous base or dialkylation (Robert, et al., 2002).  Alternative approaches where the N1 




reaction (Robert, et al., 2002).  Despite the efficiency of the reaction, it was successful and the 
product was easy to purify. 
 The next compound that needed to be synthesized was the alkyne monomer (15).  This 
was accomplished by amide bond coupling 5’-iodouracil-1-yl acetic acid (3) with the alkyne 
linker (9) using EDC·HCl as a coupling reagent to give 15 in a 61% yield.  EDC·HCl was 
chosen as an amide bond coupling reagent because it is one of the cheapest coupling reagents in 
the market and compared to other carbodiimides, like dicyclohexylcarbodiimide (DCC), it is 
water soluble (Marder & Albericio, 2003).  The water soluble property of EDC·HCl helps to 
make the purification process easier by allowing the removal of the coupling reagent in a liquid-
liquid extraction before the crude product is purified by column chromatography.  The solvents 
of choice for carbodiimides are solvents that have low dielectric constants like CH2Cl2.  These 
types of solvents reduce the chances of low yielding reactions by preventing the formation of 
poorly active N-acylurea.  Unfortunately compound 3 was not soluble in CH2Cl2 and a more 
polar solvent of higher dielectric constant needed to be used.  The use of DMF as a solvent may 
have lowered the overall yield of 15.  In addition, the secondary amine of 9 has to overcome 
steric hindrance in order to successfully react with the activated ester.  Other amide bond 
coupling reagents such as (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate) (HATU), an aminium salt of a benzotriazole, and 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), a phosphonium 
salt of a benzotriazole (Valeur & Bradley, 2008), would likely increase the yield of the reaction; 







Scheme 2-6: The synthesis of the alkyne monomer (15).  (A) 2.0 eq ICl, MeOH, 50°C, 90%; (b) 
1.5 eq. bromoacetic acid, 4 eq. NaOH, H2O, 50°C followed by HCl, pH 5 to pH 2, 46%; (c) 2 eq. 
EDC·HCl, DMF, r.t., 61%. 
 In order to generate the cytosine-triazole-uracil-iodine (CtU
I
) dimer, the alkyne monomer 
(15) and the azide monomer (18) were linked together with the click reaction using copper 
sulfate as a catalyst and sodium ascorbate to give 19 in 70% yield (Scheme 2-7).  In the absence 
of a copper-(I)-catalyst, the formation of a triazole functional group from an alkyne and an azide 
reactant takes ~10
7
-fold longer than in the presence of a catalyst (Berg & Straub, 2013).  In 
addition, the final products are a mixture of 1,4- and 1,5-regioisomers and a significant amount 
of heat is required for their synthesis (Berg & Straub, 2013).  To make the reaction more 
regiospecific, a copper catalyst was used to exclusively make the 1,4-regioisomer (Berg & 
Straub, 2013).  To generate an active Cu(I) catalyst, sodium ascorbate was used to reduce Cu(II) 
sulfate to Cu(I) (Himo, et al., 2005).  Himo, et al., found that adding this reagent in a slight 
excess also prevents the formation of any oxidative homocoupling products (Himo, et al., 2005).  
These guidelines formed the basis of the reaction conditions that were used for the click reaction 
in this study.  Finally, the reaction was performed in H2O/THF because the presence of H2O 
helps to prevent interference of any protic functional groups throughout the progress of the 




dimer synthesized by Efthymiou, et al., which used nearly identical conditions (Efthymiou, et al., 
2012). 
 In order to add hydrophobic moieties to the halogenated dimer, the Sonogashira coupling 
reaction was utilized.  When compound 19 was subjected to Pd(PPh3)4, CuI, TEA, and an excess 
of phenylacetylene, the C5 halogen was displaced by phenylacetylene to give 20 in 89% yield.  
When compound 19 was subjected to identical conditions with the exception of using propargyl 
cholesterol (24) to replace phenylacetylene, compound 25 was synthesized in 94% yield.  This 
type of reaction was performed at room temperature in DMF, and kept under nitrogen.  Iodine 
was placed on the C5 position due to its high reactivity within the Sonogashira reaction 
(Hundertmark, et al., 2000).  The reactivity of aryl halides is as follows: aryl iodide > aryl 
chloride > aryl bromide (Hundertmark, et al., 2000).  When halides of lower reactivity like aryl 
bromide are used, the temperature of the reaction typically needs to be increased to ~80°C, 
which has an obvious disadvantage compared to room temperature reactions (Hundertmark, et 
al., 2000).  Both of these reactions were performed using 5 eq. of the alkyne reactant.  The 
alkyne reactant was added to excess because it took 14 reactions to synthesize compound 19 and 
nearing the end of the synthetic scheme it was important to ensure the highest yields possible, 
even at the expense of using an abundant amount of starting material.  Literature has 
demonstrated the successfulness of the reaction using alkyne equivalents ranging from 5eq. 
(Ghilagaber, et al., 2007) to 12 eq. (Berry, et al., 2004).  This reaction was performed under 
nitrogen because it prevents homocoupling side products from forming with two terminal 
alkynes (Elangovan, et al., 2003).  In the presence of copper this mechanism is believed to 
pursue through two different cycles to synthesize 20 and 25.  The first cycle, known as the 




with 14 valence electrons (Chinchilla & Najera, 2011).  The 14 electron reactive species then 
undergoes oxidative addition to yield Pd(II) substituted with iodine and the remaining parent 
structure of 19 (Chinchilla & Najera, 2011).  The second cycle, known as the copper cycle, 
involves the coordination and substitution of copper with the terminal proton of the alkyne 
(Chinchilla & Najera, 2011).  The two newly generated species from the palladium and copper 
cycle then react to yield a substituted alkyne (Chinchilla & Najera, 2011).  The exact mechanism 
is not fully understood due to the difficulties in analyzing the two independent cycles in one pot 
(Chinchilla & Najera, 2011). 
 Next the TBS-protected alcohol of compound 20 was removed using TBAF in THF to 
give 21 in 63% yield.  The TBS-protected alcohol of compound 25 underwent the same reaction 
conditions to give 26 in 48% yield.  All protecting groups should be easy to add, remain inert in 
subsequent reactions and easily taken off.  TBS is one of the most commonly used alcohol 
protecting groups with organic reactions because silicon has a very high affinity for oxygen.  
This protecting group is removed with a source of fluoride ions.  The reaction conditions of each 




 phosphoramidites avoided the use of 
fluoride reagents to prevent TBS deprotection until required.  Fluoride ions easily deprotect 
TBS-protected alcohols because a silicon-fluorine bond (582 kJ/mol) is significantly stronger 
than a silicon-oxygen bond (368 kJ/mol).  In addition, silicon is lower in electronegativity (1.8) 
than carbon (2.5) and the bond length of a C-Si bond (1.89Å) is significantly longer than a C-C 
bond (1.54Å).  All of these properties together make silicon susceptible to attack by fluoride ions 
despite the bulkiness of the protecting group surrounding the silicon center.  The nearly identical 
conditions reported by Efthymiou, et al. to TBS deprotect the CtU dimer gave significantly 




yielding reactions remains an enigma.  Purchasing fresh TBAF in THF and re-performing the 
reaction would eliminate the idea of a shocked fluorine source.   
 The synthesis of the CtU
Ph
 phosphoramidite (22) was accomplished by reacting 
compound 21 with cyanoethyl diisopropylphosphoramidochloridite, DIPEA and DMAP under 
anhydrous conditions to give a 74% yield.  The CtU
Ch
 phosphoramidite (27) was synthesized in 
near identical conditions using compound 26 as a reactant to give a 64% yield.  For these 
reactions, all of the glassware was flame dried, DIPEA was distilled, anhydrous solvent was 
used, and the reaction vessel was purged with nitrogen to prevent the conversion of the 
phosphoramidite to a phosphonate.  These types of phosphoramidite reactions can be performed 
in the absence of DMAP (Gong & Desaulniers, 2012); however, literature has demonstrated its 
usefulness in catalyzing the coupling of phosphoramidites (Vargeese, et al., 1998).  DMAP 
works by first reacting with the phosphoramidite to displace chlorine.  The primary alcohol of 22 
or 27 can then readily attack the phosphorus center of the phosphitylating reagent and displace 




C NMRs, a 
31
P NMR was also 





 phosphoramidites due to the diasteromeric nature of the phosphorus atom.  These 
peaks correspond with P
31










 phosphoramidites. (A) 0.5 eq. CuSO4, 1.6 eq. 
sodium ascorbate, THF/H2O, r.t., 70%; (b) 0.1 eq. Pd(PPh3)4, 0.2 eq. CuI, 2.0 eq. TEA, 5 eq. 
phenylacetylene, 0.13 M DMF, r.t., 20 (89%); (c) 0.1 eq. Pd(PPh3)4, 0.2 eq. CuI, 2.0 eq. TEA, 5 
eq. alkyne-modified cholesterol, 0.13 M DMF, r.t., 25 (94%); (d) 1.6 eq. TBAF, THF, r.t., 21 
(63%) or 26 (48%); (e) 3 eq. cyanoethyl diisopropylphosphoramidochloridite, 5.6 eq. DIPEA, 




 Once the CtU
Ph
 and the CtU
Ch
 phosphoramidites were synthesized and characterized to 
confirm their structures, they were incorporated into oligonucleotides using an Applied 
Biosystems 394 DNA/RNA synthesizer.  The efficiency of the coupling reactions between all of 
the commercially available phosphoramidites was between 95-99% per reaction.  The coupling 
efficiencies of the CtU
Ph
 and the CtU
Ch
 phosphoramidites were 90% and 40%, respectively.  
These phosphoramidites were diluted to a concentration of 0.8 M in acetonitrile when compared 
to the commercially available phosphoramidites, which were diluted to a concentration of 1 M.  
The lower concentration was added to the synthesizer so that a larger library of modified siRNAs 
could be generated.  The less concentrated modified phosphoramidites may explain their lower 
coupling efficiencies.  Increasing the coupling time from 16 minutes to 20 minutes did not 





 phosphoramidites, the CtU
Ph
 phosphoramidite was soluble when dissolved in ACN 
and CH2Cl2, while the CtU
Ch
 phosphoramidite showed slight turbidity.  The lower solubility of 
the CtU
Ch
 phosphoramidite may account for its lower coupling efficiency.  All of the sequences 
that were generated were sense sequences of luciferase and BCL-2 transcripts and are shown in 
Table 2-1.  These sequences were gel purified before confirming their masses and being 





Table 2-1: The sequences of the modified oligonucleotides generated for anti-luciferase (aL) and 
anti-BCL-2 (aB) targets. 
























































aB5 5’-GUGAAGUCAACAUGCCUGCttCh -3’ 
CtU
Ph
 corresponds to the cytosine-triazole-uracil-phenylacetylene modification; CtU
Ch
 
corresponds to the cytosine-triazole-uracil-cholesterol modification; Ch corresponds to the 
commercial polyethylene-cholesterol modification 
 2.4 Chapter Summary     
 The strategic plan for synthesizing the CtU
Ph
 and the CtU
Ch
 phosphoramidites was 




C NMR and 
ESI-HRMS.  Furthermore, these phosphoramidites were successfully incorporated into 21-nt 
long oligomers.  Further investigation of the properties of these modified oligonucleotides will 

















 modified oligonucleotides that were previously synthesized on an Applied Biosystems 394 
DNA/RNA synthesizer.  All of the modified oligonucleotides were purified before confirming 
their masses with ESI Q-TOF.  These strands were then annealed to their complementary 
counterparts to generate a library of siRNAs with unique modifications.  The secondary 
structures of all of the duplexes were characterized by circular dichroism.  Their biophysical 
properties were further characterized by calculating the thermostability of their duplexes before 
undergoing in vitro biological testing. 
3.1.1 Background of Circular Dichroism 
 Circular dichroism (CD) spectroscopy is a tool used to study the secondary structure of 
macromolecules (Kelly & Price, 2000).  This technique works by passing plane-polarized light 
through a modulator subjected to an alternating (50 kHz) electric field (Kelly & Price, 2000).  
The electric field splits the plane-polarized radiation into left and right circularly polarized 
components.  The resulting light is then passed through a sample where any change in ellipticity 
can be measured (see Figure 3-1; Kelly & Price, 2000).  If the light that passes through a sample 
is in the same phase as its initial emission, it means that the left and right circularly polarized 
components of the sample were either absorbed to the same extent or not absorbed at all (Kelly 
& Price, 2000).  In this case, a signal would not be generated on a CD spectrum.  If one 




the other, the resulting circularly polarized light would be elliptically polarized (Kelly & Price, 
2000).  This change in shape is then detected by a spectrometer to generate a signal on a CD 
spectrum (Kelly & Price, 2000).   
 
Figure 3-1: A simplified diagram demonstrating how a CD spectrum is generated.  First, light is 
passed through a polarizer to make circularly polarized light.  The polarized light then passed 
through a sample where any change in ellipticity is detected by a spectrometer.  Finally, the 
spectrometer generates a CD spectrum.  
An elliptical shape can only be generated if the light that passes through the sample 
strikes a chiral compound (Kelly & Price, 2000).  All achiral compounds do not rotate polarized 
light and are optically inactive; however, these compounds do have the ability to absorb light 
(Kelly & Price, 2000).  Therefore, although there is an evident relationship between absorbance 
and ellipticity, an absorbance vs. wavelength spectrum is distinctly different than a CD (θ) vs. 






Figure 3-2: The difference between absorbance and CD spectra.  Band A is not chiral and 
generates a signal in an absorbance spectrum.  Band B is chiral with left circularly polarized light 
absorbed more than right.  This band generates a signal on an absorbance spectrum and a CD 
spectrum.  Band C is chiral with right circularly polarized light absorbed more than left.  This 
also generates a signal on an absorbance spectrum and a CD spectrum. 
An optically asymmetrical compound is not the only requirement for a molecule to 
exhibit a CD spectrum.  Within or near the chiral center of a molecule must be a chromophore 
that can absorb the circularly polarized light.  The light that is absorbed promotes electrons to 
move from their ground state to an excited state.  This electronic transition is completely 
dependent on the wavelength of light that strikes the compound, which is why peaks and troughs 
of different intensities are observed on a CD spectrum at specific wavelengths. 
3.1.2 Circular Dichroism to Measure the Secondary Structure of Nucleic Acids 
 Nucleic acids have chiral sugar units that interact with the 
*
 transitions of the 
chromophoric bases, which yield low intensity CD peaks (Ranjbar & Gill, 2009).  Higher 
intensity peaks are generated from base stacking interactions (Ranjbar & Gill, 2009).  Despite the 
individual peaks generated from individual base interactions, the overall form that a nucleic acid 




the form of an A-RNA, A-DNA, B-DNA or Z-DNA nucleic acid yields a CD spectrum with 
unique peaks and troughs that allow for secondary structure identification (Ranjbar & Gill, 
2009).  When circular dichroism spectra are taken within the 200-320 nm range, an A-RNA 
spectrum will produce a maximum peak near 260 nm and a minimum peak near 210 nm (Ranjbar 
& Gill, 2009).  These spectra will also have a small negative change in ellipticity between 290 
and 300 nm (Ranjbar & Gill, 2009).  The spectrum generated by A-DNA is very similar to A-
RNA except A-DNA has a maximum peak at 270 nm and a minimum peak near 210 nm 
(Ranjbar & Gill, 2009).  In addition, there is not a significant change in ellipticity beyond 300 
nm (Ranjbar & Gill, 2009).  B-DNA produces a spectrum distinctly different than A-RNA or A-
DNA (Ranjbar & Gill, 2009).  B-DNA has a positive peak near 275 nm and a negative peak near 
245 nm of equal intensities (Ranjbar & Gill, 2009).  Z-DNA, on the other hand, has a negative 
component at 290 nm and a positive component at 260 nm (Ranjbar & Gill, 2009). 
 Literature has shown that the secondary structure of siRNA dictates its function within 
the RISC complex (Chiu & Rana, 2002).  In order for an siRNA to be compatible with the RISC 
machinery that guides mRNA silencing, the siRNA antisense strand must form an A-form helix 
with its complementary mRNA transcript (Chiu & Rana, 2002).  Drastic changes in 
conformation reduce the activity of the siRNA (Chiu & Rana, 2002).  Therefore, circular 
dichroism spectrometry was performed on all modified siRNAs to ensure that the modification 
did not alter the natural helix of the siRNA duplex. 
3.1.3 Thermal Stability 
 There are two primary forces that are responsible for the stability of double-stranded 




between complementary bases (Yakovchuk, et al., 2006).  Second, adjacent bases have the 
ability to stack on top of one another using their pi electrons between their aromatic rings 
(Yakovchuk, et al., 2006).   The stability of such duplexes can be quantified by measuring their 
melting temperature (Tm) (Koehler & Peyret, 2005).  This is accomplished by subjecting a 
duplex to an increased gradient of heat and calculating the temperature at which 50% of the 
oligonucleotides are single-stranded (Koehler & Peyret, 2005).  
Thermal denaturation studies are commonly performed by measuring the absorption of a 
duplex at 260 nm because at this wavelength nucleobases undergo a 
*
 electronic transition 
in both purine and pyrimidine bases (Wartell & Benight, 1985).  As the temperature of the 
duplex is increased, the heat causes the strands to dissociate by breaking both the hydrogen 
bonds between complementary bases and the van der Waals interactions between stacked bases.  
The denaturation of the duplex leads to an increase in absorbance by about 15-20% and produces 
a hyperchromatic effect caused by the unstacked bases that can now absorb more light (Mergny 
& Lacroix, 2003).  This effect is responsible for the sigmoidal curve observed when absorbance 
is plotted as a function against temperature.  The inflection point of the sigmoidal shaped curve 
is known as the Tm value of a given duplex and represents the thermal stability of the duplex (see 





Figure 3-3: A thermal denaturation UV melting curve.  At low temperatures, double-strand 
nucleic acids will remain hybridized to their complementary strands.  As the temperature 
increases, hydrogen bonding and hydrophobic stacking attractions between the complementary 
strands will weaken and the strands will being to dissociate.  Once dissociated, the change in 
absorbance, caused by the exposed nucleobases, can be detected and measured to determine the 
stability of a particular duplex.  The point in which 50% of a duplex is dissociated is known as a 
Tm value, and can be calculated by measuring the inflection point of the sigmoidal melting curve. 
 There are a number of different factors that can affect the thermostability of a duplex 
including: the salt concentration, the sequence of the duplex, and chemical modifications.  When 
the salt concentration is lowered, the Tm value of the duplex also decreases (Schildkraut & 
Lifson, 1965).  Salt, such as sodium chloride, helps to hold a duplex together by acting as 
counterions for the negatively charged phosphate backbones of both strands of the duplex 
(Schildkraut & Lifson, 1965).  In its absence, there is a mutual repulsion between the less 
shielded phosphate groups (Schildkraut & Lifson, 1965).  This increases their repulsive potential 
energy, which ultimately lowers the thermal energy that is required to separate the strands 




The nucleotides that make up the sequence of the duplex can also affect its stability 
(Gewirtz, et al., 1998).  The 2-4 rule is a formula that estimates the thermal stability of a duplex 
based off of sequence length and chemical makeup (Gewirtz, et al., 1998).  The formula is as 
follows: Tm = n(2°C) + m(4°C), where n = number of A-T pairs and m = number of G-C pairs 
(Gewirtz, et al., 1998).  The stability increases with the number G-C pairs because G-C pairs 
make up three hydrogen bonds and A-T pairs make up two hydrogen bonds (Gewirtz, et al., 
1998).  Although there are more accurate formulas that can better predict the stability of a 
duplex, this initial finding highlights the importance of the sequence that makes up the duplex.   
Lastly, chemical modifications can also have a profound impact on the melting 
temperature of a duplex.  Some modifications can stabilize a duplex, like the LNA modification, 
while others can be destabilizing, like the 1`-(2,4-difluoro-5-methyl-benzyl)riobonucleotide (rF) 
modification.  LNA modifications can help to stabilize a duplex by pre-organizing nucleotides 
into an optimal helical conformation (Kierzek, et al., 2009).  This pre-assembled complex would 
result in a more favourable initial free energy to form a duplex (Kierzek, et al., 2009).  LNA 
monomers also have a locked ribose sugar that is limited in flexibility, which helps to improve 
the stacking of bases (Kierzek, et al., 2009).  The rF modification has increased stacking abilities 
due to the replacement of a base with a non-polar benzene ring; however, usage of this 
modification also results in the inability to hydrogen bond with its complement base (Xia, et al., 
2006).  This results in an overall lowering of the melting temperature of the duplex (Xia, et al., 
2006). 





modifications were measured for two main reasons.  First, in order for siRNAs to function 




physiological conditions where cellular growth occurs at 37°C and salt concentrations are low 
(Gewirtz, et al., 1998).  It is estimated that at least 12 base-pairs are required to form a stable 
duplex under such conditions (Gewirtz, et al., 1998).  SiRNAs, which are generally 21-nt long, 
greatly surpass these minimum requirements; however, site-specific incorporation of 
destabilizing CtU modifications result in a drastic decrease in Tm value of up to 13.0°C (see 




 modifications that were investigated 
in this study had the same parent structure as the CtU modification reported by Efthymiou, et al.  
The added lipophilic moieties were not suspected to further alter the thermal stability of the 
duplex because they were added at the C5 position of uracil, which should direct the lipophilic 
group outside of the duplex.  Furthermore, these added groups should not interfere with the 
hydrogen bonding of complementary base-pairs.  
 Some site-specific modifications were paired with non-complementary base-pairs 
resulting in a modified mismatched siRNA.  In literature, strands with mismatches have been 
shown to have a decreased binding affinity to their complementary strand by up to 500-fold 
(Gewirtz, et al., 1998).  Therefore, it was critical to calculate the melting temperature of these 
particular modified siRNAs to make sure that the natural state of the duplex was maintained in a 
biological system. 
A second reason for determining the melting temperature of the duplex was because site-
specific destabilizing modifications can affect proper strand selection by the RISC complex.  As 
mentioned in Section 1.8.5, the RISC complex is most likely to take up the strand whose 5`-end 
is the least thermodynamically stable.  If these modifications are destabilizing and placed on the 
5`-end of the sense strand, the antisense strand will likely have difficulty in being taken up by 




the 5`-end of the antisense strand destabilizing, the antisense strand will most likely be taken up 




 modifications within an 
siRNA can provide useful information in understanding the behaviour of siRNAs within 
biological systems.   
 
Figure 3-4: A CtU dimer synthesized and incorporated into an siRNA duplex by Efthymiou, et 




 modifications investigated in this 
study.  This point modification destabilized the duplex by 13.0°C with respect to an unmodified 
duplex. 
3.2 Experimental Procedures 
 The following experimental procedures are a continuation of the experimental procedures 
reported in Section 2.2. 
3.2.1 Ethanol (EtOH) Precipitation 
 The crude oligonucleotides were resuspended in 600 mL of EtOH, chilled in dry ice.  To 
the centrifuge tube was added 25 µL of 3 M NaOAc (pH 5.2).  This solution was vortexed and 
placed in dry ice for 1 hour.  The sample was then centrifuged for 30 minutes at 12 000 rpm at 
4°C and as much supernatant as possible was removed.  The pelleted oligonucleotide was then 
resuspended in cold EtOH.  The process was repeated three more times without adding any 




3.2.2 Oligonucleotide Quantification 
 The concentrated crude oligonucleotide sample was redissolved in 200 µL of nuclease-
free water.  From the redissolved sample, 1 µL was removed and added to 999 µL of nuclease-
free water in a 1-mL quartz cuvette.  The diluted sample was mixed thoroughly and the 
absorbance was measured using a spectrophotometer (Thermo Scientific) at 260 nm.  The optical 
density was calculated by multiplying the absorbance value calculated by the spectrophotometer 
by the total volume of the stock oligonucleotide sample (200 µL). 
3.2.3 Polyacrylamide Gel Electrophoresis (PAGE) 
 The polyacrylamide gel was made by mixing 30 mL of 40% acrylamide, 6 mL of 10X 
TBE buffer (pH 8.3) and 25.23 g of urea (7M final) topped up to 60 mL of nuclease-free water 
until all of the contents completely dissolved.  Once dissolved, polymerization was initiated by 
adding 80 µL of 25% ammonium persulfate (APS) and 80 µL of tetramethylethylenediamine 
(TEMED).  This final mixture was stirred gently for 30 seconds and immediately loaded into the 
prepared gel plates before the 12-well comb was inserted.  The gel was then left to sit for 45 
minutes until it was polymerized.  Oligonucleotide purity was assessed by loading the gel with 
0.5 OD units of oligonucleotide with denaturing loading solution for a total volume of 20 µL.  
The gel was run using a 0.5X TBE running buffer (25 mL of 10X TBE (pH 8.3) in 475 mL of 
H2O) with the voltage set to 300V and until the bromophenol blue band travelled 75% of the 
gel’s length (~ 6 hours).  Upon completion, the gel was stained in a dilute solution of ethidium 
bromide in 0.5X TBE running buffer (pH 8.3) for 30 minutes while being gently stirred on a 
shaker.  The gel was then placed on a fluorescent silica background and quickly imaged under a 





3.2.4 Crush and Soak Oligonucleotide Purification 
All strands that contained failed sequences or had poor coupling efficiency during solid-
phase synthesis were purified by loading a maximum of 2 OD units of oligonucleotide per well.  
These strands were not stained with bromophenol blue and were directly assessed under a short-
wavelength UV lamp.   Every strand was gel purified except for 3’-modified oligonucleotides, 
which showed one major product during purification assessment.  The bands that showed the 
slowest migratory rate were physically excised and placed into a centrifuge tube, which was 
further placed into a dry ice/EtOH bath for 5 minutes.  The gel pieces were then chopped up 
using a skinny scoopula and re-frozen in a dry ice/EtOH bath.  The chopped up pieces were 
suspended in 500 µL of cold gel eluting buffer and chopped up further using a centrifuge pestle 
as they defrosted in the buffer.  The slurry was refrozen in a dry ice/EtOH bath for 15 minutes 
and left to thaw for another 15 minutes at room temperature.  The slurry was then incubated for 
48 hours at 37°C on a shaker at 200 rpm. Two days later, the slurry was microcentrifuged for 30 
minutes at 12 000 rpm at room temperature and the supernatant was collected in a sterile 
microcentrifuge tube.  The sample was then dried down using a Speedvac evaporator for 16 
hours and another ethanol precipitation was performed as described in Section 3.2.1. 
3.2.5 Desalting of Gel-Purified Oligonucleotides 
 The dried down sample was redissolved in 500 µL of nuclease-free water and transferred 
to an MWCO 3000 cellulose centrifugal filter where it was microcentrifuged at 12 000 rpm at 
25°C until there was roughly 50 µL of oligonucleotide solution left (~10 minutes).  The flow-
through was then discarded and 400-500 µL of nuclease-free water was added to the remaining 
oligonucleotide solution before re-spinning the sample.  This process was repeated for a total of 




a Speedvac evaporator for 16 hours.  The purified sample was then resuspended in 100 µL of 
nuclease-free water and quantified as described in Section 3.2.2.  Note: Oligonucleotide stands 
that were not gel purified were still desalted after ethanol precipitation 
3.2.6 Procedure for Characterizing Oligonucleotides through ESI Q-TOF 
All single-stranded RNAs were gradient eluted through a Zorbax Extend C18 High-
Performance Liquid Chromatography (HPLC) column with a MeOH/H2O 5:95 (v/v) solution 
containing 200 mM hexafluoroisopropyl alcohol and 8.1 mM triethylamine, and finally with 
70% MeOH. The eluted RNAs were subjected to ESI-MS (ES
-
), producing raw spectra of 
multiply-charged anions, and through resolved isotope deconvolution, the molecular weights of 
the resultant neutral oligonucleotides were confirmed. 
3.2.7 Annealing siRNAs for Biophysical Measurements 
 To a microcentrifuge tube, equimolar amounts of chemically modified RNA (0.5 OD 
units) were mixed with their complementary sequence and dried down in a Speedvac evaporator 
for 16 hours.  On the following day, the samples were resuspended in 500 µL of sodium 
phosphate buffer (90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7) at room temperature.  
The strands were then denatured by increase the temperature of the mixture to 95°C for 2 
minutes in a hot water bath.  They were renatured and annealed together by letting the water bath 
slowly cool to room temperature.  Once annealed, the samples were transferred to a quartz 






3.2.8 Circular Dichroism and Melting Temperature Measurements 
  The sample prepared in Section 3.2.7 was placed in a spectropolarimeter (Jasco J-815) 
and CD measurements of each duplex were recorded in quadruplicate from 200-300 nm at 20°C 
with a screening rate of 10 nm/min with a 0.2 nm data pitch.  The average of the four replicates 
was calculated using Jasco’s Spectra Manager version 2 software and adjusted against a baseline 
sodium phosphate buffer.  Melting temperatures (Tm) of each sample were measured by setting 
the UV absorbance to 260 nm and increasing the temperature of the sample from 10 to 95°C at a 
rate of 0.5°C/min with the absorbance measured at the end of each 0.5°C increment.  The 
absorbance readings were automatically adjusted to a baseline sodium phosphate buffer.  The Tm 
values were calculated by using Meltwin version 3.5 software assuming the two-state model.  
Three independent experiments were run for each siRNA and the reported Tm value represents 
the average of each run. 
3.3 Results and Discussion 
 Once the oligonucleotides were purified and before they were annealed to their 
counterparts to make siRNA duplexes, their molecular weights were confirmed by ESI Q-TOF 





 phosphoramidite building blocks were successfully incorporated into the 
oligonucleotide.  Second, it confirmed that the proper sequence was entered into the synthesizer.  
Third, it confirmed that the basic conditions subjected to the oligonucleotides properly generated 
a phosphate backbone and completely deprotected all of the exocyclic amine protecting groups.  
Oligonucleotides with CtU
Ph
 modifications were properly synthesized with a predicted mass that 
matched up with the observed mass, while both of the oligonucleotides with CtU
Ch
 modifications 




yield their suspected masses.  Literature has also demonstrated difficulty in obtaining mass 
spectra of cholesterol bound oligonucleotides (Perche, et al., 2013).  This finding could mean 
that these particular cholesterol containing oligonucleotides require unique conditions for their 
detection in ESI Q-TOF experiments (Perche, et al., 2013).  Compared to the cholesterol group, 
the phenylacetylene addition is much smaller and is less likely to affect the natural migratory rate 
of an oligonucleotide during HPLC elution before being analyzed with mass spectrometry.  This 
could explain why CtU
Ph
 oligonucleotides were detected while CtU
Ch
 modifications were not.   
Despite the unsuccessful mass spectrometry analysis of cholesterol-oligonucleotides, it was 
suspected that the CtU
Ch
 phosphoramidites were successfully incorporated into the 
oligonucleotides because the coupling reaction was successful throughout the entire chain 




 modified oligonucleotides were deprotected at the 
same time, and the same reagents were used.  This means that if the CtU
Ph
 oligonucleotides were 
properly deprotected, it is very likely that the CtU
Ch
 oligonucleotides were also successfully 





Table 3-1: The predicted and recorded masses of selected oligonucleotides. 
Sample 
Number 













































ESI Q-TOF were recorded in a negative electrospray mode after HPLC elution using two mobile 
phases; MeOH/H2O 5:95 (v/v) with 200 mM hexafluoroisopropyl alcohol and 8.1 mM 
triethylamine, and 70% MeOH.  
 The secondary structure of the siRNA duplexes that targeted a pGL3 luciferase transcript 
were evaluated using CD spectroscopy.  All of the siRNAs, unmodified and modified, showed a 
positive CD band at 260 nm and a negative CD band at 210 nm.  In addition, these duplexes also 
had a shallow dip between 290-300 nm (see Figure 3-5).  These characteristics are 





modifications did not alter the natural helix of the duplex (Ranjbar & Gill, 2009).  These results 
imply that, in terms of helical structure, all of the siRNAs in this study should be compatible 
with the RISC complex.  The intensity of the modified siRNAs was smaller than that of the 
unmodified siRNAs.  The lower intensity band peaks may be a result of the reduction in the base 






Figure 3-5: The RNA duplex conformation of all of the novel anti-luciferase siRNAs in this 
study displayed through circular dichroism spectroscopy. Wild-type and modified anti-luciferase 
siRNAs (~2.4 nmol/duplex) were suspended in 500 µL of a sodium phosphate buffer (90 mM 
NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7) and the solution was scanned from 200–310 nm at 
20°C.  All scans were performed in quadruplicate and averaged using version 2 of Jasco’s 
Spectra Manager software. 





were analyzed to gather information about their compatibility within a biological environment 
and their compatibility within the RISC complex.  The unmodified wild-type siRNA duplex, 
aLwt, had a Tm value of 73.3°C.  The Tm value of this exact sequence has been reported a 
numerous amount of times within literature and other groups have reported similar values 
ranging from 70.5-73.4°C (Gong & Desaulniers, 2012; Efthymiou, et al., 2012; Addepalli, et al., 
2010; Yamada, et al., 2011).  These differences were due to the slightly different salt 
concentrations of the buffer that was used in each study.  It was critical to obtain a wild-type 
siRNA duplex that fell within this range so that the data accumulated in this study could be 






























 Modified siRNA aL4 had a Tm value that was comparable to siRNA aL3, which was 
comprised of a CtU modification at the same 7-8 position (Efthymiou, et al., 2012).  This 
demonstrated that the added modification at the C5 position of uracil did not drastically effect 
the thermal stability of the siRNA duplex.  These results were further supported when the Tm 
value of aL9 and aL10 was changed by less than 1°C when compared to siRNA aL8, which was 
comprised of a CtU modification at the same 14-15 position (Efthymiou, et al., 2012).  When a 




 position with CU residues, shown 
with aL5, the thermal stability of the duplex decreased by 13.1°C.  In a study by Addepalli, et 
al., a single mismatch at position 9 that replaced G with C resulted in a decreased thermal 
stability of 9.8°C (Addepalli, et al., 2010).  A single mismatch at position 10 that replaced A 
with U resulted in a decreased thermal stability of 6.9°C (Addepalli, et al., 2010).  The double 
mismatch reported in this study was more destabilizing than either of the single mismatches that 
were replaced with the same canonical bases by Addepalli, et al.  This finding is consistent with 
literature because the more mismatches there are within a duplex, the less hydrogen bonding 
there is to hold the bases together and the easier it is for the duplex to break apart.  SiRNAs aL6 




 duplexes at positions 9-10, respectively, and a 
double mismatch.  The mismatch at this site was suspected to decrease the thermal stability of 
the duplex based off of the observations from aL5.  The modification at this site was expected to 
further decrease the stability of the duplex because siRNAs aL4, aL8, and aL9 had demonstrated 
that internal modifications are highly destabilizing.  Therefore, siRNAs aL6 and aL7, which 
contained both a modification and a mismatch, were the least thermodynamically stable and were 
in agreement with the expected results.  Duplexes that contained modifications on the 3’-




destabilizing.  These modified siRNAs were more thermodynamically stable than all of the other 
modified siRNAs because they were not involved in the hydrogen bonding that held the duplex 
together.  Other studies have also reported modifications that are internally destabilizing but 
become more stabilizing when placed on the 3’-overhang of an siRNA (Gong & Desaulniers, 
2012; Efthymiou, et al., 2012).  
Table 3-2: The evaluation of the thermodynamic stability of anti-luciferase siRNA duplexes 
through melting temperature (Tm) measurements.   
RNA siRNA duplex Tm
a




5'- CUUACGCUGAGUACUUCGAtt -3' 






aL1 5'- CtUUACGCUGAGUACUUCGAtt -3' 






3'- ttGAAUGCGACUCAUGAAGCU -5' 
 
-- -- 
aL3 5'- CUUACGCtUGAGUACUUCGAtt -3' 






3'- ttGAAUGCGACUCAUGAAGCU -5' 
 
59.2 -14.1 
aL5 5'- CUUACGCUCUGUACUUCGAtt -3' 












3'- ttGAAUGCGACUCAUGAAGCU -5' 
 
56.8 -16.5 
aL8 5'- CUUACGCUGAGUACtUUCGAtt -3' 
























3'- ttGAAUGCGACUCAUGAAGCU -5' 
 
67.1 -6.2 
aL13 5'- CUUACGCUGAGUACUUCGAttCh -3' 
3'- ttGAAUGCGACUCAUGAAGCU -5' 
 
65.3 -8.0 
Wild-type and modified anti-luciferase siRNAs (~2.4 nmol/duplex) were suspended in 500 µL of 




measured in triplicate at 260 nm, from 10-95°C.  The temperature was increased at a rate of 
0.5°C/min and the absorbance was measured at the end of every 0.5°C increment.  The Tm’s of 
three independent experiments were averaged and calculated using Meltwin version 3.5 software 
assuming the two-state model. 
3.4 Chapter Summary 
 The inclusion of the CtU
Ph
 modification was verified through ESI Q-TOF.  The mass 
peaks of the CtU
Ch
 and commercially available Ch modified oligonucleotides were not detected 
under the applied conditions; however, consistent coupling throughout their chain elongation and 
observation of a 21-nt long oligonucleotide on a PAGE gel were indicators that the 
phosphoramidite was successfully incorporated into the strand.  The CD data that was collected 
suggested that all of the modifications retained a secondary A-type helical structure within the 
siRNA duplex.  This suggests the compatibility of the modified siRNAs with the RISC complex.  





modifications lowers the thermal stability of the duplex, but when these modifications are placed 
on the 3’-overhangs the degree of destabilizing is lessened.  Further investigation of these siRNA 
duplexes will reveal whether or not this type of modification is able to retain biological activity 
in in vitro experiments.  Furthermore, biological testing will reveal whether or not the added 









 Modified siRNA 
Duplexes 
4.1 Introduction 




 modified siRNAs to 
knockdown an exogenous target in HeLa cells was evaluated using the Dual-Luciferase Reporter 
Assay.  These constructs proved to be compatible within the RISC complex. In order to evaluate 
the cellular uptake properties of siRNAs bearing lipophilic moieties, the Dual-Luciferase 
Reporter Assay was also performed in the absence of a carrier.  To ensure that these novel 
siRNAs held promise against an endogenous gene, siRNAs targeting the mRNA transcript of 
BCL-2 was also monitored using RT-qPCR. 
4.1.1 The Dual-Luciferase Reporter Assay 
 It is well established that siRNAs function by binding to complementary mRNA 
transcripts and cleaving homologous mRNA targets with a RISC-guided complex (Lorenz, et al., 
2004).  The end result of the RNAi pathway is a sequence-specific inhibition of gene expression 
(Lorenz, et al., 2004).  This type of therapeutic downmodulates mRNA transcripts in an attempt 
to downregulate the overproduction of a problematic protein.  Therefore, in order to test the 
efficiency of an siRNA, an assay must be used that is accurate in detecting any changes in RNA 
levels within a cell.  There are many different assays that can be used to measure RNA content 
including: S1 nuclease protection, Northern blotting and RT-PCR (Kipp & Mayo, 2009).  
However, the Dual-Luciferase Reporter Assay offers superior experimental accuracy and each 




 In this study, the Dual-Luciferase Reporter Assay was used to evaluate the efficiency of 
modified siRNAs by introducing exogenous plasmid targets to mammalian cells and measuring 
the siRNA’s ability to knockdown their mRNA targets.  This was accomplished by co-
transfecting an “experimental” reporter vector, which was targeted by an siRNA, and a “control” 
reporter vector, not targeted, into HeLa cells (Promega, 2011).  The experimental vector 
consisted of a pGL3 luciferase-expressing plasmid equipped with a modified firefly luciferase 
gene.  The control vector consisted of a pRLSV40 luciferase-expressing plasmid encoding a 
modified Renilla luciferase gene.  These enzymes are different in evolutionary origin and 
therefore adopt unique conformations that have distinct substrate requirements (Promega, 2011).  
Upon transfection, the luciferase fragment of both vectors undergoes transcription and translation 
to make firefly and Renilla luciferases.  When the transfection period is complete, the activity of 
the enzymes can be independently measured by lysing the treated cells and subjecting the lysates 
to the unique substrates that activate both the firefly and Renilla enzymes (Promega, 2011).   
Within this assay, the firefly luciferase reporter enzyme is measured first by subjecting 
the lysate to its substrate, Luciferase Assay Reagent II (Lar II) (Promega, 2011).  Lar II contains 
beetle luciferin, which binds to the active site of firefly luciferase in the presence of Mg
2+
, ATP, 
and O2 to make oxyluciferin (see Figure 4-1; Promega, 2011).  During this oxidation reaction, 
AMP, PPi, CO2, and a flash of light are generated as by-products (Promega, 2011).  The light 
emitted can then be quantified on a luminometer and linked directly to the amount of firefly 
luciferase in the lysate (Promega, 2011).  When a sample is treated with an active siRNA, the 
total amount of light produced from this reaction is expected to decrease.  This occurs because 
the siRNAs used in this study contained an anti-firefly luciferase sequence that targeted the 




degraded by siRNAs, the total amount of firefly luciferase produced will also decrease.  This 
decrease in enzyme concentration would result in an insufficient conversion of beetle luciferin to 
oxyluciferin.  In this manner, the sub-optimal activity of the enzyme, which will cause dampened 
light production, can be directly associated with the potency of a particular siRNA (see Figure 4-
2). 
 
Figure 4-1: The bioluminescent reaction catalyzed by firefly luciferase to make oxyluciferin. 
Once the firefly luciferase activity is measured and quantified, a Stop & Glo® reagent is 
added to the same lysate mixture (Promega, 2011).  This reagent quenches any firefly luciferase 
luminescence within the lysate, and activates Renilla luciferase within 1 second after its addition 
(Promega, 2011).  The Stop & Glo® reagent contains coelenterazine, which acts as a substrate 
for Renilla luciferase to generate coelenteramide, CO2, and light in the presence of O2 (see 
Figure 4-3; Promega, 2011).  The light produced from this reaction, like the firefly luciferase 
reaction, can be quantified with a luminometer to determine if the activity of the siRNA is 
specific towards its target (Promega, 2011).  The quantified activity of the firefly and Renilla 
luciferase enzymes can then be normalized against a control to determine the overall potency of 
an siRNA.  The normalized data minimizes experimental variability that is otherwise caused by 






Figure 4-2: A schematic diagram demonstrating how siRNA activity can be evaluated using the 
Dual-Luciferase Reporter Assay.  On the first day, Lipofectamine 2000, an siRNA, pGL3, and 
pRLSV40 are combined and left to sit in a centrifuge tube for 20 minutes.  After the elapsed 
time, they are transfected into HeLa cells and incubated for 24 hours.  On the following day, the 
cells are lysed, Lar II is added to the lysate, and the luminescence is measured.  These 
luminescent readings are expected to be low if the siRNA can effectively prevent the pGL3 
plasmid from making firefly luciferase.  Next, the Stop & Glo® reagent is added to the same 
lysate mixture and the luminescence is measured.  These luminescent readings are expected to be 
high because the siRNAs used in this study did not target the mRNA transcript of pRLSV40.  
Finally, firefly luciferase activity is normalized against Renilla luciferase to determine the 





Figure 4-3: The bioluminescent reaction catalyzed by Renilla luciferase to make coelenteramide. 
One advantage of this system is that both the firefly and Renilla luciferase enzymes do 
not require post-translational modifications, which means that these enzymes can function as 
reporters immediately following translation (Promega, 2011).  It is extremely important to 
bypass this extra modification step because it means that there is a stronger and more direct 
relationship between the total amount of enzyme (protein) and the total amount of mRNA.  
SiRNAs function by downmodulating mRNA; therefore, if their activity is evaluated on a protein 
level there needs to be a direct relationship between protein and mRNA.  Another advantage is 
that the activity of the siRNAs is measured in one pot.  This reduces variability in pipetting 
volumes, cell lysis efficiency, and assay efficiency between otherwise separated samples 
(Promega, 2011). 
 Despite the many advantages of the Dual-Luciferase Reporter Assay, there are also many 
disadvantages using exogenous targets for siRNA testing.  For instance, the plasmids used in this 
study do not contain 3’-UTRs inserted within their reporter constructs (Promega, 2008).  
Insertion of these fragments helps to give a higher secondary structure of the mRNA transcripts 
and would more accurately represent the challenges that an siRNA must overcome to be an 




recognized by RNA binding proteins, which would further affect the function of an siRNA (Sun 
& Rossi, 2009). It is clear that the inhibition of reporter genes does not always correlate with the 
expression of endogenous RNA and protein.  Therefore, in this study, RT-qPCR was also 
performed to assess the ability of the modified siRNAs to knockdown an endogenous oncogene 
BCL-2 (B-cell lymphoma-2) transcript. 
4.1.2 BCL-2: A Target for siRNA Therapy 
 Genetically programmed cell suicide is a necessity for the proper development and 
functioning of multicellular organisms (Cory, et al., 2003).  Within mammalian cells, this 
program is regulated by the Bcl-2 family of proteins, which can be divided into three different 
classes (Youle & Strasser, 2008).   One class inhibits apoptosis (BCL-2, BCL-XL, BCL-W, 
MCL1, BCL-B, and A1), while another class promotes apoptosis (BAX, BAK, and BOK) and a 
third class of regulators known as the BH3-only proteins (BAD, BIK, BID, HRK, BIM, BMF, 
NOXA, and PUMA) function by binding to Bcl-2 proteins to promote apoptosis (Youle & 
Strasser, 2008).  Of these proteins, it is believed that upon activation, Bax and Bak play essential 
roles in promoting caspase activation, which ultimately leads to programmed cell death (see 
Figure 4-4).  These proteins promote apoptosis by converting from harmless monomers into 
destructive oligomers that insert themselves into the mitochondrial outer membrane to create a 
porous membrane (Westphal, et al., 2014).  The highly permeabilized membrane then releases 
proapoptotic factors, like cytochrome c, into the cytoplasm where they bind to Apaf-1 to 
assemble an apoptosome (Westphal, et al., 2014).  The apoptosome activates initiator caspase-9, 
which further activates downstream effector caspases, like caspase-3 (Westphal, et al., 2014).  
Ultimately, the caspase cascade causes DNA fragmentation, fragmentation of the nucleus, 




Muckherjee, et al., 2007).  In addition, the loss of cytochrome c from the mitochondria halts ATP 
production, resulting in an energy deprived cell (Westphal, et al., 2014).  One gene that helps to 
maintain the homeostatic balance between the rate of cell division and cell death is the BCL-2 
gene.  Activation of this gene leads to the production of the bcl-2 protein, which functions to 
inhibit apoptosis by antagonizing proapoptotic family members including Bax and Bak (Dlugosz, 
et al., 2006).  The exact mechanism by which Bcl-2 antagonizes the functions of these proteins 
remains unknown (Dlugosz, et al., 2006).  However, many proapoptotic proteins share a BH3 
domain, which mediates interactions between core BCL-2 family proteins (Dlugosz, et al., 
2006).  It is therefore believed that the hydrophobic BH3 binding pocket of Bcl-2 inhibits Bax 
and Bak through binding interactions with their BH3 domain (Dlugosz, et al., 2006).   
When Bcl-2 is overexpressed, antiapoptotic behaviour begins to develop within a normal 
cell.  This is commonly caused by a t(14;18) chromosomal translocation (Youle & Strasser, 
2008).  The resulting translocation juxtaposes the BCL-2 proto-oncogene next to the 
immunoglobulin heavy chain gene promoter and enhancer, which results in an excessive 
expression of BCL-2 (Youle & Strasser, 2008).  The overproduction of Bcl-2 and the cell’s 
ability to evade cell death causes the development of a cancerous cell.   
The siRNAs used in this study targeted upregulated BCL-2 transcripts in HeLa cells (Li, 
et al., 2006) in an attempt rescue the normal behaviour of the antiapoptotic cells.  There are many 
different types of cancers associated with problematic Bcl-2 regulation including:  breast, 
ovarian, prostate, renal, and lung cancer (Placzek, et al., 2010).  Therefore, targeting this 
particular gene transcript of the BCL-2 protein family would demonstrate not only the ability of 
the modified siRNAs to knockdown an endogenous target, but an endogenous target with clinical 





Figure 4-4: The role of Bcl-2 in the apoptotic pathway.  Bcl-2 functions by inhibiting the 
activity of Bax or Bak.  Bax or Bak promote apoptosis by forming pores within the 
mitochondrial membrane to release cytochrome c from the intermembrane space.  Cytochrome c, 
now in the cytoplasm of the cell, then binds to Apaf-1 to form an apoptosome.  Procaspase 9 is 
then recruited into the apoptosome, which initiates apoptosis by causing a caspase cascade.  
4.2 Experimental Procedures 
 The following experimental procedures are a continuation of the experimental procedures 
reported in Section 3.2. 
4.2.1 Culturing of HeLa Cells 
4.2.1.1 Thawing HeLa Cells 
 A 50 mL Falcon tube filled with 20 mL of growth medium (Dulbecco’s Modified Eagle’s 




Streptomycin (P/S) (Sigma) was warmed in a water bath to 37°C in preparation for the thawing 
of HeLa cells.  From a liquid nitrogen dewar, a cryovial containing 9.5x10
5
 frozen HeLa cells 
was removed from the vapor phase of liquid N2 and placed into a portable cooler at -80°C.  
Immediately, 500 µL of the pre-warmed growth medium was added to the frozen stock and 
gently mixed until the cells began to thaw.  The 500 µL mixture of medium and thawed cells was 
then removed from the cryovial and re-added to the Falcon tube containing warm growth 
medium.  Another 500 µL of the same growth medium was then added to the cell containing 
cryovial, mixed, and returned to the Falcon tube containing warm growth medium.  The process 
was repeated until all of the frozen cells from the cryovial were transferred into the Falcon tube.  
The thawed cells were then centrifuged for 5 minutes at 1200 rpm at 37°C and the medium was 
discarded to remove residual DMSO from the frozen stock.  The pellet of cells was resuspended 
in 1 mL of new 37°C growth medium and added to a 25 cm
2
 culture flask containing 10 mL of 
the same growth medium.  The cells were then incubated at 37°C with 5% CO2 for 24 hours, 
after which they were passaged (refer to Section 4.2.1.2) and added to a 75 cm
2
 culture flask 
containing 25 mL of growth medium. 
4.2.1.2 Sub-Culturing of HeLa Cells 
 Either 24 hours post-cell thawing or when cells reached 70-80% confluency during cell 
maintenance, culturing began by dispensing the 25 mL of growth medium (DMEM and 10% 
FBS and 1% P/S) from a 75 cm
2
 culture flask and washing the cells with 10 mL of a 1X 
phosphate buffered saline (PBS) solution (0.01 M phosphate buffered saline (NaCl 138 mM; KCl 
2.7 mM; pH 7.4)) (Sigma) two times.  To cleave adhesion proteins involved in cell-to-cell and 
cell-to-matrix interactions, 2 mL of 37°C 0.25% trypsin (SAFC bioscience) was added to the 75 
cm
2




cells were then resuspended in 10 mL of growth medium and transferred to a 50 mL Falcon tube 
for centrifugation at 37°C for 5 min at 1200 rpm.  The supernatant was discarded to remove 
residual amounts of trypsin and 5 mL of growth medium was added to the Falcon tube to 
resuspend the pellet.  The concentration of suspended cells was determined using a 
haemocytometer (mix 100 µL of cells with 100 µL of Trypan blue (Sigma)).  After determining 
the stock concentration of cells, the stock was diluted to a concentration of 1x10
6
 cells/mL using 
37°C growth medium.  From this stock, 1 mL of diluted cells was added to a new 75 cm
2
 culture 
flask containing 24 mL of 37°C growth medium.  The passaged cells were then placed in an 
incubator at 37°C with 5% CO2 until they reached 70-80% confluency.  When the cultured cells 
reached a passage number of 25 they were discarded and a new batch of cells were thawed and 
passaged as outlined.  Note: Growth medium without antibiotics (DMEM containing 10% FBS) 
was used after trypsinization when cells were plated in preparation for transfection. 
4.2.2 Preparation of pGL3/pRLSV40 Plasmids for the Dual-Luciferase Reporter Assay 
4.2.2.1 Competent DH5α E. coli Preparation 
 A portion of DH5α cells was scraped off of the top of a frozen glycerol stock (stored at -
80°C) and streaked onto a lysogeny broth (LB) plate.  The streaked plates were incubated for 5 
minutes at room temperature, turned upside down, and stored in an incubator at 37°C for 16-20 
hours.  On the following day, a single colony of E. coli was selected and inoculated in a 5 mL 
starter culture of LB medium without antibiotics.  The culture was then grown at 37°C with 
shaking at 250 rpm for 16 hours.  On the third day, 1 mL of the saturated overnight culture was 
inoculated with 100 mL of LB medium and placed back on a shaker at 37°C.  Bacterial growth 
was monitored until OD600 = 0.4 (usually 2-3 hours).  Growth was stopped by placing the culture 




The culture was split into two parts by pouring about 50 mL into pre-chilled 50 mL Falcon tubes.  
The cells were harvested by centrifugation at 2700x g for 10 minutes at 4°C followed by the 
decanting of the supernatant from the Falcon tube.  The pellets were resuspended with 1.6 mL of 
ice cold 100 mM CaCl2 and this mixture was left on ice for 30 minutes before being centrifuged 
at 2700x g for 10 minutes at 4°C.  The medium was removed and the cell pellet was resuspended 
with 1.6 mL of ice-cold 100 mM CaCl2 for a second time.  The resulting mixture was incubated 
on ice for 20 minutes.  After the elapsed time, the newly formed competent cells were combined 
into one tube and 0.5 mL of ice-cold 80% glycerol was added to the mixture.  The final stock of 
competent cells was then swirled to ensure equal concentration throughout the mixture before 
being split into 50 µL aliquots.  The aliquots were immediately frozen using liquid nitrogen and 
stored in a freezer at -80°C. 
4.2.2.2 Transformation of Competent DH5α E. coli Using pGL3/pRLSV40 Plasmids 
 Competent DH5α cells in 50 µL aliquots were taken out of a -80°C freezer and thawed on 
ice.  To these thawed cells was added 100 ng of the pGL3 or pRLSV40 plasmid (each equipped 
with Amp
r
 conferring ampicillin resistance in E. coli) and the resulting solution was gently 
mixed.  The cells were then placed on ice for 15 minutes, heat-shocked at 42°C for 1 minute, and 
replaced back on ice for 2 minutes.  To these cells was added 950 µL of LB medium (without 
ampicillin) and this mixture was incubated at 37°C for 1 hour on a shaker set to 250 rpm.  The 
cells were then pelleted at 14 000 rpm for 30 seconds, upon which the supernatant was discarded 
and the cells were resuspended in 100 µL of LB medium (without ampicillin).  The cells were 
then plated onto ampicillin-containing (100 µg/mL) agar plates and grown overnight at 37°C.  




from the freshly streaked plate and inoculated with 5 mL of LB medium containing 100 µg/mL 
of ampicillin.  These cultures were then incubated for 12-16 hours at 37°C with vigorous stirring. 
4.2.2.3 Isolation and Purification of pGL3/pRLSV40 Plasmids from Transformed DH5α E. 
coli 
 The plasmids, pGL3 and pRLSV40, were isolated and purified from transformed E. coli 
DH5α cells using the QIAprep Spin Miniprep kit (Qiagen #27106) according to the 
manufacturer’s protocol.  Bacterial cells were harvested by centrifugation at 6800x g for 3 
minutes at 20°C.  After decanting the supernatant, the pelleted bacterial cells were resuspended 
in 250 µL of pre-lysis buffer (Buffer P1) treated with 100 µg/mL of RNase A inhibitor and 
transferred to a centrifuge tube.  An additional 250 µL of lysis buffer (Buffer P2) was added and 
mixed into the solution by inverting the tube 6 times.  The appearance of a blue coloured solution 
indicated that the bacterial cells were successfully lysed.  The solution was then neutralized by 
adding 350 µL of neutralizing solution (Buffer N3) and gently inverting the tube 6 times.  The 
transformation of the blue solution to a milky cloudy solution indicated successful neutralization.  
The samples were then centrifuged for 10 minutes at 17 900x g, which made a compact white 
pellet.  From this mixture, the supernatant was placed into the QIAprep spin column and the 
compact white pellet was discarded.  The column was then flash centrifuged for 60 seconds and 
the flow-through was discarded.  The column was washed by adding 750 µL of a washing buffer 
(Buffer PE) and flash centrifuged for 60 seconds.  The flow-through was discarded and flash 
centrifuged a second time for an additional 60 seconds to remove any remaining washing buffer 
that was left in the column.  The QIAprep column was then placed into a sterile 1.5 mL 
eppendorf tube.  The plasmids were eluted by adding 50 µL of eluting buffer (Buffer EB; 10 mM 




the column was flash centrifuged for another minute, and the final purified plasmids were stored 
in a freezer at -20
o
C until needed.  The purified plasmids were quantified as described in Section 
3.2.2. 
4.2.3 The Dual-Luciferase Reporter Assay 
4.2.3.1 Co-transfection of HeLa Cells with pGL3/pRLSV40 Plasmids and siRNAs With 
Lipofectamine 2000 
 After passaging and achieving a 1x10
6
 cell concentration (Section 4.2.1.2) using growth 
medium without antibiotics, 100 µL (100 000 cells) was added to a 12-well plate pre-warmed 
with 1 mL of identical growth medium in each well.  The plates were then placed in an incubator 
at 37°C with 5% CO2 for 24 hours.  On the following day, 100 ng of pRLSV40 and pGL3 
plasmids were transferred to a centrifuge tube and placed on ice.  To the chilled tube, various 
siRNAs with concentrations ranging from 0.08-800 pM were also added to the plasmid 
containing centrifuge tubes.  Finally, this mixture was topped off with 100 µL of Gibco’s Opti-
Mem Reduced Serum Medium 1X (Invitrogen).   While the plasmids/siRNAs remained on ice, 1 
µg of Lipofectamine 2000 (Invitrogen) and 100 µL of Opti-Mem were added to a separate 
centrifuge tube that was kept at room temperature.  After 5 minutes, this solution was combined 
with the plasmid/siRNA containing tube, mixed thoroughly, and left to stand at room 
temperature for 20 minutes.  After the elapsed time, the plasmid/siRNA/Opti-
Mem/Lipofectamine 2000 containing centrifuge tube was added to its appropriate well on the 12-
well plate.  The loaded 12-well plates were then gently rocked for 5 minutes and incubated for 24 
hours at 37°C with 5% CO2 to allow transfection to take place.  Positive controls consisted of 




4.2.3.2 Co-transfection of HeLa Cells with pGL3/pRLSV40 Plasmids and siRNAs in the 
Absence of Lipofectamine 2000 
After passaging and achieving a 1x10
6
 cell concentration (Section 4.2.1.2) using growth 
medium without antibiotics, 50 µL of cells (50 000 cells) was added to a 24-well plate pre-
warmed with 350 µL of identical growth medium in each well.  The plates were then placed in 
an incubator at 37°C with 5% CO2 for 24 hours.  On the following day, 100 ng of pRLSV40 and 
pGL3 plasmids were transferred to a centrifuge tube and placed on ice.  This mixture was topped 
off with 50 µL of Opti-Mem and placed back on ice.  In a separate centrifuge tube, 50 µL of 
Opti-Mem was added to 1 µg of Lipofectamine 2000 at room temperature.  After 5 minutes, this 
solution was combined with the plasmid containing centrifuge tube and mixed thoroughly.  After 
the mixture was left to stand at room temperature for 20 minutes, the plasmid/Opti-
Mem/Lipofectamine 2000 containing centrifuge tube was added to its appropriate well on the 24-
well plate.  The loaded 24-well plates were then gently rocked for 5 minutes and incubated for 4 
hours at 37°C with 5% CO2 to allow transfection to take place.  After 4 hours, the growth 
medium was discarded from each well and washed twice with 500 µL of 1X PBS buffer.  The 
emptied wells were then filled with 200 µL of growth medium without FBS or antibiotics as 
quickly as possible to maintain an optimal growth environment for the transfected cells.  The 
contents of the pre-prepared tubes containing 50 µL of Opti-Mem and the desired concentration 
of a particular siRNA ranging from 0.2 µM to 3 µM were then transferred into their appropriate 
wells on the 24-well plate.  The plates were then re-incubated at 37°C with 5% CO2 for 16 hours 




 4.2.3.3 Measuring siRNA Activity using the Dual-Luciferase Reporter Assay in the 
Presence (and Absence) of HeLa Cells Transfected with Lipofectamine 2000 
 After 24 hours (or 16 hours in the absence of Lipofectamine 2000) of transfection, the 
medium was decanted and each well was washed twice with 1 mL (or 500 µL in the absence of 
Lipofectamine 2000) of 1X PBS.  The wells were then treated with 250 µL (or 125 µL in the 
absence of Lipofectamine 2000) of 1X Passive Lysis Buffer (Promega) and placed on a shaker 
for 20 minutes at room temperature.  The lysates were then transferred to an opaque 96-well 
plate (Costar) in 10 µL aliquots and plated in triplicates.  Using a multichannel pipette, 50 µL of 
firefly luciferase substrate (LAR II) was quickly added and mixed to each set of triplicates.  
Enzymatic activity, represented by luminescence, was measured using a Synergy HT (BioTek) 
plate reader using the KC4 program.  The program was set to measure: luminescence, 3 samples 
per well, a 2000 msec delay before sampling, a 255 msec delay between samples, a high well 
value of 99998, and a starting autosensitivity of 35.  Once the plate was finished recording the 
luminescence of each well, 50 µL of Stop & Glo® substrate was added to the same triplicate 
wells to quench the firefly luciferase reaction and activate the Renilla luciferase reaction.  The 
quantified luminescence signals generated from firefly and Renilla luciferase were logged and 
the triplicates were averaged.  SiRNA activity was measured by determining the ratio of 
firefly/Renilla luminescence, and normalizing the activity as a percentage against a positive 
control.   
4.2.4 Quantitative Real-Time PCR 
4.2.4.1 Transfection of HeLa cells with Lipofectamine 2000 
 After passaging and achieving a 1x10
6
 cell concentration (Section 4.2.1.2)  using growth 




warmed with 350 µL of identical growth medium in each well.  The plates were then placed in 
an incubator at 37°C with 5% CO2 for 24 hours.  On the following day, various siRNAs with 
concentrations ranging from 1-20 nM were added to a chilled centrifuge tube.  This mixture was 
then topped off with 50 µL of Opti-Mem and placed back on ice.  In a separate centrifuge tube, 
50 µL of Opti-Mem was added to 1 µg of Lipofectamine 2000 at room temperature.  After 5 
minutes, this solution was combined with the siRNA containing centrifuge tube and mixed 
thoroughly.  After the mixture was left to stand at room temperature for 20 minutes, the 
siRNA/Opti-Mem/Lipofectamine 2000 containing centrifuge tube was added to its appropriate 
well on the 24-well plate.  The loaded 24-well plates were then gently rocked for 5 minutes and 
incubated for 24 hours at 37°C with 5% CO2. 
4.2.4.2 HeLa Cell Reverse Transcription (RT) Preparation 
 After the expired transfection period (Section 4.2.4.1), the growth medium was decanted 
and each treated well was washed twice with 4°C 1X PBS buffer.  The cells were suspended by 
adding 100 µL of 0.25% trypsin to each well and incubated for 2 minutes at 37°C with 5% CO2.  
The detached cells from each well were then added to separate microfuge tubes containing 900 
µL of 37°C growth medium without antibiotics.  The trypsinized cells were then centrifuged at 
1200 rpm for 5 minutes at 37°C.  The supernatant was discarded and the pelleted cells were 
resuspended with 500 µL of the same growth medium.  The suspended cells were then counted 
to ensure equal cell concentration for each sample for a maximum of 250k cells/sample.  After 
counting, the cells were re-pelleted at 1200 rpm for 5 minutes at 4°C, the supernatant was 
discarded and the pellets were placed on ice.  The pelleted cells were resuspended in 500 µL of 




remove any trace amounts of medium.  The supernatant was then decanted and the pellets were 
placed back on ice. 
4.2.4.3 RT-PCR using the Ambion Cells-to-cDNA kit  
 The following protocol uses reagents found in the Cells-to-cDNA kit purchased from 
Ambion.  To the pellet on ice was added 100 µL of ice cold Cell Lysis II Buffer and each sample 
was mixed by vortexing.  Once the samples were mixed, they were immediately transferred to a 
pre-heated 75°C water bath and left to heat for 10 minutes.  The samples were then removed 
from the water bath and placed on ice.  To each centrifuge tube, 2 µL of DNase I (2 U/µL stock) 
was added and these mixtures were gently vortexed followed by a brief centrifugation to 
concentrate the sample.  A genomic wipeout was accomplished by incubating the DNase I 
reaction at 37°C for 15 minutes.  The samples were then heated to 75°C for 5 minutes to 
deactivate DNase I.  To new nuclease-free microfuge tubes, was added 5 µL of cell lysate 
(RNA), 4 µL of dNTP mix (2.5 mM stock for each dNTP), 2 µL of random decamers (50 µM 
stock) and 9 µL of nuclease-free water.  The resulting mixture was then heated to 70°C for 3 
minutes to denature the RNA template, placed on ice for 1 minute, flash centrifuged, and placed 
back on ice.  The remaining RT reagents including: 2 µL of 10X RT Buffer, 1 µL of M-MLV 
Reverse Transcriptase (or 1 µL of nuclease-free H2O for a no reverse transcription (NRT) 
control) and 1 µL of RNase inhibitor (10 U/µL stock) were added, gently mixed, and centrifuged 
briefly.  Reverse transcription was initiated by warming the samples to 42°C using a thermal 
cycler for 45 minutes.  Reverse transcriptase was inactivated by incubating the samples at 95°C 
for 10 minutes.  The samples were then stored in a -20°C freezer until the following day when 




4.2.4.4 Quantitative Real-Time PCR 
  To each reaction tube within the 96-well PCR plate (BIO-RAD) was added: 2 µL of 
cDNA template (or 2 µL of nuclease-free H2O for a no template control (NTC)), 10 µL of 
SsoFast EvaGreen Supermix (BIO-RAD) containing EvaGreen dye as a source of fluorescent 
nucleic acid dye and Sso7d-fusion polymerase to amplify DNA, 1 µL of a 10 M stock of forward 
and reverse BCL-2 primers (final 500 nM) or 1 µL of a 1 M stock of forward and reverse 18S 
rRNA primers (final 50 nM) and 6 µL of nuclease-free H2O to give a total volume of 20 µL.  
Master and Sub-Master Mixes were created in order to reduce pipetting error between triplicates; 
therefore, only requiring the addition of 18 µL of Sub-Master Mix and 2 µL of cDNA template 
(or 2 µL of nuclease-free H2O for NTC) to each reaction tube.  The q-PCR reaction was 
performed and recorded by a CFX96 Real-Time reactor (BIO-RAD).  NRT controls were 
performed during standard curve analysis to confirm that amplification of the PCR product was 
cDNA and not genomic DNA.  NTC controls were also performed to ensure that amplification of 
the PCR product was not a result of primer-dimers. 
 The BCL-2 forward and reverse primers were 5’-CTG GTG GGA GCT TGC ATC AC-
3’ and 5’-ACA GCC TGC AGC TTT GTT TC-3’, respectively, yielding a 150-bp amplicon.  
The 18S rRNA forward and reverse primers were 5’-CGG CTA CCA CAT CCA AGG AAG-3’ 
and 5’-CGC TCC CAA GAT CCA ACT AC-3’, respectively, yielding a 247-bp amplicon.  The 
protocol that was utilized to amplify the BCL-2 and 18S rRNA PCR products consisted of the 
following steps: pre-heat to 95°C for 2 minutes, 40 cycles of denaturing at 95°C for 5 seconds, 
annealing at 52°C for 15 seconds, and extension at 72°C for 10 seconds.  A melting curve 
analysis was performed on each amplicon by raising the temperature from 65°C to 95°C at 




normalized to 18S rRNA in triplicates by performing a gene study analysis using Bio-Rad CFX 
Manager (Version 3.1) software with 18S rRNA selected as a reference gene. 
4.3 Results and Discussion 
4.3.1 The Evaluation of Modified siRNAs using the Dual-Luciferase Reporter Assay 
 Anti-luciferase siRNAs were synthesized with a sequence that was designed to target 
firefly luciferase.  Their activities were monitored using the Dual-Luciferase Reporter Assay by 
measuring their ability to downregulate the production of firefly luciferase in HeLa cells.  Using 
Lipofectamine 2000 as a transfection reagent, exogenous firefly luciferase was expressed within 
the cells by transfecting a pGL3 plasmid coding for firefly luciferase.  To ensure that the 
knockdown was a result of a target-specific sequence carried by the siRNAs, a pRLSV40 
plasmid coding for Renilla luciferase was co-transfected into the same cells.  The signals 
generated from firefly luciferase were then normalized to the signals generated from Renilla 
luciferase, and the potency of the anti-luciferase siRNAs was evaluated. 
 In order to evaluate the sensitivity of firefly luciferase against anti-luciferase siRNAs, a 
wide range of concentrations (8-800 pM) were transfected into HeLa cells (see Figure 4-5).  At 
an 800 pM concentration, all siRNAs almost completely abolished firefly luciferase activity.  
Decreasing the concentration of the treated samples to 80 pM reduced the activity of every 
siRNA construct except for aL11, which maintained its efficacy.  At an 8 pM concentration 
siRNA activity was further reduced.  Anti-luciferase siRNAs that were tested at 8 pM generally 
had activity that was low enough to prevent baseline readings and high enough to detect variable 








 siRNAs at an 8 pM concentration made for the best 
comparisons. 
 
Figure 4-5: The reduction of firefly luciferase expression related to the potency of chemically-
modified siRNAs using the Dual-Luciferase Reporter Assay.  The siRNAs were tested at 8, 80, 
and 800 pM, with firefly luciferase expression normalized to Renilla luciferase.  All error bars 
represent the standard deviation of the mean.  
 
As shown in Table 3-2, phenylacetylene and cholesterol lipophilic moieties at the C5 
position do not significantly alter the thermodynamic stability of the duplex when compared to 
site-specific CtU modifications.  When comparing 5’-end modified siRNAs, it is clear that aL1 is 
more potent at lower concentrations than aL2.  According to the thermodynamic asymmetry rule 
of an siRNA duplex, the strand that is most likely to be taken up by the RISC complex is the 
strand whose 5’-end is the least thermodynamically stable (Kawamata & Tomari, 2010).  The 5’-
modifications used in this study were slightly destabilizing and therefore should have favoured 
the incorporation of the wrong strand (sense strand) into the RISC complex.  However, the 





























be better explained with crystalized structures that exhibit the interactions between Argonaute 
and the antisense strand.  Crystallized structures, derived from Argonaute loaded with the 
antisense strand, have revealed that the Mid domain of Argonaute has a 5’-phosphate binding 
pocket that recognizes the 5’-end of the antisense strand (Wang, et al., 2008).  This makes it very 
unlikely for the wrong strand (sense strand) to be incorporated into the RISC complex because 
the 5’-modifications used in this study do not maintain the natural phosphate group of an siRNA.  
This provides a reasonable explanation for why aL1 is more potent than aLwt.   It is not clear 
why the activity of aL2 is significantly less than aLwt or aL1.  The loss in activity could be due 
to the bulky phenylacetylene group interfering with assembly of the RISC complex at this 
specific position. 
  When the site-specific modification was moved from the 5’-position to occupy the 7-8 
position of the sense strand, as seen with aL3 and aL4, the efficacy of the siRNA was either 
enhanced or remained comparable to aLwt.  Addepalli, et al. showed that destabilizing the 5’-
end of the sense strand with single base-pair mismatches ranging from the 1
st
 position to the 8
th
 
position resulted in a decrease in siRNA potency (Addepalli, et al., 2010).  This is consistent 
with the thermodynamic asymmetry rule.  Once the mismatches reached the 9
th
 position, the 
siRNAs had superior activity as a result of destabilizing the Argonaute site.  Therefore, the 
highly destabilizing modifications of aL3 and aL4 may have played a larger role in destabilizing 
the vicinity of the Argonaute site (between positions 9 and 10 of the sense strand) than the effect 
that they may have had on the thermodynamic asymmetry of the duplex.  This could explain why 
aL3 had comparable activity to aLwt.  Nevertheless, the highly enhanced activity of aL4 was an 
odd observation.  To better understand the behaviour of this siRNA, its activity was evaluated at 




high degree of potency (see Figure 4-6).  The dose-response curve of aL4 (IC50 = 2.52 pM) 
revealed that it was not as effective as aL11 (IC50 = 1.26 pM) and aL12 (IC50 = 1.28 pM); an 
observation that would not have been concluded from Figure 4-5.  In addition, the activity of 




Figure 4-6: Dose-response curves of selected siRNAs using the Dual-Luciferase Reporter 
Assay.  The siRNAs were tested at concentrations ranging from 0.08-800 pM with firefly 
luciferase expression normalized to Renilla luciferase.  All IC50’s were calculated with Prism 
using the variable slope model.  The IC50’s of the selected siRNAs were as follows: aLwt (3.88 
pM), aL4 (2.52 pM), aL9 (4.52 pM), aL10 (6.52 pM), aL11 (1.26 pM), aL12 (1.28 pM), and 








































 modifications occupying the 
Argonaute site, a new control sequence was synthesized.  The natural sequence of the sense 





positions, respectively.  The modification used in this study consisted of a cytosine-uracil dimer.  
Therefore adding a CtU
Ph
 or a CtU
Ch
 modification at this position would not only result in the 
incorporation an unnatural PNA-like scaffold, but the incorporation of two mismatched bases.  In 




 modifications, a sequence that contained 





 positions, respectively.  Consistent with Addepalli, et al.’s findings, this highly 
destabilizing modification that lacked hydrogen bonding between 2 bases within the Argonaute 









 positions to make aL6 and aL7, the activity 
of the siRNAs dropped substantially.  The triazole backbone modification at this site replaces the 
facile phosphodiester bond that is necessary for strand cleavage.  When cleavage is blocked 
through chemical modification, a slower backup pathway is required to remove the sense strand 
and liberate a mature RISC complex (Matranga, et al., 2005).  Literature has demonstrated that 
phosphorothioate linkages between positions 9 and 10, which also replace the natural phosphate 
backbone, decrease the rate of strand separation by ~3 fold when compared to wild-type siRNAs 
or strands that have phosphorothioate modifications that are adjacent to the Argonaute site 










positions of the sense strand to make aL9 (IC50 = 4.52 pM) and aL10 (IC50 = 6.52 pM), 




thermodynamic stability of the duplex, these results are in agreement with literature because 
destabilizing mismatches within this region did not enhance or diminish the activity of an siRNA 
(Addepalli et al., 2010).  Furthermore, their activity is comparable to aL8, which shows that the 
added C5 hydrophobic moieties do not present an obstacle for the RISC complex at this position. 
When siRNAs were modified at their 3’-ends they had activity that was greater than or 
comparable to wild-type siRNA.  Modified aL11 (IC50 = 1.26 pM) and aL12 (IC50 = 1.28 pM) 
were the most potent siRNAs analyzed in this study, with aL13 (IC50 = 3.23 pM) having 
comparable activity to aLwt.  There are two main reasons that explain why these siRNAs 
inherited the ability to effectively knockdown their targets.  First, these modifications are slightly 
destabilizing at the 3’-end of the sense strand, which favours the incorporation of the proper 
antisense strand into the RISC complex.  Second, CtU modifications have demonstrated the 
ability to evade degradation by exonucleases thereby making them last longer with the cell, and 
having more time to reach the RISC complex (Efthymiou, et al., 2012).  Modified aL11 and 
aL12 maintain the parent CtU structure and therefore, should also resist exonucleases.  
Commercially available aL13 has a long polyethylene glycol (PEG)-lyated chain with a 
conjugated cholesterol group that also likely prevents exonucleases; however, this modification 
does not eliminate the substrate required for exonucleases like aL11 and aL12.  This could 
explain the slight decrease in activity when compared to the other 3’-modified siRNAs.  In 
addition, investigation of the length of the linker between an siRNA and its lipophilic group has 
demonstrated that linkers that are longer than 10 carbon atoms have a retarded gene silencing 
effect and decrease the efficiency of mRNA silencing (Petrova, et al., 2012).  Commercially 




Overall, there was not a significant difference between the two different lipophilic 




 modifications were 
placed within the Argonaute site or at the 3’-end of the sense strand; their activity corresponded 
well with literature.  Conversely, when the CtU
Ph
 modification was placed near the 5’-end of the 
sense strand the activity of the siRNA was unpredictable. 
4.3.2 The Evaluation of Modified siRNAs in a Carrier-Free Environment 
 When the siRNAs were transfected with Lipofectamine 2000 and evaluated for activity 
using the Dual-Luciferase Reporter Assay, endosomal escape was not a biological hurdle.  This 
transfection reagent has a fusogenic lipid, DOPE (dioleylphosphatidyl-ethanolamine), which 
interacts with endosomal membranes, and facilitates siRNA release (Petrova, et al., 2012).  
Therefore, the use of this reagent isolates the assessment of siRNAs within the RISC complex, 
but it does not accurately predict how siRNAs would behave in the presence of natural biological 
barriers.  To more accurately predict the behaviour of siRNAs in vivo, the activity of selected 
siRNAs was evaluated in a carrier-free environment.   
 The Dual-Luciferase Reporter Assay protocol provided by Promega outlines that the 
pGL3 and pRLSV40 plasmids should be co-transfected with siRNAs using Lipofectamine 2000, 
followed by a 24 hour waiting period, lysing of the cells, and measuring of the activity of the 
siRNAs (Promega, 2011).  Plasmids are generally quite large, and need a transfection reagent to 
assist their cellular uptake.  Therefore, in order to test the ability of the added lipophilic groups to 
promote cellular uptake, the plasmids and the siRNAs had to be transfected at different times.  
This was accomplished by transfecting HeLa cells with the pGL3 and pRLSV40 plasmids in the 




Technologies, it takes 4-6 hours for DNA-lipofectamine complexes to be taken up by cultured 
cells.  Therefore, after the elapsed time, the medium was replaced with fresh DMEM without 
FBS; as FBS contains exonucleases that could cleave the siRNA before entering into the cell 
(Petrova, et al., 2012).  The siRNAs were then diluted in Opti-Mem and added to the cells as 
suggest by Petrova, et al (Petrova, et al., 2012).  At this point it was not known how long of a 
transfection period is needed before the siRNAs will produce a response.  To reveal this 
information, a time-dependent assay was performed in 4 hour increments for 24 hours after 
siRNA transfection (see Figure 4-7).  The time-dependent assay displayed that siRNA activity 
was highest after a 16 hour transfection period.  The aL13 construct was chosen for this 
experiment because literature has demonstrated that cholesterol-conjugated siRNAs with long 
linkers can promote cellular uptake in in vitro testing.  Additionally, this modification came from 
a commercially available source so it proved logical to experiment with a readily available 




 modified siRNAs.  Overall, this new 
protocol is an efficient way to measure the activity of anti-luficerase siRNAs in a carrier-free 
environment.  One drawback is that the plasmids have 4 hours to undergo transcription and 
translation to produce luciferase without being targeted by siRNAs.  This makes it impossible to 
have highly potent siRNAs as observed in Figure 4-5 because once the luciferase enzyme is 






Figure 4-7: A reduction in the firefly luciferase expression of aL13 in a time-dependent manner 
using the Dual-Luciferase Reporter Assay in the absence of a transfection reagent.  The siRNAs 
were tested at 0.2 and 3.0 µM, with firefly luciferase expression normalized to Renilla luciferase 
in 4 hour increments for 24 hours after siRNA transfection.  All error bars represent the standard 
deviation of the mean. 
 All of the 3’-modified siRNAs that showed relatively high activity using the Dual-
Luciferase Reporter Assay in the presence of a transfection reagent were also tested using the 
newly developed carrier-free protocol.  In addition, aLwt was also tested as a control (see 
Figure 4-8).  At a 0.2 µM concentration, aL11 showed activity that was comparable to aLwt.  In 
comparison, aL12 showed the highest degree of potency and aL13 showed intermediate activity 
at both concentrations.  The results obtained from aL11 suggest that the PNA-like scaffold and 
the added phenylacetylene lipophilic group do not greatly enhance the cellular uptake of an 
siRNA.  The cholesterol-modified siRNAs, aL12 and aL13, on the other hand, may add a 
driving force that assists the crossing of the negatively charged cellular membrane.  There are 
many different hypotheses outlining the mechanisms involved in carrier-free uptake of lipophilic 
siRNAs in in vitro studies.  One mechanism involves the use of the transmembrane protein SID-





























2012).  Another method involves the transport of lipophilic conjugated siRNAs through 
endocytosis/pinocytosis (Petrova, et al., 2012).  The data presented in Figure 4-8 can be 
explained by taking into consideration both methods of siRNA transport.  If SID-1 can actively 
transport any source of double-stranded RNA, it is possible that aLwt could enter into the cell, 
despite having a negatively charged repulsive backbone, and being deprived of a lipophilic 
group.  The higher activity seen in aL12 and aL13 can be better described using the 
endocytosis/pinocytosis hypothesis.  In this case, there are two factors that could influence the 
absorption of a lipophilic siRNA: the hydrophobicity of the conjugates, and the length of the 
linker that increases the distance between the negatively charged cellular membrane and the 
anionic siRNA (Petrova, et al., 2012).  SiRNA aL12 and aL13 both contain more hydrophobicity 
than aL11, which means that they are more likely to lie adjacent to the cell membrane before 
endocytosis/pinocytosis occurs.  Commercially available aL13; however, has a linker, which 
provides an optimal distance between the cell membrane and the negatively charged siRNA 
when compared to aL12.  This should promote the cellular uptake of aL13 over aL12.  
However, siRNAs that have linkers above 10 carbon atoms have difficulty in escaping the 
endosome that encapsulate them (Petrova, et al., 2012).  This explanation, combined with the 
data obtained from Figure 4-6, which suggests that aL13 is not as effective at silencing mRNA 
when compared to aL12, could explain why the activity of aL13 was less than aL12.  Despite 
the slightly lower activity of aL13 compared to aL12, other studies have demonstrated that 
cholesterol-siRNAs targeting luciferase in HeLa cells in the absence of a transfection reagent 
have a half-maximal inhibitory concentration of about 0.2 µM (Soutscheck, et al., 2004).  This 
IC50 value is close to that of aL13, which demonstrates the accuracy of the assay, and 




2000 and furthermore, this reagent is not stable within blood plasma.  Therefore, the cholesterol-
modified siRNAs could prove to be a valuable therapeutic that can effectively cross cell 
membranes. 
 
Figure 4-8: A reduction of firefly luciferase expression related to the potency of chemically-
modified siRNAs in the absence of the cationic carrier, Lipofectamine 2000, using the Dual-
Luciferase Reporter Assay.  Chemically-modified siRNAs were tested at 0.2 and 3 µM with 
firefly luciferase expression normalized to Renilla luciferase.  All error bars represent the 
standard deviation of the mean. 
4.3.3 The Evaluation of Modified siRNAs using RT-qPCR 
 The last part of this study explored whether or not the modified siRNAs held promise 
against an endogenous gene.  The endogenous target used in this study was the transcript of the 
BCL-2 gene.  This target was chosen because it is an upregulated oncogene that is of clinical 
relevance.  Additionally, literature has already identified an effect target site for siRNAs on the 





























to cleavage by siRNAs avoids the obstacle of designing siRNAs that cannot contact their target 
site due to the secondary structure of their mRNA target.   
In order to evaluate mRNA knockdown of the BCL-2 gene, RT-qPCR was performed 
using the cells-to-cDNA II Kit supplied by Ambion.  The activity of the BCL-2 gene was 
referenced against the 18S rRNA housekeeping gene.  The protocol that was used to collect the 
data in the following discussion can be found in Section 4.2.4.   
The primers that were used in this study were chosen because they have been cited in 
literature a numerous amount of times and their resulting amplified regions are less than 250-bps 
(Efthymiou, et al., 2012; Ferrer, et al., 2010).  Amplifying short sequences is more likely to 
result in the complete synthesis of the amplicon.  In order to evaluate the efficiency of the 18S 
rRNA and BCL-2 primers, standard curves were performed.  The standard curve for the 18S 
rRNA primers had an efficiency value of 95.6% when plotted as a 10-fold dilution series (see 
Figure 4-9a).  This falls within an accepted range of 90% to 105%, fulfilling the minimum 
information for publication of quantitative real-time PCR experiments (MIQE) expectations.  
The melt curve analysis of the 18S rRNA amplicon displayed a single sharp peak (83.5°C), 
which confirmed the specificity of the reaction (see Figure 4-9b).  The standard curve for the 
BCL-2 primers had an efficiency value of 98.4% when plotted as a 3-fold dilution series (see 
Figure 4-10a).  Again, this falls within an accepted range, fulfilling MIQE expectations.  The 
melt curve analysis of the BCL-2 amplicon displayed a single sharp peak (81°C), which also 
confirmed the specificity of the reaction (see Figure 4-10b).  When comparing the melt curves 
of the 18S rRNA and BCL-2 amplicons, the 18S rRNA amplicon had a higher Tm vale than the 
BCL-2 amplicon.  This result was expected because the 18S rRNA amplicon is ~100-bps longer 




NTC was run to confirm that the observed amplification was not a result of primer-dimers.  An 
NRT control was also performed to confirm that the observed amplification was not a result of 
genomic DNA.  With both controls, amplification was not observed.  Together, all of these 
findings suggest that an effective protocol was developed to monitor the activity of siRNAs 
using RT-qPCR.  
Figure 4-9: The verification of the efficiency and the specificity of the 18S rRNA primers 
through standard curve and melt curve analysis. (A) The 18S rRNA standard curve had an 
efficiency value of 95.6%, an R
2
 value of 0.966 and a slope of -3.432.  (B) The 18S rRNA melt 





After establishing a concrete RT-qPCR protocol, the activity of anti-BCL-2 siRNAs 
(sequences shown in Table 4-1) could be evaluated.  In reviewing Figure 4-11, all siRNAs had a 
dose-dependent response with the exception of aB1, which maintained efficacy at all 
concentrations.  In general, all modified siRNAs were more potent than aBwt.  The Tm values of 
these duplexes were not calculated; however, it is quite clear from Table 3-2 that the internal 




 modification is greatly destabilizing and terminal placements 





 positions.  Consistent with the thermodynamic asymmetry rule, these siRNAs 
will favour the incorporation of the antisense strand into the RISC complex (Kawamata & 
Tomari, 2010).  This could explain their increased potency when compared to aBwt.  When the 
modification was moved to the 3`-end, in reference to aB3, aB4, and aB5, the activity of the 
siRNAs was enhanced at 10 and 20 nM concentrations when compared to aBwt.  As described in 
Figure 4-10: The verification of the efficiency and the specificity of the BCL-2 primers through 
standard curve and melt curve analysis.  (A) The BCL-2 standard curve had an efficiency value 
of 98.4%, an R
2
 value of 0.965 and a slope of -3.360.  (B) The BCL-2 melt curve analysis 





Section 4.3.1, this may be caused by either their ability to avoid exonucleases or because the 
slightly destabilizing modification favours the incorporation of the antisense strand into the RISC 
complex (Efthymiou, et al., 2012; Kawamata & Tomari, 2010).  Consistent with the findings in 
Figure 4-5, commercially modified aB5 is not as potent as aB3 or aB4.  This could be a result of 
the long linker on aB5 that could be interfering with the assembly of the RISC complex.  
Overall, the RT-qPCR data was consistent with literature, and the trends observed in this 
experiment matched the data provided by the Dual-Luciferase Reporter Assay. 
Table 4-1: The sequences of the anti-BCL-2 (aB) siRNAs. 





5'- GUGAAGUCAACAUGCCUGCtt -3' 





































 corresponds to the cytosine-triazole-uracil-phenylacetylene modification; CtU
Ch
 
corresponds to the cytosine-triazole-uracil-cholesterol modification; Ch corresponds to the 





Figure 4-11: The reduction in BCL-2 expression in the presence of chemically-modified 
siRNAs.  The siRNAs were tested at 1, 10 and 20 nM with BCL-2 expression normalized to 18S 
rRNA using RT-qPCR.  All error bars represent the standard deviation of the mean. 
4.4 Chapter Summary 




modifications on the sense strand of the 
duplex were RNAi substrates for gene silencing when evaluated using the Dual-Luciferase 
Reporter Assay.  When these modifications were placed on the 3`-end of the sense strand, the 
potency of the siRNA was enhanced.  Further investigation demonstrated that the 3`-CtU
Ch 
modification was able to effectively cross the cell membrane and maintain effective siRNA 
activity in a carrier-free environment.  This specific modification displayed better activity than 
the commercially available triethyleneglycol cholesterol modification.  Finally, after a concrete 
RT-qPCR protocol was established, these modified siRNAs were able to maintain their potent 








































Chapter 5: Conclusion and Future Prospects 
 Since the discovery that double-stranded RNA could interfere with the function of an 
endogenous target in a sequence-dependent manner, numerous siRNA-based strategies have 
undergone development (Fire, et al., 1998; Opalinska & Gewirtz, 2002).  These types of 
therapeutics offer many advantages over traditional small organic molecules.  For instance, the 
majority of pharmaceutical drugs sold in the market today consist of peptides or proteins and 
antibodies that bind directly to a protein target to inhibit its activity (Prasad & Roy, 2008).  The 
problem with these conventional therapies is that their target specificity is limited to proteins that 
have unique domains (Prasad & Roy, 2008).  Therapeutic siRNAs that target RNA, on the other 
hand, have selective recognition towards a specific sequence held by their target.  With the 
human genome project having identified ~25 000 genes coding for ~85 000 different mRNA 
targets, this type of therapeutic approach offers a less complicated and quicker way to 
downregulate a problematic protein (Prasad & Roy, 2008). 
     Despite the many advantages that therapeutic siRNAs offer, the full potential of these 
drugs will not be attained unless better methodologies are developed to enhance target delivery 
and the stability of the siRNA constructs.  These issues can be addressed by chemically 
modifying oligonucleotides to improve their pharmacokinetic and pharmacodynamic properties.  
The work presented within this study focussed on chemically modifying the sense strand of an 
siRNA duplex with a triazole backbone unit to enhance resistance against exonucleases and a 
pyrimidine-modified lipophilic moiety to enhance the delivery of the siRNA therapeutic.  The 
incorporation and assessment of this modification was accomplished by characterizing the 









 phosphoramidite building blocks.  All of the intermediate 





NMR and ESI-HRMS.  Next, the CtU
Ph
 and the CtU
Ch
 phosphoramidite building blocks were 
successfully incorporated into site-specific locations of an oligonucleotide using solid-phase 
RNA phosphoramidite chemistry.  When the resulting modified oligonucleotides were annealed 
to their complementary strands, biophysical measurements revealed that all of the siRNA 
duplexes maintained an RNA A-form helical structure that was required for their gene silencing 
activity (Chiu & Rana, 2002).  The thermodynamic profile of the CtU
Ph
 and the CtU
Ch
 modified 
siRNAs demonstrated that internal modifications of the sense strand were greatly destabilizing, 
while modifications that were placed at the 3’-overhangs were only slightly destabilizing.  
Furthermore, the lipophilic residues protruding off of the C5 position of uracil did not seem to 
alter the stability of the duplex.  On a genetic level, these siRNAs were able to effectively 
knockdown firefly luciferase targets derived from a transfected exogenous plasmid.  





 internal modifications.  Placement of these modifications on the 3’-end were 
also more potent than the commercially available triethyleneglycol cholesterol modification.  
Carrier-free assays further demonstrated that 3’-CtU
Ch
 modification has the ability to enhance 





 modified siRNAs held promise against an endogenous chromosomal BCL-2 
target. 









that could have been performed to either further validate the RT-qPCR results or give a better 
insight into the altered behaviour of the modified siRNAs.  In terms of validation, a gel analysis 
of the PCR products could have been performed to ensure that the length of the BCL-2 and 18S 
rRNA amplicons were the appropriate size.  Alternatively, the amplicons could have been 
sequenced, which would have provided a direct analysis of each individual nucleotide within the 
PCR product.  In this study only one reference gene was used, which could have potentially been 
affected by the experimental conditions.  Therefore, using three or four reference genes derived 
from different metabolic pathways could have provided more accurate results.  Passive reference 
dyes, like the ROX
TM
 dye, are also frequently used in real-time PCR to correct for fluctuations of 
reporter dyes that are not PCR-based.  These fluctuations are commonly caused by slight 
changes in reaction concentrations between wells, and errors in instrumental scanning.  These 
types of dyes do not interfere with the real-time PCR reaction, and offer more accurate PCR 
readings. 
In this study, the behaviour of siRNAs within HeLa cells were analyzed in relation to 
their compatibility within the RISC complex.  Following this experiment, their behaviour was 
also analyzed in the presence of a cellular membrane barrier without a transfection reagent, 
followed by their ability to downregulate mRNA after crossing the membrane.  An experiment 
was not conducted that strictly measured the ability of the modified siRNAs to cross the 
membrane.  To measure the migration of CtU
Ph
 modified siRNAs, UV-confocal microscopic 
images could have been taken after transfection.  The CtU
Ph
 modification has a highly conjugated 
system between the uracil base and the added phenylacetylene group that would have allowed 




The carrier-free assay that was designed using the Dual-Luciferase Reporter Assay could 
also be used to test the ability of other modified siRNAs to knockdown mRNA transcripts in the 
absence of a transfection reagent.  This opens up the door for further investigation of PNA, 
triazole, and gapmer-containing siRNAs targeting firefly luciferase that have already been 
synthesized in the laboratory of Dr. Jean-Paul Desaulniers. 
  In order to better understand the effects of the CtU
Ch
 and the commercially available 
triethyleneglycol cholesterol modifications in vitro, cholesterol binding assays could have been 
performed.  The commercially available triethyleneglycol cholesterol addition contains a long 
linker that projects cholesterol away from the siRNA duplex.  This could make it easier for 
cholesterol trafficking proteins to interact with the highly accessible lipophilic moiety.  This type 
of information would further confirm the results observed using the Dual-Luciferase Reporter 
Assay system and the results obtained from RT-qPCR (Ikone, 2008). 
 Ultimately, the end goal of siRNA therapy is to downregulate the overexpression of a 
protein.  To confirm that the results obtained from RT-qPCR were translated to the 
downregulation of the Bcl-2 protein, a Western Blot could have been performed.  This type of 
assay would have solidified the speculation that the downregulation of the BCL-2 mRNA 
transcript did in fact cause the down regulation of the Bcl-2 protein. 
 In conclusion, this is the first report that explores the effect of a non-ionic linkage unit 
derivatized with a base-modified lipophilic moiety within siRNAs.  Furthermore, the unique 
strategy that was used to incorporate this modification allowed for its site-specific internal 




enhance the properties of a natural siRNA molecule and helped to further understand the 
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